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1. INTRODUCTION 
  
1.1 Aim of study 
 
Copper-64 (t1/2 = 12.7 h, β
–
 (0.578 MeV, 38.4%), β+ (0.653 MeV, 17.8%), EC 
(43.8%), Auger electron emission) is of special interest to nuclear medicine as it decays 
by both electron and positron emission, and is thus of potential use in medical imaging 
via positron emission tomography (PET) and for targeted radiotherapy of cancer.  The 
half-life of 12.7 h is ideal for the purposes of nuclear medicine, as it allows for 
experiments extending over several days, yet is short enough to limit the patient’s 
exposure.  Over the past two decades the production of copper-64 by means of a 
biomedical cyclotron has been optimized (Szelecsenyi et al., 1993, McCarthy et al., 
1997), and copper-64 is now being produced at several medical and research facilities in 
North America and Europe. 
Given these characteristics, it is somewhat surprising that as of the beginning of 
2007, no copper-64 radiopharmaceutical was routinely being used in the clinic.  There are 
various reasons for this:  First, although copper-64 production has grown, it still has not 
reached the level of commonly used PET isotopes like fluorine-18 or carbon-11.  Second, 
being a radiometal, copper-64 must be incorporated into a radiopharmaceutical via a 
bifunctional chelator (BFC).  DOTA and TETA are examples for tetraazamacrocyclic 
chelators extensively used for copper-64 complexation, but their copper complexes have 
low stability in vivo (Boswell et al., 2004), and trans-chelate to serum proteins (Bass et 
al., 2000, Boswell et al., 2004).  Additionally, they display poor acid stability and are 
prone to reduction and loss of copper(I) from the complex (Woodin et al., 2005).  
Therefore, there is a need for new chelators with optimized copper-64 binding 
characteristics.  One promising new class of chelators for radiometals are the cross-
bridged cyclens and cyclams (Weisman et al., 1990, Hubin et al., 2000, Wong et al., 
2000, Sun et al., 2002, Hubin et al., 2003), and one such compound, CB-TE2A, was more 
closely examined in this study.  Such a novel chelator can then be attached to a biological 
targeting molecule like a peptide or an antibody, and the resulting copper-64 
radiopharmaceutical tested for its biological activity in vitro and in vivo. 
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Much work has been done on copper-64-labeled peptide analogues of 
somatostatin targeting somatostatin receptor subtype 2 (SSTr2) (Lewis et al., 1999c, Li et 
al., 2002).  These radiopharmaceuticals have successfully been used to image endocrine 
tumors in humans (Anderson et al., 2001) and in tumor-bearing rats (Sprague et al., 
2004), and inhibited the growth of tumors in rats (Anderson et al., 1998).  Copper-64 
from these radiopharmaceuticals has been shown to enter the nucleus of tumor cells  
(Wang et al., 2003), but the exact mechanism of copper transport to the nucleus remains 
unknown. 
In the present study, copper-64-labeled somastostatin analogues and the     
copper-64-labeled EGFR antibody cetuximab were used to quantify and explain nuclear 
localization of copper-64 in tumor cells and to examine new applications of copper-64-
labeled radiopharmaceuticals in the receptor-mediated imaging and targeted radiotherapy 
of cancer.  In particular, the study addressed the following: 
 
 Characterization of somatostatin analogues coupled to novel cross-bridged 
heteromacrocyclic chelators, including a peptidic somatostatin antagonist, by 
receptor binding studies and biodistribution. 
 Confirmation of the hypothesis that dissociation of copper-64 from its chelator 
precedes transport to the nucleus by comparing two chelators differing in 
copper binding stabilities in a cell line stably transfected with SSTr2. 
 Testing the hypothesis that higher nuclear localization of copper-64 leads to 
improved killing of tumor cells. 
 Examination of the potential role of tumor suppressor protein p53 in 
trafficking of copper-64 to tumor cell nuclei. 
 Correlating transcription, translation and receptor function of epidermal 
growth factor receptor (EGFR) in several cervical cancer cell lines using the 
EGFR antibody 
64
Cu-DOTA-cetuximab. 
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1.2 Targeting cell receptors for tumor imaging and therapy 
 
Cells communicate with each other by a variety of means:  through adhesion 
molecules with their immediate neighbors, through paracrine substances with cells in 
their vicinity, and through endocrine hormones with cells anywhere in the body.  Steroids 
and peptides are the two most important classes of endocrine hormones.  Steroids bind to 
intracellular receptors, whereas peptides target transmembrane receptors on the surface of 
cells.  Both steroids and many peptide hormones, such as the growth factors or insulin, 
regulate cell proliferation and metabolism.  As tumor cells are characterized by 
uncontrolled proliferation and enhanced cell growth, it has been observed that most 
tumor cells over-express one or several hormone receptors (Weiner and Thakur, 2005).  
Radiopharmaceuticals which target receptors occurring in much higher numbers on the 
surface of tumor cells can be used to visualize and/or treat cancer.  Molecular imaging of 
tumors via single photon computed tomography (SPECT) or positron emission 
tomography (PET) using targeted radiopharmaceuticals delivers functional information 
about the disease, and complements and enhances anatomical information acquired by 
computed tomography (CT) and magnetic resonance imaging (MRI).  Positrons (β+) 
travel only a few millimeters before they encounter an electron, which leads to the 
formation of two annihilation photons at a 180° angle.  Simultaneous detection of these 
two 511 keV photons by the scanner forms the basis of PET imaging.  The resolution of 
clinical PET scanners is in the low millimeter range, which is not as high as MRI     
(100–500 μm), but higher than the alternative method for imaging specific molecular 
targets, SPECT (3–6 mm).  Therefore, interest in PET has steadily increased over the past 
few decades, and more advanced image reconstruction techniques are being developed to 
further improve its resolution.  After a tumor is diagnosed, a targeted radiopharmaceutical 
can be used to determine the optimal therapy by identifying molecular markers on the 
tumor cells.  During the course of therapy, the radiopharmaceutical can be used by the 
physician to monitor the success of the chosen treatment, e.g. by non-invasive imaging of 
any change in the size of the tumor, or of its metastatic state.  Finally, at the end of 
therapy, PET or SPECT may be able to identify tumor remnants or new metastases when 
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anatomical imaging modalities suggest complete remission.  Table 1 shows peptides and 
their respective receptors which are commonly over-expressed in the listed cancers. 
 
 
Table 1: Potentially useful peptides for tumor imaging and/or therapy (modified from 
Weiner and Thakur, 2005). 
Peptide Receptor Function Target 
Somatostatin 
and 
analogues 
Somatostatin 1–5 Inhibits growth 
hormone release 
Neuroendocrine tumors, 
SCLC, breast cancer, 
monocytes, and lymphocytes 
EGF EGF Growth promoter Breast cancer, colon cancer 
Bombesin GRP CNS and GI tract 
activity 
Glioblastomas, SCLC, 
prostate, breast, gastric, colon, 
and pancreatic cancer 
CCK/gastrin CCK 1–2 Gallbladder 
contraction, acid 
secretion 
SCLC, GI tumors, pancreatic 
cancer, adenomas, and 
medullary thyroid cancer 
Gastrin-
releasing 
peptide 
GRP Promotes gastrin 
secretion 
Glioblastomas, SCLC, 
prostate, breast, gastric, colon, 
and pancreatic cancer 
α-MSH Melanocortin 1–5 Regulation of skin 
pigment, CNS 
Melanoma cells 
Neurotensin Neurotensin 1–3 GI and cardiac 
activity, 
neuromodulator 
Prostate and pancreatic cancer 
VIP VIP 1–2 Vasodilator, 
growth promoter, 
immunomodulator 
NSCLC, breast, colon, 
pancreatic, prostate, bladder, 
and ovarian cancer 
RGD 
analogues 
αvβ3 integrin Endothelial 
adhesion molecule 
Angiogenetic tumors 
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Most endogenous peptide hormones have to be modified before becoming 
clinically useful due to their short biological half-lives.  Chemical modifications include 
the incorporation of D-amino acids or amino acid analogues, and the reduction of the 
peptide’s amide bonds.  These changes aim to reduce the ability of in vivo degradation by 
endopeptidases.  Modification of terminal amino acids (end-capping) can provide 
protection against cleavage by exopeptidases (Weiner and Thakur, 2005).  Apart from a 
prolonged biological half-life, desirable characteristics of peptide analogues for tumor 
imaging and therapy include:  a high affinity for their biological target comparable to the 
biological peptide, rapid clearance from non-target organs, and internalization into target 
cells (Riccabona and Decristoforo, 2003) to retain activity in the tumor, and maximize 
damage to tumor cells. 
Extensive research has been done on somatostatin and its analogues (Froidevaux 
and Eberle, 2002, Guillermet-Guibert et al., 2005).  The somatostatin analogue         
111
In-DTPA-octreotide (Octreoscan
®
) was the first radiolabeled peptide approved for 
human use in the United States and Europe.  Somatostatin and EGF, as well as their 
receptors, are the focus of this study, and they will be more extensively introduced in 
Sections 2.1.1 and 2.2.1, respectively. 
The 14-amino-acid peptide bombesin was originally isolated from frog skin.  It 
has a high affinity for the gastrin-releasing peptide receptor (GRPR), which is over-
expressed in a variety of cancers (Table 1) and whose activation leads to increased cell 
growth and proliferation (Weiner and Thakur, 2005).  Bombesin analogues labeled with 
technetium-99m (Nock et al., 2003), indium-111 (Breeman et al., 2002), lutetium-177, 
and yttrium-90 (Zhang et al., 2004) have been synthesized and are currently being 
investigated. 
Cholecystokinin (CCK) regulates a variety of functions in the gastrointestinal 
tract, but it can also act as a growth factor for normal and malignant cells (Reubi et al., 
1997).  CCK-B receptors occur in 90% of medullary thyroid cancers (Reubi et al., 1997), 
and a variety of CCK and gastrin derivatives were labeled with technetium-99m,   
indium-111, yttrium-90, and iodine-131 and evaluated for this tumor (Weiner and 
Thakur, 2005).  A 111In-DTPA derivative of gastrin identified 91% of the lesions in 
patients with occult disease (Behe and Behr, 2002). 
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PET imaging with radiolabeled α-melanocyte-stimulating hormone (α-MSH) is 
very effective for the detection of melanoma lesions.  DOTA is the most widely used 
chelator, which allows the use of a variety of radiometals (Chen et al., 2001, Froidevaux 
et al., 2002a).  The compound 111In-DOTA-MSH has been evaluated in vivo and showed 
high tumor to non-target organ ratios (Froidevaux et al., 2002a), but 50% of the 
compound cleared from the tumor at 24 h. 
The receptor for the 13-amino-acid peptide neurotensin is upregulated in 
pancreatic cancer and some other human tumors. Several radiolabeled neurotensin 
analogues have been synthesized (Bergmann et al., 2002, Achilefu et al., 2003), however, 
fast degradation in vivo, low tumor uptake, and rapid washout are problems that remain 
unresolved. 
Integrins are heterodimeric transmembrane glycoproteins important in cell 
adhesion.  They have a pronounced role in metastatic invasion by tumor cells and tumor-
induced angiogenesis (Weiner and Thakur, 2005).  Antagonists to the integrin αvβ3 have 
been shown to bind to tumor cells, block angiogenesis associated with the tumor, and 
cause tumor regression (Haubner et al., 2001).  αvβ3 integrin binds peptides with the 
sequence RGD (Arg-Gly-Asp), and the radiopharmaceutical 
111
In-DOTA-ε-(c[RGDfK]) 
has shown promising tumor uptake and tumor-to-blood ratios (Janssen et al., 2002). 
Labeled with yttrium-90, this compound seems also suitable for therapy (Janssen et al., 
2002).  RGD peptides have also been successfully labeled with copper-64 and used for 
the imaging of brain tumors (Chen et al., 2004c, Wu et al., 2005), and breast cancer 
(Chen et al., 2004a, Chen et al., 2004b). 
Cell surface receptors can also be targeted by antibodies, which often have a 
higher specificity and affinity for the receptor they were designed to bind to.  However,  
in contrast to peptides, they often induce an immune reaction, as they are most frequently 
derived from murine molecules.  To avoid this problem, mouse antibodies can be 
humanized, or antibody fragments can be used.  The pharmacokinetics of antibodies are 
rather slow, and if fast diffusion is desired, peptides are the agents of choice.  Additional 
advantages of peptides as receptor targeting agents include their inexpensive and fast 
synthesis, and their tolerance of harsher radiolabeling conditions.  In this dissertation, 
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peptidic somatostatin analogues and the EGFR antibody cetuximab were used to target 
the cell surface receptors SSTr2 and EGFR, respectively. 
 
 
 
1.3 Copper-64 radiopharmaceuticals 
 
1.3.1 Biochemistry of the transition metal copper 
 
Copper is one of the most important trace metals in humans, being surpassed in 
abundance only by iron and zinc (Sun and Anderson, 2004).  The body of a healthy 
human adult weighing 70 kg contains approximately 110 mg copper (Linder, 1991), and 
it is estimated that 0.6–1.6 mg copper are ingested every day with about 50% being 
absorbed (Linder et al., 1998).  Studies with copper-64 and copper-67 have identified 
albumin (Mr = 66 kDa) and transcuprein (Mr = 270 kDa) (Weiss and Linder, 1985) as 
immediate chelators of copper after entry from intestinal cells into the interstitial fluid 
and blood plasma.  There is a high-affinity site for Cu
2+
 at the amino terminus of most 
albumins, but the binding affinity of transcuprein is even higher.  Copper is exchangeable 
between these two plasma proteins, and most of the copper bound by albumin and 
transcuprein is rapidly deposited in the liver, and to a lower extent, the kidney.  In the 
liver, copper can be incorporated into the protein ceruloplasmin (CP) during its synthesis, 
and the holoprotein is subsequently secreted.  CP cannot exchange its copper with other 
plasma components, and it is the main carrier that delivers copper to organs other than 
liver and kidney.  Excess copper usually is not stored in mammals.  The rate of excretion 
is the main process maintaining copper homeostasis (Linder and Hazegh-Azam, 1996). 
It is believed that most of the copper inside the body is functional, serving as a 
necessary cofactor of enzymes such as cytochrome-c oxidase (CCO), superoxide 
dismutase (SOD), copper-thionein (a metallothionein), protein-lysine 6-oxidase, 
dopamine-β-monooxygenase (DBM), and various others (Linder and Hazegh-Azam, 
1996).  Table 2 summarizes the function of the most important enzymes containing 
copper as a redox cofactor.  The role of copper in these enzymes is the catalysis of 
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oxidation-reduction reactions, all of which involve oxygen or oxygen radicals.  In water 
and in biological systems, copper predominantly occurs as Cu(II) (cupric state), although 
it is also found as Cu(I) (cuprous state).  Copper is such an important cofactor in 
biological oxidation-reduction reactions due to its ability to act as an electron acceptor or 
donor in one-electron reactions, which also permits to scavenge radicals. 
 
 
 
The slightly positive electrochemical potential for the reduction of cupric to 
cuprous ion in aqueous solution may be dramatically different when the metal is 
incorporated into enzymes, as ligands alter the copper ions’ electromotive force and make 
the system more or less easily oxidized or reduced (Roat-Malone, 2002).  Cu+ is a 
relatively soft ion and prefers sulfur ligands or ligands with large polarizable electron 
clouds, whereas the relatively hard Cu
2+
 ion prefers harder nitrogen ligands (Roat-
Malone, 2002). 
 
Table 2:  Enzymes with a copper cofactor. 
Enzyme Function 
Cytochrome-c oxidase Terminal enzyme of electron transport and oxidative 
phosphorylation 
Superoxide dismutase Antioxidant defense 
Copper-thionein, Storage of excess copper, detoxification, antioxidant 
defense 
Ceruloplasmin Iron metabolism, copper transport 
Protein-lysine 6-oxidase Maturation and cross-linking of elastin and collagen fibers 
Dopamine-β-monooxygenase Catecholamine anabolism, converts dopamine to 
norepinephrine 
Peptide-α-amidating 
monooxygenase 
Pituitary hormone maturation 
Monophenol monooxygenase 
(Tyrosinase) 
Melanin anabolism, converts tyrosine to 
dihydroxyphenylalanine 
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Cytochrome-c oxidase (CCO), superoxide dismutase (SOD), and metallothionein 
are ubiquitous in living cells and shall be discussed shortly to illustrate the biochemical 
functions of the cofactor copper. 
CCO is among the most highly conserved proteins in nature.  It is the terminal 
catalyst in the electron transport chain in bacterial cell membranes and in the 
mitochondria of eukaryotes, receiving electrons from cytochrome c and transferring them 
to oxygen, which is reduced to water.  Two heme moieties and two copper atoms mediate 
this transfer. 
SOD is part of the cell’s antioxidant defense by catalyzing the dismutation of two 
oxygen radicals (·O2
–
) to O2 and H2O2.  Most organisms have a copper- and zinc-
containing SOD, but forms with manganese and iron occur in some bacteria.  Mammalian 
SOD is a homodimer, and each subunit contains one zinc and one copper atom, which are 
coordinated by one aspartate and six histidine residues.  Superoxide is bound at the 
copper site.  Copper-zinc SOD is critical to antioxidant defense, which has been shown 
by knockout and transfection experiments (Rosen, 1993, Yang et al., 1994).  The reaction 
catalyzed by SOD produces hydrogen peroxide, which needs to be degraded by other 
enzymes such as heme-dependent catalase or selenium-dependent glutathione peroxidase.  
This group of enzymes prevents superoxide from forming the much more reactive 
hydroxyl radical (·OH), which can damage unsaturated lipids in cell membranes and 
other molecules within cells.  Not surprisingly, SOD has been found in every animal cell 
investigated (Linder and Hazegh-Azam, 1996). 
Metallothioneins form a class of small polypeptides which bind divalent transition 
metal ions, with the exception of Fe(II).  The binding affinity decreases as follows: 
mercury > copper > cadmium > silver > zinc.  Nickel, cobalt, and even gold are bound in 
low amounts as well, however, only zinc, copper, and cadmium binding is significant     
in vivo (Linder and Hazegh-Azam, 1996).  Mammalian metallothioneins generally consist 
of 61 amino acids, 20 of which are cysteines, whose sulfhydryl groups can bind 11 or 12 
copper ions per molecule.  Thus, the main function of metallothionein is to store and 
detoxify excess copper ions.  It can also scavenge hydroxyl and superoxide radicals, 
which means it is part of the cell’s antioxidant defense (Felix et al., 1993). 
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Although copper is of critical importance in so many biochemical processes, free 
copper, i.e. uncomplexed Cu
+
 or Cu
2+
 ions, is actually cytotoxic.  Free cuprous ions 
readily react with H2O2 forming the deleterious hydroxyl radical.  Toxicosis is rare, 
however, because there is little copper in fresh water and most food items.  Under rare 
circumstances, such as when CuSO4 was utilized on crops to deter certain 
microorganisms, or when food was consistently prepared in containers that leached high 
doses of copper, poisoning manifested itself by the development of liver cirrhosis, 
hemolysis, and damage to the brain, renal tubules, and the gastrointestinal tract (Davis 
and Mertz, 1987).  As copper redox proteins are highly conserved, one can assume that 
cells have minimized the amount of free copper for more than 3.5 billion years.  In yeast, 
the total concentration of free copper is less than 10
–18
 M, which corresponds to less than 
one atom of free copper per cell (Rae et al., 1999).  An estimate for human blood plasma 
content of free Cu(II) is 10
–13
 M (Linder and Hazegh-Azam, 1996).  Copper is instead 
bound to chelation sites, which include small molecules (e.g. the amino acid histidine), 
vesicular sites for concentration of copper, specific copper proteins, and detoxification 
systems such as the metallothioneins discussed above (Linder and Hazegh-Azam, 1996, 
O'Halloran and Culotta, 2000).  As free copper is generally unavailable in biological 
systems, a specialized set of enzymes (metallochaperones) is needed to assist in the 
intracellular trafficking of copper, and the delivery to the correct metalloenzyme.     
Table 3  lists the most important copper transporters and chaperones. 
Copper is brought into mammalian cells by the protein Ctr1 (Fig. 1).  It transports 
copper in the form of Cu
+
, acting as a permease or by endocytosis.  This means that 
cupric ions have to be reduced before transport, however, the mechanism for this 
reduction prior to uptake remains unknown (Prohaska and Gybina, 2004). 
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Table 3:  Mammalian copper transporters and chaperones. 
Protein Function 
Transporters  
Ctr1 Copper transport into cells, acts as a permease or by 
endocytosis 
Chaperones Copper binding and delivery in cytosol and mitochondria 
Cox17 Delivery of copper to mitochondrial cytochrome-c oxidase 
Cox11, Sco1, Sco2 Assist with copper transfer to cytochrome-c oxidase 
CCS Delivery of copper to SOD 
Atox1 Delivery of copper to copper-transport ATPases in the 
transgolgi network 
ATPases Delivery of copper to the secretory pathway 
ATP7B Copper-transport ATPase in the liver 
ATP7A Copper-transport ATPase in other cells (e.g. neurons) 
Putative chaperones  
Murr1 Associates with ATP7B 
APP May be involved in copper export from the brain 
 
 
The first copper chaperone to be discovered was Atx1 in Saccharomyces 
cerevisiae (Lin and Culotta, 1995).  It was found that the oxygen toxicity in yeast 
mutants lacking copper-zinc SOD can be suppressed by overproduction of Atx1.  It was 
later shown that Atx1 is a copper chaperone (Lin et al., 1997).  The human homologue is 
Atox1.  These proteins deliver copper to P-type transporters, which are ATPases that use 
energy derived from ATP hydrolysis to drive membrane transport of copper ions.  They 
are located in the transgolgi network (Fig. 1).  In humans, there are two isoforms of this 
transporter, ATP7B found in hepatocytes, and ATP7A, which was characterized in 
neurons and astrocytes.  Biliary excretion of excess copper, and the synthesis and 
endocytosis of ceruloplasmin (CP) are routed through the transgolgi network in 
hepatocytes, and thus depend on functional Atox1 and ATP7B.  In Wilson’s disease, 
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ATP7B is mutated, and as a result, CP levels decrease and copper accumulates in the 
liver.  ATP7A has a homologous role in the delivery of copper to enzymes such as 
peptide-α-amidating monooxygenase (PAM), and dopamine-β-monooxygenase (DBM) in 
certain neuronal cells.  If ATP7A or Atox1 are non-functional, synthesis of 
catecholamines and neuropeptide maturation is impaired (Linder and Hazegh-Azam, 
1996, Prohaska and Gybina, 2004). 
 
 
Fig. 1: Copper chaperones (ellipses) and cuproenzymes (rectangles) in two types of 
mammalian cells. MT = metallothionein, PAM = peptide-α-amidating monooxygenase, 
CCO = cytochrome-c oxidase, (a)CP = (apo)ceruloplasmin, DBM = dopamine-β-
monooxygenase, TGN = transgolgi network; for other abbreviations see Table 3 (from 
Prohaska and Gybina, 2004). 
 
CCS, the copper chaperone for SOD, was second to be recognized (Culotta et al., 
1997).  It is located in the cytosol and the mitochondrial intermembrane space, where it 
transfers copper to SOD.  This transfer brings copper from an all-sulfur coordination 
environment (cysteines in CCS) to an all-nitrogen coordination environment (histidines in 
SOD).  A mechanism for this transfer has been proposed (Rae et al., 2001) but remains 
under debate. 
The chaperone which supplies copper to cytochrome-c oxidase (CCO), Cox17, 
was first described in 1996 (Glerum et al., 1996).  It is present in the cytoplasm and the 
mitochondrial intermembrane space.  At least three other copper chaperones are involved 
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in the process (Fig. 1):  Cox11 mediates the transfer of copper to the CuB site of CCO 
subunit I (Cox1), and Sco1 and Sco2 are necessary for the transfer of copper to the CuA 
site of CCO subunit II (Cox2) (Prohaska and Gybina, 2004). 
Putative copper chaperones include Murr1, which associates with ATP7B and 
whose absence in canines results in copper toxicosis, and APP.  The latter is a membrane 
protein with a copper-binding site. APP-null mice have markedly elevated copper levels 
in the brain compared to wild-type mice (White et al., 1999). 
Copper, in the form of copper-64, has also been shown to translocate to the nuclei 
of tumor cells (Wang et al., 2003).  However, none of the recent reviews on copper 
chaperones (Rosenzweig, 2001, Field et al., 2002, Markossian and Kurganov, 2003, 
Prohaska and Gybina, 2004) discuss copper transport to the cell nucleus.  Thus far, no 
copper chaperone and no mechanism for copper transport to the nucleus have been 
discovered. 
 
 
1.3.2 Properties of copper-64 
 
Copper has the atomic number Z = 29, and isotopes with 23 to 51 neutrons 
(copper-52 to copper-80) occur naturally or have been generated and studied.  All 
isotopes from copper-60 to copper-69 have a half-life of one minute or more, or are not 
radioactive (copper-63 and copper-65).  Copper-60, copper-61, copper-62, copper-64, 
and copper-67 all possess half-lives, decay modes, and energy spectra that make them 
potentially suitable for molecular imaging and/or targeted radiotherapy (Sun and 
Anderson, 2004), and the decay characteristics of these isotopes are summarized in  
Table 4.  The half-lives range from just under 10 minutes to 62 hours.  Beta minus, 
positron and gamma emission occur and enable various copper isotopes to be used for 
targeted radiotherapy, and imaging by positron emission tomography as well as gamma 
scintigraphy.  Copper-64 is the only copper isotope that possesses all three decay 
modalities, and it has a half-life (12.7 h) favorable for biological studies.  The detailed 
decay scheme of copper-64 is shown in Fig. 2.  It can undergo electron capture (EC) and 
β+ emission to nickel-64, and β– emission to zinc-64.  Both daughter nuclides are stable.  
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Table 4:  Decay characteristics of major copper isotopes (Sun and Anderson, 2004). 
Copper-64 branching ratios from Qaim et al. (2007). 
Isotope Half-life β
–
 MeV (%) β+ MeV (%) EC % γ MeV (%) 
60
Cu 23.4 min - 3.92 (6) 
3.00 (18) 
2.00 (69) 
7.4 0.85 (15) 
1.33 (80) 
1.76 (52) 
2.13 (6) 
61
Cu 3.32 h - 1.22 (60) 40 0.284 (12) 
0.38 (3) 
0.511 (120) 
62
Cu 9.76 min - 2.91 (97) 2 0.511 (194) 
63
Cu STABLE - - - - 
64
Cu 12.7 h 0.578 (38.4) 0.653 (17.8) 43.8 1.35 (0.54) 
0.511 (35.6) 
65
Cu STABLE - - - - 
67
Cu 62.0 h 0.577 (20) 
0.484 (35) 
0.395 (45) 
- - 0.184 (40) 
0.092 (23) 
 
 
Fig. 2:  Decay scheme of copper-64 (from Qaim et al., 2007). 
INTRODUCTION 
 15 
Table 5 shows the maximum energies and intensities of all particles and 
electromagnetic rays emitted that have energies over 1 keV.  Electron capture (Intensity   
I = 43.8%) involves a p→n conversion, monoenergetic neutrino emissions, and branching 
to either the 1345.77 keV-level (I = 0.54%) or the ground state (I = 43.3%) of nickel-64.  
The excited level of nickel-64 decays via a 1346 keV γ-ray to the ground state.  Electron 
capture is also accompanied by characteristic Auger and X-ray emissions, which result 
from filling the electron vacancy in the inner electron shell with higher-level electrons.  
Decay by positron emission (I = 17.8%) also produces the nickel-64 daughter and is 
accompanied by neutrino emission and γ annihilation radiation (I = 35.6%).  Decay via β– 
emission (I = 38.4%) to the ground state of zinc-64 is accompanied by antineutrino 
emission. 
 
 
Table 5:  Maximum energies and intensities of particles and electromagnetic emissions 
from the decay of copper-64 (Makkonen-Craig, 2006, Qaim et al., 2007). 
Mode of decay Emission Emax/keV Intensity/% 
EC Neutrino 321.00 0.54 
γ 1345.77 0.54 
Neutrino 1666.77 43.8 
X Ni Kα2 7.461 4.72 
X Ni Kα1 7.478 9.3 
X NI Kβ1,3 8.265 1.68 
Auger Ni L 0.84 57.4 
Auger Ni K 6.54 22.39 
β+ Neutrino 653.10 17.8 
e
+
 653.10 17.8 
γ 511 35.6 
β– Antineutrino 578.7 38.4 
e
–
 578.7 38.4 
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Copper-64 can be produced in a nuclear reactor or with particle accelerators (Sun 
and Anderson, 2004).  The reactor-based method utilizes fast neutrons to produce  
copper-64 with the 
64
Zn(n,p)
64
Cu reaction.  The target is high-purity natural zinc metal 
which contains 48.6% zinc-64.  Copper-64 with high specific activity has been produced 
in amounts of approximately 250 mCi (Zinn et al., 1994), however, this method is not 
commonly used, due to the production of significant amounts of undesirable impurities, 
stemming from thermal neutron reactions with different zinc isotopes (Sun and Anderson, 
2004). 
 The accelerator-based production of copper-64 was first proposed in 1993 
(Szelecsenyi et al., 1993), and has been optimized over the following years (McCarthy et 
al., 1997).  Via the 64Ni(p,n)64Cu reaction, activities of 1 Ci (37 GBq) of copper-64 can 
be produced (Sun and Anderson, 2004).  The stable nickel-64 target occurs naturally in 
low amounts (0.9%) and is enriched to 99.6% before approximately 10–50 mg are plated 
onto a gold disk.  In this approach, 15.5 MeV protons are used with a current of           
15–45 μA and a bombardment time of 4 h (Sun and Anderson, 2004).  Typical yields at 
Washington University School of Medicine are 0.2 mCi/(μA·h) per mg of nickel-64.  The 
unreacted nickel-64 can be recovered and used for future productions.  Other methods for 
the production of copper-64 have been reported, but are not routinely used: 
64
Ni(d,2n)
64
Cu (Zweit et al., 1991), 66Zn(d,α)64Cu, and 68Zn(p,αn)64Cu (Hilgers et al., 
2003), among others. 
 
 
 
1.3.3 Applications of copper-64 in nuclear medicine and biology 
 
Radioisotopes of copper have different applications depending on their half-life.  
Shorter-lived isotopes are typically used to measure blood flow and hypoxia (Anderson 
and Welch, 1999).  For example, the bis(thiosemicarbazone) complexes 62Cu-PTSM and 
62
Cu-ATSM have been evaluated as blood flow agents in humans with coronary artery 
disease (Herrero et al., 1996), and to image hypoxic tissue in myocardium (Fujibayashi 
et al., 1997) and tumors (Lewis et al., 1999b), respectively.  The main application of 
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copper-64 and copper-67 is the radiolabeling of biological molecules, like peptides and 
antibodies, which can be used to target tumors, or certain types of cells and tissues, 
described in Section 1.2.  In addition, these longer-lived isotopes were initially used to 
elucidate the basic biochemistry of copper transport and metabolism. 
 Unlike the traditional PET isotopes carbon-11 or fluorine-18, which are 
covalently incorporated into biological molecules, ionic copper needs to be linked via a 
bifunctional chelator (BFC).  BFCs complex the radiometal, and can be covalently 
attached to the targeting molecule via a functional group.  Much research has been done 
on copper chelators and its chemistry, summarized by Wadas et al., (2007).  An optimal 
BFC must have the following characteristics: 
 
 Rapid complexation kinetics, so that the radiocopper complex can easily be 
synthesized 
 Kinetic inertness1 to Cu(II) decomplexation (proton-assisted, or due to 
transchelation or transmetallation) in vivo to maximize uptake of the copper 
radionuclide in the tissue or organ of interest 
 Resistance of the radiocopper complex to reduction of Cu(II) to Cu(I) and 
subsequent loss of cuprous ion from the complex 
 A functional group that allows for incorporation into a wide spectrum of 
biomolecules 
 
Many chelators have been synthesized for the complexation of copper(II) (Wadas 
et al., 2007), including acyclic polyaminocarboxylate and bis(thiosemicarbazone) 
ligands, tetraazamacrocycles, triaminocyclohexane ligands, hexaamine sarcophagine 
chelators, and cross-bridged tetraazamacrocyclic ligands.  
EDTA (ethylenediaminetetraacetic acid) and DTPA (diethylenetriamine-
pentaacetic acid) (Fig. 3) are acyclic polyaminocarboxylate ligands that complex a wide 
variety of divalent cations.  Their copper complexes display high thermodynamic 
stability, however, in vivo evaluation by serum stability measurements using their  
                                                   
1
  Kinetic inertness is defined by the rate constants for exchange of ligand with water.  In the simple case of 
a metal ion coordinated by water, ions are classified as inert for rate constants ranging from 10
–3–10–6 s–1 
(Roat-Malone, 2002).  The copper-chelator complexes used in this study have been tested for kinetic 
inertness via acid stability experiments (see below). 
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copper-67 complexes were disappointing (Cole et al., 1986).  Therefore, EDTA and 
DTPA very rarely serve as BFCs themselves, but both compounds are still routinely used 
during the purification of copper radiopharmaceuticals, as they readily complex 
unchelated radiocopper.  The EDTA and DTPA complexes are then separated from the 
desired copper radiopharmaceutical using, for example, SepPak
®
 or mini-size exclusion 
methods.  The acyclic bis(thiosemicarbazone) ligands, diacetyl bis(N4-methylthio-
semicarbazone) (ATSM) and pyruvaldehyde bis(N4-methylthiosemicarbazone) (PTSM) 
(Fig. 3), are used as blood flow and hypoxia imaging agents and gain their usefulness 
from the instability of their copper complexes (Wadas et al., 2007).  Copper-64 
preferentially dissociates from 
64
Cu-ATSM in hypoxic tumor cells, and thus has potential 
as a radiotherapeutic agent for hypoxic cancer (Lewis et al., 2001a).  This inherent 
instability prevents the bis(thiosemicarbazone) ligands from being used as chelators for 
targeted radiopharmaceuticals. 
 
N N
EDTA DTPA
CO2H
CO2HHO2C
HO2C
N N NHO2C
HO2C CO2H
CO2H
CO2H
N
N
HS NH
N
HN SH
N N
N
HS NH
N
HN SH
N
ATSM PTSM  
Fig. 3:  Acyclic polyaminocarboxylate and bis(thiosemicarbazone) ligands (modified 
from Wadas et al., 2007).  
 
Tetraazamacrocyclic ligands, in particular the macrocyclic 
polyaminocarboxylates DOTA (derived from cyclen) and TETA (derived from cyclam) 
depicted in Fig. 4, as well as their derivatives, have become the most extensively used 
class of chelators for copper-64 (Wadas et al., 2007).  Compared to acyclic chelating 
agents, they display enhanced kinetic inertness and thermodynamic stability.  The 
chelation of copper by nitrogen and oxygen donor atoms is enhanced by the macrocyclic 
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effect, which results in greater geometric constraints on the copper complex.  DOTA can 
chelate a variety of multivalent cations, and has been extensively used in 
radiopharmaceutical sciences.  Examples include radiopharmaceuticals containing 
copper-64 and copper-61 (Li et al., 2001), yttrium-90 and indium-111 (Li et al., 1994), 
yttrium-86 (Forster et al., 2001), gadolinium-153 (Wedeking and Tweedle, 1988), 
lutetium-177 (Erion et al., 1999), gallium-66 (Ugur et al., 2002), and gallium-68 
(Hofmann et al., 2001, Breeman et al., 2005).  These isotopes have been utilized in many 
studies, underlining the importance of DOTA as a metal chelator.  However, the in vivo 
stability of its copper complexes is comparatively low.  Copper-64 complexes of TETA, 
which chelates copper with a much higher selectivity over other metals, are more 
resistant to loss of copper, but evaluation in vivo has again demonstrated that better 
copper chelators with higher stability are warranted.  For example, at 20 h post-injection 
into Sprague-Dawley rats, almost 70% of the copper-64 from 
64
Cu-TETA-octreotide in 
the liver was transchelated to a 25 kDa protein, possibly superoxide dismutase (Bass      
et al., 2000).  Another study reported the transchelation of copper-67 from the TETA 
derivative BAT to ceruloplasmin (Mirick et al., 1999). 
 
Cyclen Cyclam
NH HN
HNNH
NH
NH
HN
HN
N N
NN
TETA
CO2H
HO2C
DOTA
CO2H
HO2C
N
N
N
N CO2HHO2C
CO2HHO2C
 
Fig. 4:  Cyclen, cyclam, and tetracarboxylate derivatives DOTA and TETA (modified 
from Wadas et al., 2007). 
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Three new classes of copper chelators promise to be more stable.  Ligands based 
on the cis,cis-1,3,5-triamino-cyclohexane scaffold, like tachpyr and IM (Fig. 5), have 
been synthesized and complexed with copper-64 and copper-67.  No transfer to serum 
proteins has been observed in human serum stability experiments over a period of          
14 days (Ma et al., 2002).  However, in vivo evaluation of these chelators is still pending, 
and the lack of a functional group means that they cannot currently be used as BFCs.  
Introduction of any substituent would result in the loss of molecular symmetry, and could 
possibly create complications due to cross-linking (Wadas et al., 2007). 
 Hexaazamacrobicyclic cage type ligands like Sar or SarAr (Fig. 5) have also been 
used to chelate copper-64.  Radiolabeling of SarAr was 100% complete at 25 °C within 
several minutes, and serum stability experiments showed that 98% of copper-64 activity 
remained complexed after 7 days (Di Bartolo et al., 2001).  Biodistribution studies of the 
chelators (Di Bartolo et al., 2001) and evaluation of SarAr-B72.3 murine antibodies 
labeled with copper-64 (Di Bartolo et al., 2006) have demonstrated the potential of the 
sarcophagine ligand as copper-64 chelators. 
 
HN NH
HN
N
N
HN NH
HN
N
NN
N
N N
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N
N N
N N
N N
HH
HH
Sar
H H
SarAr
N N
N N
N N
HH
HH
H H
H2N NH
NH2
 
Fig. 5:  Triaminocyclohexane and hexaamine sarcophagine ligands (modified from 
Wadas et al., 2007). 
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Ethylene cross-bridged cyclen and cyclam and their derivatives were designed to 
complex selected metal cations like Li
+
, Zn
2+
, and Cu
2+
 in the 1990s by Weisman and 
coworkers (Weisman et al., 1990, Weisman et al., 1996).  Attachment of two 
carboxymethyl groups produced the chelators CB-DO2A and CB-TE2A shown in Fig. 6. 
 
CB-TE2ACB-DO2A
N N
NN
CO2H
HO2C
N
N
N
N CO2H
HO2C
 
Fig. 6:  Cross-bridged tetraamine ligands (modified from Wadas et al., 2007). 
 
Many lines of evidence suggest that this class of chelators can be successfully 
utilized in the development of copper-64 radiopharmaceuticals:  Their copper(II) 
complexes have been shown to be of exceptional kinetic inertness in aqueous solutions 
(Woodin et al., 2005).  The half-life for acid decomplexation of Cu(II)-CB-TE2A in        
5 M HCl at 90 °C was 155 h, which is approximately three orders of magnitude more 
inert than CB-cyclam and cyclam.  CB-TE2A compares favorably with the sarcophagine 
copper complex diamSar (Table 6), and both the cross-bridged cyclam backbone as well 
as two enveloping carboxymethyl arms are required for this unusual inertness (Wadas    
et al., 2007). 
 
Table 6:  Pseudo-first order half lives of the Cu(II) complexes (Wadas et al., 2007). 
 CB-TE2A diamSar CB-cyclam TETA DOTA Cyclam 
5 M HCl, 90 °C 155 h 40 h 11.7 min 4.6 min <3 min <3 min 
12 M HCl, 90 °C 1.6 h <3 min <3 min <3 min <3 min <3 min 
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Cyclic voltammetric studies of the Cu(II) complexes of several 
tetraazamacrocyclic complexes revealed that Cu(II)-CB-TE2A is not reduced in            
0.1 N sodium acetate until a negative potential of E = –1.07 V (vs. Ag/AgCl), and that 
this reduction is quasi-reversible, unlike with Cu(II)-DOTA, Cu(II)-TETA, and             
Cu(II)-diamSar (Woodin et al., 2005).  This suggests that the copper complex of the 
cross-bridged cyclam is electrochemically stable, and thus reduction of Cu(II)-CB-TE2A 
to Cu(I)-CB-TE2A in vivo does not necessarily result in copper dissociation.  Fig. 7 
shows the crystal structures of the copper(II) complexes of DOTA and TETA, and their 
cross-bridged analogues. 
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Fig. 7:  Crystal structures of copper(II) complexes of tetraazamacroheterocyclic ligands 
(Riesen et al., 1986, Riesen et al., 1988, Wong et al., 2000, Sun et al., 2002). 
 
Biological studies with 
64
Cu-CB-TE2A confirmed the stability of this complex.  
There was no dissociation of copper-64 in rat serum out to 24 h, and biodistribution 
studies showed rapid clearance from the blood, liver and kidney (Sun et al., 2002).  
Metabolism studies in rats showed that cross-bridged ligands are less susceptible to 
transchelation than their analogues that lack the bridge (Boswell et al., 2004, Boswell et 
al., 2005).  When cross-bridged chelators are covalently linked to a biomolecule via one 
of the two carboxymethyl groups, this group is not available anymore for the 
complexation of copper.  Thus, there were initial concerns that this group of chelators 
will lose their exceptional kinetic inertness to copper(II) loss, and be more susceptible to 
copper(II) reduction when linked to a targeting moiety.  However, studies with the 
somatostatin analogue 
64
Cu-CB-TE2A-Y3-TATE (Sprague et al., 2004) confirmed that 
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CB-TE2A retains its superior copper chelation characteristics even after it its linked to a 
peptide via one of its carboxymethyl arms.  64Cu-CB-TE2A-Y3-TATE was found to have 
a greater affinity for somatostatin-positive tissues compared to its TETA analogue.  As 
accumulation in the blood, the liver, and at earlier time points, the kidney, was lower for 
64
Cu-CB-TE2A-Y3-TATE, it can be assumed that the cross-bridged compound is more 
resistant to transchelation that 
64
Cu-TETA-Y3-TATE. 
 
  In summary, copper is an important trace element in all biological systems, 
mainly due to its role in copper redox enzymes.  Unbound copper ions are cytotoxic, and 
therefore metal transporters and copper chaperone proteins form complexes with copper 
ions and deliver them to their respective targets within the body or inside cells.  
Radioisotopes of copper have played an important role in elucidating these processes. 
More recently, they have been examined for their usefulness in the molecular imaging 
and targeted radiotherapy of cancer.  Copper-64, with its half-life of 12.7 h and three 
decay modes, has the widest range of applicability of the various instable copper 
isotopes.  The most prominent use of copper-64 in targeted radiotherapy and PET 
imaging of tumors over the past few decades involved copper-64-labeled somatostatin 
analogues to target the somatostatin receptors.  Radiolabeling of monoclonal antibodies 
constitutes another important application.  Copper-64, like all radiometals used in nuclear 
medicine, must be connected to the pharmaceutical via a bifunctional chelator, and cross-
bridged heteromacrocycles have shown excellent kinetic and thermodynamic stability as 
well as pharmacokinetics.  The aspects of optimizing copper BFCs, subcellular 
localization of copper, and the targeting of cell receptors with copper-labeled 
somatostatin analogues and a monoclonal antibody against the epidermal growth factor 
receptor (EGFR) have been addressed in this study.  
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2. RESULTS 
 
2.1 COPPER-64-LABELED SOMATOSTATIN ANALOGUES 
 
2.1.1 Introduction – somatostatin and cancer 
 
Somatostatin is a neuropeptide discovered as an inhibitor of growth hormone 
release from the pituitary gland in 1973 (Brazeau et al., 1973, Guillemin, 1978).  Many 
other functions have been discovered since, including the inhibition of the endocrine 
secretion of thyroid-stimulating hormone, thyrotrophin-releasing hormone, 
corticotrophin-releasing hormone, gastrin, insulin, glucagon, chylecystokinin, vasoactive 
intestinal peptide (VIP) and secretin, the inhibition of exocrine secretion in the stomach, 
the pancreas, and the intestines, and the inhibition of intestinal motility, absorption of 
nutrients and ions and vascular contractility (Froidevaux and Eberle, 2002, Weckbecker 
et al., 2003).  Somatostatins are produced by endocrine, gastrointestinal, immune, 
neuronal cells, and in certain tumors, and there are three active forms:  somatostatin-14, 
which consists of 14 amino acids and is thought to function primarily as a neuropeptide;  
somatostatin-28, containing the somatostatin-14 sequence plus 14 additional amino acids 
on the N-terminus, which primarily acts as a circulating hormone; and the recently 
discovered cortistatin-14, which has 11 amino acids in common with somatostatin-14 
(Guillermet-Guibert et al., 2005).  The peptide sequences of the native somatostatins are 
shown in Fig. 8. 
There are five somatostatin receptors (SSTr1–5) which exhibit a high degree of 
sequence similarity (39–57%) and are encoded by five different genes on five different 
chromosomes.  Only the gene for SSTr2 possesses an intron and can be spliced into one 
of two isoforms, SSTr2A, and the somewhat shorter SSTr2B mainly observed in rats and 
mice (Guillermet-Guibert et al., 2005).  SSTrs are G-protein-coupled receptors (GPCRs) 
located in the cell membrane, and they have seven transmembrane α helices.  All SSTrs 
bind the three naturally occurring ligands with a similarly high affinity in the nanomolar 
range, with the exception of SSTr5, which has a 10-fold higher affinity for
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Fig. 8:  Structures of naturally occurring somatostatins.  The SSTr binding site is identified 
in orange. 
 
somatostatin-28.  There is also an orphan receptor named MrgX2 which is a potential 
somatostatin receptor (Robas et al., 2003). 
 Somatostatin signaling can directly and indirectly inhibit the progression of cancer 
(Table 7).  Somatostatin’s antisecretory activity reduces the secretion of growth factors and 
hormones by endocrine cells as well as the tumor itself.  This is mediated by the inhibition 
of adenylate cyclase via a pertussis toxin-sensitive G-protein (Giα1–3), and the regulation of 
potassium ion channels and voltage-dependent calcium channels.  Secondly, there are 
several mechanisms by which somatostatin can induce cell growth arrest: the stimulation of 
tyrosine phosphatases, the regulation of MAP kinases, the inhibition of a Na
+
-H
+
 exchanger 
(NHE1), the inhibition of neuronal nitric oxide synthase (nNOS), and the restoration of 
functional gap junctions (Guillermet-Guibert et al., 2005). 
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  Somatostatin has also been shown to promote apoptosis by both the cell-extrinsic 
and the cell-intrinsic pathway in normal and tumor cells (Sharma and Srikant, 1998, 
Teijeiro et al., 2002).  Somatostatin and its analogues also indirectly control tumor 
development by hindering angiogenesis, and thus limit the growth and invasion of 
tumors.  This happens by inhibiting the synthesis and the effects of angiogenic factors 
such as platelet-derived growth factor (PDGF), vascular-endothelial growth factor 
(VEGF), insulin-like growth factor 1 (IGF-1), and fibroblast growth factor 2.  One 
possible molecular mechanism is the inhibition of mitogen-activated protein kinase 
(MAPK) and endothelial nitric oxide synthase (eNOS) activity (Florio et al., 2003). 
 
Table 7:  Antiproliferative effects of somatostatin (from Guillermet-Guibert et al., 2005). 
 Effect Receptor 
 
Direct 
effects 
Inhibition of autocrine secretion of growth factors and 
hormones 
SSTr2 
Inhibition of growth-factor induced cell cycle progression SSTr1, 2, 4, 5 
Induction of cell death SSTr2, 3 
 
Indirect 
effects 
Inhibition of endocrine secretion of growth factor and 
trophic hormones 
SSTr1, 2, 5 
Inhibition of angiogenesis SSTr2, 3 
Modulation of immune system ? 
 
  
This broad spectrum of anti-proliferative effects has led to the evaluation of 
somatostatin as a cancer therapy agent.  However, the native hormone contains at least 
five sites prone to enzymatic degradation (Fig. 9).  Consequently, the biological half-life 
of somatostatin is in the range of only a few minutes, and therefore, it cannot be used 
efficiently as a pharmaceutical.  Amino acids 7–10, including the cleavage-susceptible 
Trp
8–Lys9 bond, have been identified as critical for somatostatin binding and activity by 
the systematic deletion of every amino acid residue, and via an Ala scan (Marbach et al., 
1988), which substitutes every residue by alanine.  The replacement of Trp8 by its          
D-isomer  rendered   the   peptide   resistant   to   endopeptidases  and  even  increased  its 
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Fig. 9:  Somatostatin-14 and important peptidic somatostatin agonists. Peptide bonds 
prone to enzymatic degradation in somatostatin-14 are identified by arrows. SSTr 
binding sites are indicated in orange. Modified from Froidevaux and Eberle (2002). 
 
biological potency.  The Phe
7–D-Trp8–Lys9–Thr10 sequence is the basis for all peptidic 
somatostatin analogues (Fig. 9). 
Octreotide (SMS-201-995), which contains a C-terminal amino alcohol, was 
identified in 1982 (Bauer et al., 1982) and has a biological half-life of 80–100 minutes 
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while being a 45–70 times more potent inhibitor of growth hormone secretion than native 
somatostatin.  This analogue has a high binding affinity for SSTr2, a lower affinity for 
SSTr3 and SSTr5, and it does not bind to SSTr1 and SSTr4 (Reubi et al., 2000b).  
Octreotide is now being used routinely in the clinic together with two other cyclic 
octapeptide analogues (Fig. 9), vapreotide (RC-160) and lanreotide (BIM-23014), for the 
treatment of carcinoid tumors, endocrine pancreatic tumors, and pituitary tumors 
(Froidevaux and Eberle, 2002).  Therapy consists of either subcutaneous administration 
two or three times a day, or of continuous infusion of peptides for 14–30 days.  Side 
effects are rather mild and include nausea, transient abdominal cramps, flatulence, and 
diarrhea (Froidevaux and Eberle, 2002).  Octreotide treatment resulted in a substantial 
improvement of hormonal symptoms (flushing, diarrhea, cardiac vascular lesions) in 
more than 90% of patients with carcinoid tumors, however, reduction of tumor size was 
noted in <10% of patients (Gorden et al., 1989).  Octreotide is also used to control 
hormonal hypersecretion associated with endocrine pancreatic tumors such as 
insulinomas, gastrinomas, VIP-omas, glucagonomas, and somatostatinomas (Froidevaux 
and Eberle, 2002).  Symptomatic and biochemical improvements occur in >80% of 
patients with VIP-omas, >50% of patients with insulinomas, and >90% of patients with 
gastrinomas (Maton, 1989).  Octreotide is also used to reduce hormone hypersecretion in 
pituitary adenomas which cannot be removed surgically.  In half of the patients, tumor 
size is reduced by >20% and growth hormone and IGF-1 secretion is reduced 
permanently, i.e. the tumor does not develop resistance against octreotide.  In all other 
cancers mentioned before, this escape phenomenon is a serious caveat of octreotide 
therapy:  eventually, all patients escape from somatostatin analogue therapy with regard 
to tumor growth and hormone hypersecretion (Eriksson and Oberg, 1999).  The average 
duration of tumor growth control is 8–16 months.  Possible explanations for the escape 
phenomenon include down-regulation of SSTrs, desensitization, or selection of rapidly 
growing clones lacking SSTrs (Froidevaux and Eberle, 2002).  Recently, octreotide has 
been modified to yield Y3-octreotide, octreotate (TATE), and Y3-octreotate (Y3-TATE).  
These new somatostatin analogues have been used extensively for the study of 
somatostatin-based radiopharmaceuticals.  They differ somewhat in their binding 
affinities to the various SSTr subtypes (Reubi et al., 2000b), and have shown excellent 
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uptake in SSTr-expressing tissues (Froidevaux and Eberle, 2002).  Y3-octreotide was 
modified by replacing Phe
3
 of octreotide with a tyrosine residue to increase the 
hydrophilicity of the peptide for improved renal clearance.  In addition, the phenylalanine 
residue can be used for dual labeling with iodine-125 for potential therapy applications 
(Heppeler et al., 1999).  Y3-TATE-based somatostatin analogues have an approximately 
10-fold higher affinity for SSTr2, whereas their affinity to SSTr3 and SSTr5 were found 
to be lower (Reubi et al., 2000b). 
Peptide analogues of somatostatin have been labeled with a variety of 
radionuclides, including isotopes for gamma scintigraphy and PET imaging, as well as   
β– emitters for peptide receptor radionuclide therapy applications.  123I-Y3-octreotide was 
the first radiolabeled somatostatin analogue used for external imaging (Krenning et al., 
1989).  Tumors could be visualized, however, dehalogenation and unspecific uptake were 
a major problem.  Somatostatin analogues labeled with iodine-123, iodine-125, and 
iodine-131 were synthesized, but rapid clearance from the tumor, and uptake in the liver, 
the thyroid, and the abdomen remained problematic (Froidevaux and Eberle, 2002, Li et 
al., 2005a).  The positron-emitting radiohalogens fluorine-18 and bromine-76 have also 
been used to label somatostatin analogues,  but high uptake in liver and intestines due to 
the compounds’ lipophilicity have so far prevented clinical use (Li et al., 2005a). 
Most somatostatin radiopharmaceuticals contain a bifunctional chelator (BFC) in 
order to incorporate a radiometal, and a list of these agents is given in Table 8.          
111
In-DTPA-octreotide (OctreoScan
®
) was the first such compound explored in patients 
and approved for clinical use in the United States and Europe (Bakker et al., 1991a, 
Bakker et al., 1991b).  It is now commercially available and routinely used to image 
SSTr-expressing neuroendocrine tumors.  The introduction of the BFC DOTA broadened 
the range of radioisotopes that could be incorporated, and some of the radiometal-labeled 
DOTA-conjugated somatostatin analogues had a more favorable biodistribution than 
111
In-DTPA-octreotide in both animal models and patients and could potentially be used 
for the targeted radiotherapy of cancer (Froidevaux and Eberle, 2002).  Three 
radioisotopes of gallium (the positron emitters gallium-66 and gallium-68, and the           
gamma emitter gallium-67) have been incorporated into DOTA-Y3-octreotide.  The three 
compounds displayed a similarly high tumor uptake, rapid blood clearance, and low 
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kidney accumulation (Ugur et al., 2002), with the fastest blood clearance and lowest 
kidney accumulation being found with 
66
Ga-DOTA-Y3-octreotide.  A recent study 
reported even better pharmacokinetics of radiogallium-labeled DOTA-conjugated 
somatostatin analogues using 1-Nal
3
-octreotide (1-Nal = 1-Naphthylalanine) and         
Y3-TATE (Antunes et al., 2007).  Two yttrium isotopes have been incorporated into 
somatostatin analogues: Yttrium-90 is a pure β– emitter and thus not suitable for SPECT 
or PET, but it is highly advantageous for cancer therapy.  The pharmacokinetics and 
dosimetry of yttrium-labeled somatostatin analogues have been established using the PET 
tracer 
86
Y-DOTA-Y3-octreotide (Jamar et al., 2003). 
 
Table 8:  Somatostatin analogues labeled with radiometals (includes information from 
Froidevaux and Eberle, 2002). 
Chelator SST analogue Radiometal References 
DTPA Octreotide 
111
In Bakker et al. (1991b), Krenning et al. 
(1993), Wang et al. (2003) 
86
Y Wester et al. (1997) 
Y3-octreotide, 
Y3-TATE 
111
In de Jong et al. (1998) 
Vapreotide 
111
In Breeman et al. (1994) 
DOTA Octreotide 
111
In, 
90
Y Froidevaux et al. (2000) 
67
Ga Froidevaux et al. (2002b) 
TATE 
86
Y
 Jamar et al. (2003) 
111
In
 Forrer et al. (2004) 
177
Lu
 Kaltsas et al. (2005) 
Y3-TATE 
177
Lu de Jong et al. (2001), Kwekkeboom et al. 
(2001), Lewis et al. (2001b), Kwekkeboom 
et al. (2003), Valkema et al. (2005) 
64
Cu, 
90
Y
 Lewis et al. (2000) 
67
Ga, 
111
In
 Froidevaux et al. (2002b) 
68
Ga
 Kowalski et al. (2003) 
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Table 8 continued. 
Chelator SST analogue Radiometal References 
DOTA Y3-octreotide 64Cu Lewis et al. (2000) 
111
In
 de Jong et al.  (1998), Froidevaux et al. 
(2000), Forrer et al. (2004) 
90
Y
 Otte et al. (1999), Froidevaux et al. (2000), 
Lewis et al. (2000), Breeman et al. (2004), 
Meier et al. (2004), Pless et al. (2004), 
Kaltsas et al. (2005), Ferrari et al. (2006) 
67
Ga
 Froidevaux et al. (2002b), Ugur et al. 
(2002) 
68
Ga
 Henze et al. (2001), Ugur et al. (2002) 
66
Ga
 Ugur et al. (2002) 
86
Y
 Rosch et al. (1999) 
177
Lu
 Forrer et al. (2005), Nayak et al. (2005) 
213
Bi
 Nayak et al. (2005) 
Vapreotide 111In, 
90
Y Froidevaux et al. (2000) 
Lanreotide 111In Virgolini et al. (1998), Froidevaux et al. 
(2000) 
90
Y
 Froidevaux et al. (2000) 
TETA Octreotide 64Cu Anderson et al. (1995), Lewis et al. (1999c), 
Anderson et al. (2001), Wang et al. (2003), 
Parry et al. (2007) 
Y3-TATE 64Cu
 Sprague et al. (2004), Eiblmaier et al. 
(2007) 
Octreotate, Y3-
octreotide, Y3-
TATE 
64
Cu Lewis et al. (1999c) 
CB-
TE2A 
Y3-TATE 64Cu
 Sprague et al. (2004), Eiblmaier et al. 
(2007) 
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64
Cu-DOTA-labeled somatostatin analogues have been synthesized and evaluated 
(Lewis et al., 2000), however, as discussed above, the chelator TETA has a much higher 
specificity for binding copper and is more stable in vitro and in vivo.  64Cu-TETA-
octreotide was synthesized in 1995 and showed high affinity for SSTr both in vitro and  
in vivo (Anderson et al., 1995).  It was excreted primarily through the kidneys and had 
low liver uptake.  This compound was later evaluated as a PET imaging agent for 
neuroendocrine tumors in eight patients, and it detected more SSTr-positive lesions than 
OctreoScan
®
 in two of these patients (Anderson et al., 2001).  A comparative study 
investigated a series of 
64
Cu-TETA-labeled somatostatin analogues with the goal to 
optimize the peptide portion of the radiopharmaceutical for target tissue uptake and non-
target tissue clearance (Lewis et al., 1999c).  Among octreotide, Y3-octreotide, TATE, 
and Y3-TATE, 
64
Cu-TETA-Y3-TATE showed the best targeting and clearance 
properties.  Y3-TATE thus has become a very important candidate for the development 
of new copper-64-labeled somatostatin analogues.  A Y3-TATE-based copper-64 
radiopharmaceutical containing a cross-bridged macrocyclic chelator, 
64
Cu-CB-TE2A-
Y3-TATE, displayed improved target tissue uptake and blood and liver clearance 
compared to 
64
Cu-TETA-octreotide and 
64
Cu-TETA-Y3-TATE (Sprague et al., 2004). 
Copper-64 from 
64
Cu-TETA-octreotide has also been shown to localize to the cell 
nucleus of tumor cells (Wang et al., 2003).  It is hypothesized that copper-64 dissociates 
from its chelator prior to trafficking to the nucleus.  To gather further support for this 
hypothesis, in studies described here, 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-       
Y3-TATE, which differ in their chelate stability, were compared regarding their receptor 
binding (section 2.1.2.3), and nuclear uptake (section 2.1.3) in the human non-small cell 
lung cancer cell line A427-7, which had been transfected with SSTr2 (Parry et al., 2007). 
Receptor binding of the established somatostatin agonist 
64
Cu-TETA-octreotide was one 
of the methods used to evaluate SSTr2 expression in this new cell line (section 2.1.2.1).  
A possible effect of nuclear transport of somatostatin radiopharmaceuticals on cell killing 
of A427-7 tumor cells was investigated via clonogenic survival assays and cellular 
dosimetry (section 2.1.4).  As the in vivo properties of copper-64-labeled somatostatin 
analogues are still not optimal, Y3-TATE has been coupled to a series of new cross-
bridged macrocyclic chelators, and two of them will be discussed in section 2.1.2.2. 
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Thus far, research has focused on the use of somatostatin analogues that act as 
agonists, like octreotide, Y3-octreotide, or Y3-TATE.  After binding to the somatostatin 
receptor, agonists trigger a signal transduction cascade and are rapidly internalized 
(Weckbecker et al., 2003).  Somatostatin antagonists also display a high affinity for their 
respective receptors, but they do not internalize or induce signal transduction.  They even 
inhibit signal transduction when additional agonists are present.  It is mostly due to their 
lack of internalization that they have not been intensely researched as imaging and 
therapy agents for somatostatin-positive tumors, because uptake into the tumor cells has 
been viewed as necessary in order to accumulate enough activity to visualize the lesion or 
deliver doses high enough to damage the tumor.  Recently, the antagonists 
111
In-DOTA-
sst3-ODN-8 (with a high affinity for SSTr3), and 
111
In-DOTA-sst2-ANT (with a high 
affinity for SSTr2) have been tested as tumor targeting agents (Ginj et al., 2006).  
Biodistributions in HEK-sst3 and HEK-sst2 tumor-bearing nude mice resulted in much 
higher tumor uptake and tumor-to-non-target organ ratios compared to the established 
somatostatin agonists 
111
In-DOTA-NOC and 
111
In-DTPA-TATE.  In this study, sst2-ANT 
was conjugated to the optimized copper chelator CB-TE2A, and 
64
Cu-CB-TE2A-       
sst2-ANT was investigated as a cancer imaging agent (section 2.1.5). 
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2.1.2 Receptor binding of somatostatin agonists 
 
Receptor binding studies are a well-established first step in the characterization of 
a new pharmaceutical or a new cell line for research.  The binding affinity of new drugs 
can be compared with the affinity of the currently used standard, and only equal or better 
candidates will advance to clinical trials.  New cell lines are examined for their maximum 
receptor densities present on the cell membrane, which is necessary to determine if this 
specific cell line can be used as a model system.  There are various methods for acquiring 
receptor binding data, and many ways of analyzing them.  They all provide information 
on the progressive saturation of receptors by the ligand of interest (Klotz, 1983).  If the 
ligand is bound by a receptor with only one binding site, the hyperbolic relationship 
derived by Langmuir for equilibrium adsorption and by Michaelis and Menten for 
enzyme velocities can be used to describe ligand binding 
 
 
 
with [RL] being the concentration of the receptor-ligand complex, which is also the 
concentration of bound ligand, [L] being the concentration of free ligand, Bmax being the 
maximum receptor density, and Kd being the dissociation constant, often simply called 
binding constant.  Four assumptions must be fulfilled to be able to use this simple model: 
 
1) The reaction must be at equilibrium, i.e. at the time of measurement, the 
rates of binding and dissociation of ligand must be equal. 
2) There must be no ligand depletion, i.e. >90% of added ligand must not be 
bound to the receptor (Goldstein and Barrett, 1987). 
3) Specific binding to the cell surface receptor should be significantly higher 
than unspecific binding to any component of the test system. 
4) In order to calculate the Bmax with confidence, specific binding must be 
measured up to a concentration at which it reaches a plateau. 
 
These assumptions are often violated even in published receptor binding studies.  
As was pointed out by Klotz (1982, 1983), using a Scatchard plot to linearize binding 
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data is a very common cause to violate assumption #4.  Scatchard plots can be used as a 
sole method for calculating binding parameters when every binding site is identical in 
nature and has the same affinity for the ligand.  In most cases, saturation binding curves 
allow for a more precise determination of binding parameters.  In this study, saturation 
binding curves were acquired, and supplemented by Scatchard plots whenever possible. 
Competitive binding curves, which are more prone to errors due to ligand 
depletion and often cannot be carried out at concentration extremes necessary to ensure 
adequate curve fitting (Goldstein and Barrett, 1987), were acquired when two 
radiopharmaceuticals were compared to a reference drug.  The equation used for 
competitive binding was 
 
 
 
with [B] being the amount of radiotracer bound, [L] being the total concentration of 
radiotracer and competitor, Total being the activity measured when no competitor is 
present (total binding, the top plateau), NS being the activity measured at very high 
competitor concentrations (and thus unspecific binding, or the bottom plateau), and IC50 
being the concentration at which 50% of specific binding has been replaced by 
competitor. 
 Unless mentioned otherwise, receptor binding experiments were carried out using 
the Millipore Multiscreen assay system in 96-well filtration plates, which has been 
evaluated as a practical, semiautomated approach to evaluate binding to SSTr2 (Birzin 
and Rohrer, 2002). 
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2.1.2.1 64Cu-TETA-octreotide 
 
Saturation receptor binding of the well-characterized somatostatin analogue   
64
Cu-TETA-octreotide was utilized as one of several methods to characterize clones of 
the human non-small cell lung carcinoma cell line A427 stably transfected with SSTr2 
(Parry et al., 2007).  These cells were the first example of clones of a single human cell 
line that stably express various levels of SSTr2.  Thus far, most studies on somatostatin 
analogues have been performed with the rat pancreatic cell lines AR42J and CA20948 
(e.g. Lewis et al., 1999a, Schottelius et al., 2004, Capello et al., 2005).  A427 clones 
expressing various levels of human SSTr2 could be useful tools for the evaluation of 
potential imaging agents, or dose responds of therapeutic agents. 
TETA-octreotide was labeled with copper-64 for receptor binding experiments as 
previously described (Anderson et al., 1995).  Specific activity was 0.50 mCi/μg, and 
radiochemical purity was >97%.  Receptor binding data is most often presented in the 
literature as a hyperbolic binding curve, and a transformation to a Scatchard plot is shown 
as an inset.  In order to illustrate the data acquisition process in this first example, total 
binding and unspecific binding of three A427 clones are shown in Fig. 10.  Total binding 
was measured by incubating isolated tumor cell membranes with a defined mass of 
membrane protein (20 μg, 20 μg, and 5 μg for clones #2, #5, and #7, respectively) with 
increasing concentrations of 
64
Cu-TETA-octreotide.  Unspecific binding was measured in 
the presence of 200 nM TETA-octreotide to block SSTr2 receptors.  Ideally, unspecific 
binding is proportional to ligand concentration, and should be parallel to the curve for 
total binding at higher concentrations, where specific binding has leveled out. 
 
 
Fig. 10:  Total (full symbols) and unspecific binding (open symbols) of 64Cu-TETA-
octreotide to A427 cell membranes (■ = clone #7, ▲ = clone #2, ● = clone #5). 
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 After subtraction of unspecific binding from total binding, specific binding results 
in hyperbolic curves as shown in Fig. 11.  In this representative experiment, clone #7 had 
a maximum receptor density Bmax = 9,800 ± 200 fmol/mg, clone #2 was measured at   
Bmax = 3,000 ± 40 fmol/mg, and clone #5 at Bmax = 1,400 ± 30 fmol/mg.  The Kd values 
were very similar among the three clones, which was to be expected for the interaction of 
one ligand and one receptor: 1.5 ± 0.1 nM for clone #7, 2.4 ± 0.1 nM for clone #2, and 
3.3 ± 0.2 nM for clone #5. 
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Fig. 11:  Specific binding of 64Cu-TETA-octreotide to three A427 human non-small cell 
lung carcinoma cell line clones (■ = clone #7, ▲ = clone #2, ● = clone #5). 
 
Fig. 12 illustrates the data from Fig. 11 transformed to a Scatchard plot. The 
curves for all three clones are linear (r
2
 = 0.97, 0.98, and 0.97 for clones #7, #2, and #5, 
respectively).  Kd values derived from this Scatchard plot (slope = –1/Kd) are close to the 
values obtained from the hyperbolic curve (1.2, 2.7, and 3.4 nM, respectively).             
Bmax values can also be obtained from the Scatchard plot (they correspond to the             
x-intercept).  In this case, the x-intercepts are in nM and have to be retransformed to 
fmol/mg.  As parameters obtained from Scatchard plots are generally less accurate than 
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from the hyperbolic binding curve (Klotz, 1982, Klotz, 1983), Scatchard plots were used 
here primarily to estimate ligand depletion and to confirm the adequateness of assuming 
one binding site per receptor, which should result in linear Scatchard curves.  Ligand 
depletion under 10% was almost completely achieved in this experiment.  Only at lower 
ligand concentrations with clone #7 did the Bound/Free ratio reach 16%.  It should be 
pointed out that the Bound/Free ratio overestimates ligand depletion, which is defined as 
Bound/Total <10%. 
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Fig. 12:  Scatchard plots of receptor binding of 64Cu-TETA-octreotide to three A427 
human non-small cell lung carcinoma cell line clones (■= clone #7, ▲ = clone #2,       
● = clone #5). 
 
A427 stable clones have also been characterized by fluorescence-activated cell 
sorting (FACS) assays (Jesse Parry, Ph. D., and Buck Rogers, Ph. D., WUSM) and by 
biodistribution and microPET imaging (Laura A. Meyer, WUSM).  Table 9 compares 
results from FACS and receptor binding with 
64
Cu-TETA-octreotide.  Transfection has 
produced three clones that stably express the SSTr2 in the order clone #7 > clone #2 > 
clone #5.  SSTr2 could not be detected in clone #4 which served as a negative control 
(Parry et al., 2007). 
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Table 9:  Fluorescence-activated cell sorting (FACS, N = 4) and saturation binding 
assays (two experiments performed in quadruplicate) of SSTr2 expression in A427 stable 
clones (from Parry et al., 2007). 
Clone FACS analysis (MFU) Binding assay (fmol/mg) 
2 15.4 ± 5.7 2,750 ± 250 
4 0.5 ± 0.4 NA 
5 1.9 ± 0.4 1,300 ± 150 
7 40.9 ± 6.5 7,000 ± 2,800 
 
These new clones of a human carcinoma cell line stably expressing various levels 
of human SSTr2 will be valuable for the evaluation of new somatostatin analogues.  In 
this study, they have been used to compare nuclear localization of copper-64 from two 
copper-64-labeled Y3-TATE conjugates (section 2.1.3). 
 
 
 
2.1.2.2  64Cu-BS353 and 64Cu-BS354 
 
The targeting, uptake and imaging properties of 
64
Cu-CB-TE2A-Y3-TATE and 
64
Cu-TETA-Y3-TATE were evaluated by Sprague et al. (2004) in normal rats bearing 
SSTr2-positive AR42J pancreatic tumors.  
64
Cu-CB-TE2A-Y3-TATE demonstrated 
superior liver and blood clearance properties when compared to 
64
Cu-TETA-Y3-TATE 
and led to improved tumor detection sensitivity and higher tumor uptake.  While liver and 
blood clearance of 
64
Cu-CB-TE2A-Y3-TATE were very good, kidney clearance was far 
from optimal after 24 h.  One explanation for this could be the net positive charge of the 
radiopharmaceutical.  Changing the net charge of 
64
Cu-CB-TE2A-Y3-TATE from 
positive to either neutral or negative may alter the biodistribution characteristics of this 
peptide chelator conjugate and reduce the radiation dose to the kidney.  Positively 
charged complexes clear from the kidney slowly, as has been observed previously with 
111
In-DTPA-peptide conjugates, as well as, copper-64-labeled azamacrocycles (Rogers et 
al., 1996, Akizawa et al., 1998, Jones-Wilson et al., 1998, Akizawa et al., 2001b, Akizawa 
RESULTS 
 40 
et al., 2001a).  New derivatives of CB-TE2A-Y3-TATE incorporate a benzamide 
(BS353) or a sulfonamide (BS354) linker between CB-TE2A and Y3-TATE (Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These linkers were designed to contain protons capable of ionization at 
physiological pH, which would alter the charge on the radiopharmaceutical from +1 to 
neutral, and this was envisioned to change the biodistribution properties of these 
conjugates, and reduce the radiation dose delivered to the kidney. 
64
Cu-BS354 was obtained at a purity of >95% and a specific activity of             
0.3 mCi/µg (Thaddeus J. Wadas, Ph. D., WUSM).  A single product peak was observed 
by radio-TLC (Rf = 0.43) and radio-HPLC (retention time = 14 min).  A single product 
peak (Rf = 0.50) was observed by radio-TLC and radio-HPLC (retention time = 9 min) 
for 
64
Cu-BS353, which was synthesized >95 % pure at a specific activity of 0.3 mCi/µg 
(Thaddeus J. Wadas, Ph. D., WUSM).  AR42J cell membranes with a mass of 25 g of 
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Fig. 13:  Structures of CB-TE2A-Y3-TATE and its derivatives BS353 and BS354. 
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protein per well were used to determine the binding parameters of BS353 and BS354.   
Kd (0.60 ± 0.07 nM) and Bmax (1400 ± 40 fmol/mg) values of 
64
Cu-BS354 were very 
similar to the parameters published for 
64
Cu-CB-TE2A-Y3-TATE (Fig. 14, Table 10, 
Sprague et al., 2004).  For competitive binding assays, 64Cu-CB-TE2A-Y3-TATE     
(0.03 nM)
 
was displaced with increasing concentrations (0.02–1 μM) of natCu-BS353 or 
nat
Cu-BS354.  The IC50 values for 
nat
Cu-BS353 and 
nat
Cu-BS354 were determined to be 
2.9 nM (2.56–3.30 nM; 95% confidence interval, CI) and 1.93 nM (1.69–2.19 nM;     
95% CI), respectively.  The displacement curves are depicted in Fig. 15. 
 
 
Table 10:  Summary of binding parameters for Cu-BS353 and Cu-BS354. Data for      
Cu-CB-TE2A-Y3-TATE (Sprague et al., 2004) are included for comparison. For data 
derived from competitive binding, 95% CI are given in parentheses. 
 Cu-BS353 Cu-BS354 Cu-CB-TE2A-Y3-TATE 
Kd (nM) ND 0.60 ± 0.07 1.7 (1.2–2.4) 
Bmax (fmol/mg) ND 1,400 ± 40 1,596 (1,088–2,103) 
IC50 (nM) 2.9 (2.6–3.3) 1.9 (1.7–2.2) 2.3 (1.7–3.2) 
 
 
 
 
Fig. 14:  Saturation receptor binding of 64Cu-BS354. 
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Fig. 15:  Competitive receptor binding of Cu-BS353 (▲) and Cu-BS354 (■). 
 
 Both radiopharmaceuticals were further evaluated in biodistribution studies 
(Thaddeus J. Wadas, Ph. D., WUSM) and demonstrated high affinity for somatostatin 
receptor positive tissues.  Significant target tissue uptake of these radiopharmaceuticals 
was observed; however, it was lower than that of 
64
Cu-CB-TE2A-Y3-TATE in the same 
tumor model.  Finally, despite the incorporation of ionizable benzamide (BS353) or 
sulfonamide (BS354) linker groups into the radiopharmaceutical design, kidney uptake 
was still elevated after 24 h post-injection, and thus retention of these 
radiopharmaceuticals and/or their metabolites within the kidney remained. 
 
 
 
2.1.2.3 64Cu-TETA-Y3-TATE and 64Cu-CB-TE2A-Y3-TATE 
 
These two Y3-TATE conjugates were chosen to investigate the relationship 
between chelate stability and nuclear localization of copper-64 (section 2.1.3).  Y3-TATE 
has been shown to possess very favorable pharmacokinetics in several studies (Lewis et 
al., 1999c, Sprague et al., 2004).  CB-TE2A was previously shown to be a highly stable 
bifunctional copper chelator (see section 2.1.1) (Boswell et al., 2004, Sprague et al., 
2004).  Radiolabeling with copper-64 produced 64Cu-TETA-Y3-TATE and               
RESULTS 
 43 
64
Cu-CB-TE2A-Y3-TATE with ≥95% radiochemical purity as determined by radio-TLC 
(C18 plate, mobile phase 10% ammonium acetate:methanol = 3:7).  The Rf values for 
these compounds were significantly different (0.79 ± 0.01, N = 6, for 64Cu-TETA-       
Y3-TATE, 0.63 ± 0.01, N = 9, for 64Cu-CB-TE2A-Y3-TATE, Student’s t = 11.51,          
df = 13, P <0.0001). 
Competitive and saturation receptor binding assays were performed to examine 
the interaction of both somatostatin analogues with SSTr2 in transfected A427 clone #7 
(A427-7) cells.  Assays were conducted using isolated A427-7 cell membranes with a 
defined amount of membrane protein (5–30 μg/well).  In competitive receptor binding 
experiments, 
64
Cu-TETA-Y3-TATE (0.070 nM) and 
64
Cu-CB-TE2A-Y3-TATE      
(0.057 nM) were displaced from A427-7 membranes by increasing concentrations of 
nat
Cu-TETA-Y3-TATE and 
nat
Cu-CB-TE2A-Y3-TATE, respectively.  The IC50 values for 
both compounds were not significantly different:  4.87 nM ± 1.11 nM for 
64
Cu-TETA- 
Y3-TATE, and 3.71 nM ± 1.09 nM for 
64
Cu-CB-TE2A-Y3-TATE. 
The binding constants (Kd) were not significantly different (
64
Cu-TETA-          
Y3-TATE: 0.22 nM ± 0.02 nM, N = 3; 64Cu-CB-TE2A-Y3-TATE: 0.61 nM ± 0.24 nM,  
N = 3; P = 0.18), and were found to be in the expected range for Y3-TATE analogues 
(Sprague et al., 2004).  Even though the maximum binding capacities Bmax were not 
significantly different (
64
Cu-TETA-Y3-TATE: 5,440 fmol/mg ± 1,110 fmol/mg, N = 3; 
64
Cu-CB-TE2A-Y3-TATE: 11,400 fmol/mg ± 1,960 fmol/mg, N = 3; P = 0.06), there 
was a clear tendency to higher values for 
64
Cu-CB-TE2A-Y3-TATE.  This phenomenon 
has been observed previously with AR42J cells for these two compounds (Sprague et al., 
2004).  Plots of the competitive and representative saturation binding experiments are 
shown in Fig. 16, and Table 11 summarizes the receptor binding parameters for both 
compounds. 
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Fig. 16:  Competitive (A) and (B) and saturation (C) and (D) receptor binding of      
64Cu-TETA-Y3-TATE (■) and  64Cu-CB-TE2A-Y3-TATE (▲) to A427-7 cell membranes. 
 
 
 
Table 11:  SSTr2 receptor binding parameters for two somatostatin analogues in A427-7 
human non-small cell lung carcinoma cells. 
 IC50 (nM) Kd (nM) Bmax (fmol/mg) 
64
Cu-TETA-Y3-TATE 4.87 ± 1.11 0.22 ± 0.02 5,440 ± 1,110 
64
Cu-CB-TE2A-Y3-TATE 3.71 ± 1.09 0.61 ± 0.24 11,400 ± 1,960 
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2.1.3 Uptake of copper-64 from radiolabeled somatostatin analogues into the cell 
nucleus 
 
When designing a radiopharmaceutical for peptide receptor radiotherapy, one of 
the goals is to maximize damage to the tumor cells.  Irradiating the DNA is an effective 
way to injure and eventually kill cells; thus, a radionuclide that localizes to the cell 
nucleus of a tumor cell potentially enhances the efficacy of the radiopharmaceutical.  
This may be especially true for radionuclides whose ranges in tissues are short.  In the 
case of
 
copper-64, in addition to the emission of β+ and β– particles, there are two Auger 
electrons emitted per decay (840 eV and 6.8 keV), and due to the very restricted range of 
these low energy electrons in biological tissues, nuclear localization of copper-64 could 
increase the probability of cell killing from DNA damage.  Additionally, the 
transmutation process itself (from a copper-64 nucleus to a stable nickel-64 or zinc-64 
nucleus) has been proposed (Apelgot, 1983) and shown (Apelgot et al., 1989) to have 
lethal effects on mammalian cells when occurring in close proximity to DNA molecules, 
because transmutation is accompanied by the release of energy and a change in charge.   
Thus far, chelators have been optimized for high stability to increase uptake in target 
organs and avoid accumulation of the radiometal in non-target tissues.  However, for 
targeted radiotherapy with copper-64-labeled tumor-targeting peptides or monoclonal 
antibodies, the use of a chelator that complexes copper-64 less stably after uptake into the 
cell could indeed prove to be more efficacious than using a chelator that complexes the 
copper radionuclide more stably.  It has been demonstrated that copper-64 from        
64
Cu-TETA-octreotide localizes to the nucleus of AR42J rat pancreatic tumor cells, and it 
is hypothesized that dissociation of the radiometal from the chelator is the first step in 
this process.  Here, the nuclear localization of copper-64 from two radiopharmaceuticals, 
64
Cu-TETA-Y3-TATE, and 
64
Cu-CB-TE2A-Y3-TATE, was compared.  Y3-TATE-based 
radiopharmaceuticals are highly specific for somatostatin receptor subtype 2, have a 
higher affinity (typically IC50 <2 nM (Reubi et al., 2000b)) and are more rapidly 
internalized into cells expressing this receptor than octreotide-based analogues (Anderson 
et al., 1998, Lewis et al., 1999c).  The two compounds differ substantially with respect to 
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in vivo stability of the copper-64 chelate, and this should have important consequences 
for the translocation of copper from these compounds to the cell nucleus. 
In nuclear localization experiments, A427-7 cells were continuously incubated 
with 
64
Cu-TETA-Y3-TATE or
 64
Cu-CB-TE2A-Y3-TATE.  At various time points, 
medium and cell aliquots were taken.  The remaining cells were used to harvest cell 
nuclei by subcellular fractionation (Wang et al., 2003).  Copper-64 activity in the 
medium, whole cells, and cell nuclei was measured.  Fig. 17 depicts the localization of 
copper-64 from 
64
Cu-TETA-Y3-TATE and
 64
Cu-CB-TE2A-Y3-TATE in A427-7 nuclei 
in % ID/mg.  The yield of nuclei was determined by counting cells with a hemocytometer 
before the start of the protocol and comparing it to cell nucleus counts at the end of the 
experiment.  Typical yields ranged from 94–97 %, so no correction for the yield of nuclei 
was necessary. 
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Fig. 17:  Nuclear localization of 64Cu-TETA-Y3-TATE (■) and 64Cu-CB-TE2A-            
Y3-TATE (▲) in A427-7 cells. 
 
The rate of internalization differed substantially for the two compounds (Fig. 18, 
Sprague et al., 2004), with 64Cu-CB-TE2A-Y3-TATE entering the cells faster than    
64
Cu-TETA-Y3-TATE.  Therefore, more 
64
Cu-CB-TE2A-Y3-TATE was present inside 
cells and available for trafficking to the nucleus. 
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Fig. 18:  Internalization of 64Cu-TETA-Y3-TATE (■) and 64Cu-CB-TE2A-Y3-TATE (▲) 
in A427-7 cells. 
 
To correct for the increased internalization of 
64
Cu-CB-TE2A-Y3-TATE the data 
are plotted as percentage of cell-associated activity (% CAA), rather than % ID, in       
Fig. 19, which corresponds to the ratio of activity in the nuclear fraction and in whole   
A427-7 cells, multiplied by 100.  This standardization resulted in more consistent data, 
especially for 
64
Cu-CB-TE2A-Y3-TATE at earlier time points.  Fig. 17–19 are 
summaries of five independent experiments with five different copper-64 productions. 
Incubation with 
64
Cu-CB-TE2A-Y3-TATE did not lead to accumulation of 
copper-64 in the nuclear fraction (1.3 ± 0.1% CAA at 24 h), and was low throughout the 
entire time course (Fig. 19).  In contrast, there was considerable uptake of 
64
Cu-TETA-
Y3-TATE in nuclei of A427-7 cells (9.4 ± 1.7% CAA at 24 h).  This nuclear uptake only 
slightly surpassed 
64
Cu-CB-TE2A-Y3-TATE at early time points, but increased 
substantially after the first 12 h of the experiment. 
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Fig. 19:  Nuclear localization of 64Cu-TETA-Y3-TATE (■) and 64Cu-CB-TE2A-            
Y3-TATE (▲) in A427-7 cells in % cell-associated activity. 
 
The nuclear uptake experiment with
 64
Cu-TETA-Y3-TATE was repeated under 
similar conditions, the only difference being a change to fresh medium after 4 h of 
incubation time (Fig. 20), when internalization of the radiopharmaceutical had peaked 
(see Fig. 18).  Nonetheless, transport of copper-64 to the cell nucleus continued, and was 
comparable to the continuous uptake experiment.  
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Fig. 20:  Nuclear localization of 64Cu-TETA-Y3-TATE (■) in A427-7 cells in                  
% cell-associated activity with a 20-h efflux period.  The horizontal line at 4 h indicates 
the change to fresh medium. 
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Samples of isolated nuclei were treated with fluorescein isothiocyanate (FITC, 
excitation at λ = 450–490 nm, emission at λ = 515–565 nm), which stains protein, and 
propidium iodide (PI, excitation at λ = 546 nm, emission at λ = 590 nm), which stains 
nucleic acids, to confirm purity.  As previously demonstrated (Wang et al., 2003), no 
visible cellular debris was detected in the nuclear fractions (Fig. 21). 
 
 
Fig. 21:  Isolated A427-7 cell nuclei stained with propidium iodide (PI, red, left) and 
fluorescein isothiocyanate (FITC, green, right). 
 
In conclusion, there was a pronounced difference in nuclear uptake of copper-64 
from the two somatostatin analogues under investigation.  These results are consistent 
with the hypothesis of dissociation of copper-64 from the TETA chelator in 
64
Cu-TETA-
Y3-TATE, but not from CB-TE2A in 
64
Cu-CB-TE2A-Y3-TATE, prior to copper-64 
trafficking to the cell nucleus. 
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2.1.4 Dosimetry of copper-64-labeled somatostatin analogues in A427-7 cells 
 
Dosimetry estimates from internalization and efflux experiments were obtained in 
order to calculate the absorbed dose to A427 cells.  By measuring the activity within cells 
and on the cell surface at various time points and integrating over time, the total activity 
the cells were exposed to during treatment with the radiopharmaceutical can be 
estimated.  The activity A (Ci) can be converted to absorbed dose D (Gy) by a linear 
combination of the radiation dose factor, or dose rate factor, S (using cellular S values for 
copper-64), and the integrated activity A (Goddu et al., 1997): 
 
    
 
As the monitoring of uptake accompanying the nuclear localization studies has 
shown, internalization of 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-Y3-TATE was fast 
and peaked at 2–4 h (see Fig. 18).  Thus, a 4-h internalization period was chosen in order 
to avoid extensive radiation by radiopharmaceuticals remaining in the medium, after 
which the medium containing any non-internalized drug was removed.  Retention and 
efflux of 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-Y3-TATE were monitored for 20 h. 
 
 
 
2.1.4.1 Internalization and efflux profiles 
 
Previous studies have measured uptake of somatostatin analogues utilizing a ratio 
of somatostatin receptor:somatostatin analogue = 10:1, in order to avoid saturation of the 
receptors (Wang et al., 2003).  Since the SSTr2 densities on A427-7 cells have been 
determined (see section 2.1.2.3), the mass of peptide required can be calculated.  In a 
preliminary study, the effect of varying this ratio was investigated using 
64
Cu-TETA-  
Y3-TATE.  500,000 cells per well (0.27 mg protein) had an estimated 1.5 pmol of SSTr2 
(Bmax = 5,440 fmol/mg).  Adding 0.15 pmol of 
64
Cu-TETA-Y3-TATE would establish a 
ratio of receptor:ligand = 10:1.  Internalization and efflux profiles were required at a 
slightly higher ratio (30:1, 0.05 pmol of 
64
Cu-TETA-Y3-TATE), and a slightly lower 
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ratio (6:1, 0.26 pmol of 
64
Cu-TETA-Y3-TATE).  As the delivered dose at these ratios 
was predicted to be low, one high-dosage treatment was also included (1:5, 7.5 pmol 
64
Cu-TETA-Y3-TATE).  In this case, the amount of ligand was 5-fold higher than the 
amount of receptor.  Internalization profiles are shown in Fig. 22. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22:  Internalization (■) of 0.05 pmol (A), 0.26 pmol (B), and 7.5 pmol (C) of       
64Cu-TETA-Y3-TATE into A427-7 cells. (▲) depicts the surface-bound fraction. 
 
As was observed in nuclear uptake studies, internalization into cells peaked at, or 
shortly after, 2 h.  There was no receptor overload, since increasing the dose from        
0.05 pmol to 0.26 pmol (a 5-fold increase) resulted in an increase of maximum uptake 
from ~14 fCi/cell to ~80 fCi/cell (a 5-fold increase).  At the highest dose of 7.5 pmol      
(a 150-fold increase), 1500 fCi/cell were internalized (a 107-fold increase).  It is also 
apparent from these profiles that most uptake occurred within the first hour.  Follow-up 
experiments therefore included time points at 10, 20, and 40 min.  At all time points, the 
surface-bound copper-64 activity was very low compared to internalized activity, 
confirming the rapid internalization of somatostatin analogues. 
Retention and efflux of 
64
Cu-TETA-Y3-TATE over the following 20 h is shown 
in Fig. 23.  Copper-64 activities in the medium, on the cell surface and inside cells were 
measured.  There was considerable efflux into the medium at all three concentrations, 
0 1 2 3 4
0.0
2.5
5.0
7.5
10.0
12.5
15.0
Time/h
fC
i/
c
e
ll
0 1 2 3 4
0
10
20
30
40
50
60
70
80
Time/h
fC
i/
c
e
ll
0 1 2 3 4
0
250
500
750
1000
1250
1500
Time/h
fC
i/
c
e
ll
A B C 
RESULTS 
 52 
however, it is worth noting that a large part of the reduction in intracellular activity is due 
to decay of copper-64 (t1/2 = 12.7 h).  Again, the profiles are very similar for all three 
dosages, suggesting that a cell killing experiment with a dose higher than the suggested 
10:1 receptor-to-ligand ratio does not overstimulate SSTr2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The internalization-efflux time course was repeated giving 5 pmol of 
64
Cu-TETA-
Y3-TATE with three different specific activities.  These were achieved by radiolabeling 
TETA-Y3-TATE with copper-64 at a specific activity of 0.41 mCi/μg and diluting the 
final product 1:2 and 1:4 with the unmarked peptide.  Fig. 24 shows that the internalized 
activities are very close to this 1:2:4 ratio at all time points.  As cells do not distinguish 
between cold and radiolabeled analogue, the curve for % ID over time is identical for all 
three activities.  Again, internalization peaked at 2 h.  Panel A shows the combined effect 
of copper-64 decay and efflux, whereas the decrease of activity in cells due to efflux 
alone can be seen in panel B. 
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Fig. 23:  Efflux of copper-64 (●) from A427-7 cells incubated for 4 h with 0.05 pmol (A), 
0.26 pmol (B), and 7.5 pmol (C) of 64Cu-TETA-Y3-TATE. (▲) depicts the surface-bound 
fraction, (■) the remaining activity within cells. 
RESULTS 
 53 
 
Fig. 24:  Internalization and efflux of copper-64 from A427-7 cells incubated for 4 h with 
5 pmol 64Cu-TETA-Y3-TATE with three different specific activities: (■) = 414μCi/μg, 
(▲) = 207 μCi/μg (1:2), (●) = 104 μCi/μg (1:4). Activity-time curves are shown in (A), 
% ID in (B). 
 
The absorbed dose to cells and nuclei from this treatment was very low (see 
section 2.1.4.3).  Therefore a peptide mass of 50 pmol was used to compare the 
internalization and efflux of 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-Y3-TATE    
(Fig. 25), and for cell killing studies.  The amount of 
64
Cu-CB-TE2A-Y3-TATE 
internalized and bound to the surface of A427-7 cells exceeded the amount of surface-
bound 
64
Cu-TETA-Y3-TATE at all time points.  This finding was consistent with the 
higher Bmax measured for 
64
Cu-CB-TE2A-Y3-TATE.  For both compounds, the amount 
of internalized activity peaked at 3 h.  The decrease in activity after the change to fresh 
medium was mostly due to radioactive decay of copper-64, and not to efflux of either 
64
Cu-TETA-Y3-TATE or 
64
Cu-CB-TE2A-Y3-TATE, which can be seen by replotting the 
data as % ID over time (Panel B).  Nuclear uptake data (section 2.1.3) were used to 
estimate the percentage of internalized activity that translocated to A427-7 nuclei.     
Panel C displays copper-64 activities in A427-7 nuclei.  Despite 
64
Cu-CB-TE2A-        
Y3-TATE being more efficiently internalized, the amount of copper-64 from             
64
Cu-TETA-Y3-TATE entering the cell nucleus is similar to that of 
64
Cu-CB-TE2A-   
Y3-TATE at early time points and higher at later time points. 
A B 
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Fig. 25:  Internalization and efflux of 50 pmol of 64Cu-TETA-Y3-TATE (■) and         
64Cu-CB-TE2A-Y3-TATE (▲) in A427-7 cells in kBq (A) and % ID (B). Open symbols 
(□, Δ) depict the surface-bound fraction for each compound. Uptake of both compounds 
into A427-7 cell nuclei is shown in (C). 
 
 
 
2.1.4.2 Dosimetry calculations and conclusions for cell killing 
 
Internalization/efflux data were replotted in dps/cell in order to calculate the 
disintegrations per cell over the course of the experiment, by using the area-under-curve 
integration function of GraphPad Prism.  Cell numbers were estimated from protein mass 
as determined by a bicinchoninic acid (BCA) protein assay.  Several control experiments 
confirmed that there were ~1.9∙106 cells/mg protein for A427-7 cells.  Disintegrations per 
cell were used to calculate the absorbed dose D to the whole cell and to the cell nucleus:  
A427-7 cells were exposed to 0.40 Gy in the case of 
64
Cu-TETA-Y3-TATE, 0.15 Gy of 
which could be partitioned to A427-7 cell nuclei.  With 
64
Cu-CB-TE2A-Y3-TATE, the 
respective values were 1.06 Gy and 0.38 Gy (Fig. 26). 
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Fig. 26:  Absorbed dose to A427-7 cells from 50 pmol 64Cu-TETA-Y3-TATE and       
64Cu-CB-TE2A-Y3-TATE.  Fraction of the dose delivered to nuclei is indicated in black.  
 
The nuclear dose from 
64
Cu-CB-TE2A-Y3-TATE was higher than from         
64
Cu-TETA-Y3-TATE, even though more 
64
Cu-TETA-Y3-TATE was transported to 
A427-7 cell nuclei.  This stems from the substantial contribution of cytosolic activity to 
the nuclear dose (more 
64
Cu-CB-TE2A-Y3-TATE is internalized, see Fig. 25), and from 
the fact that copper-64 from 
64
Cu-TETA-Y3-TATE appeared in the nuclei only later in 
the time course.  Table 12 summarizes the dosimetry calculations for A427-7 cells 
exposed to copper-64-labeled Y3-TATE analogues. 
 
Table 12:  Summary of dosimetry calculations for A427-7 cells exposed to copper-64-
labeled Y3-TATE analogues. 
Conjugate Mass 
(pmol) 
Activity 
(μCi/μg) 
Absorbed dose 
(cells, cGy) 
Absorbed dose 
(nuclei, cGy) 
64
Cu-TETA-Y3-TATE 5 414 28 6 
64
Cu-TETA-Y3-TATE 5 207 14 2 
64
Cu-TETA-Y3-TATE 5 104 3 1 
64
Cu-TETA-Y3-TATE 50 100 40 15 
64
Cu-CB-TE2A-Y3-TATE
 
50 107 106 38 
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There are several reasons for the low absorbed dose values.  First,                  
64
Cu-CB-TE2A-Y3-TATE was labeled with low specific activity (147 μCi/nmol), and 
64
Cu-TETA-Y3-TATE was diluted to the same specific activity in order to make 
comparison possible.  Second, A427-7 cells and nuclei are large (cellular radius: 10 μm, 
nuclear radius: 9 μm), which means the cellular S values for dosimetry calculations were 
low (Goddu et al., 1997).  Third, an external beam irradiation experiment (Buck E. 
Rogers, Ph. D., WUSM) suggested that this cell line is relatively radiation-resistant.  
After exposure to various doses of x-rays, a colony-forming assay was performed and the 
data were fit using the linear-quadratic model for cell survival
2
 (Fig. 27).  These data 
showed that the /  ratio (the dose at which the linear and quadratic components of 
radiation damage are equal) for A427-7 cells was 2.5 and the D10 (the dose required to 
kill 90% of the cells) was 5.6 Gy.  The low /  ratio and the high D10 indicate that this 
cell line is relatively radiation-resistant (Buck E. Rogers, Ph. D., WUSM, personal 
communication). 
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Fig. 27:  Survival of A427-7 cells exposed to various doses of x-rays. 
 
                                                   
2
 The equation for the linear-quadratic model for cell survival S is 
 
 –  
 
   in which the effect E is a linear-quadratic function of the dose D. α and β are parameters. 
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 Treatment of A427-7 cells with external beam irradiation (Fig. 27) at 1 Gy of 
radiation dose, comparable to the dose delivered by 50 pmol of 
64
Cu-CB-TE2A-          
Y3-TATE, killed less than 20% of the cells.  Although cell killing by x-rays and     
copper-64 irradiation could potentially have two very different mechanisms, doses of      
1 Gy or lower were predicted to have a very limited effect on survival of A427-7 cells.  
Indeed, cells exposed to 50 pmol of 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-         
Y3-TATE, under identical conditions as for the internalization-efflux profiles, showed 
high survival rates in a colony-forming assay (plating and colony counting performed by 
Rebecca Andrews, WUSM, Fig. 28).  The highest activity added (6 μCi) corresponded to 
the absorbed dose of 40 and 106 cGy delivered by 
64
Cu-TETA-Y3-TATE and            
64
Cu-CB-TE2A-Y3-TATE, respectively.  Other cells were given 50% and 25% of that 
activity.  All treatments resulted in a cell killing effect, however, it was low (<20%), as 
predicted by the external beam experiment.  The response did not depend on the amount 
of activity delivered. It cannot be attributed to the growth-inhibiting effect of 
somatostatin analogues, as data was standardized to a control treatment with 50 pmol of 
the respective unlabeled Y3-TATE conjugate.  Treatment with unlabeled somatostatin 
analogues (50 pmol) had an additional inhibitory effect on colony formation (reduction of 
8.8 ± 2.3% compared to no treatment), although the difference was not significant          
(P = 0.06, Student’s t = 2.565, df = 4 for TETA-Y3-TATE, P = 0.29, Student’s t = 1.216, 
df = 4 for CB-TE2A-Y3-TATE). 
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Fig. 28:  Survival of A427-7 cells measured by a clonogenic colony-forming assay after 
incubation for 4 h with a copper-64-labeled Y3-TATE conjugate, followed by a 20-h 
efflux period.  Data is standardized to control treatment with 50 pmol of unlabeled 
conjugates. 
 
 
 
 In summary, high doses could not be delivered to A427-7 cells using copper-64-
labeled Y3-TATE conjugates, and thus no significant effect on tumor cell survival was 
observed.  The increased nuclear uptake of copper-64 from 
64
Cu-TETA-Y3-TATE    
(Fig. 19) did not result in a higher absorbed dose to either the cell or the nucleus, as it 
was compensated by higher levels of internalization of 
64
Cu-CB-TE2A-Y3-TATE     
(Fig. 18). 
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2.1.5 The somatostatin antagonist sst2-ANT conjugated to CB-TE2A 
 
Until recently, somatostatin antagonists have not been considered as imaging or 
therapy agents for neuroendocrine tumors, because they do not internalize or function as 
inhibitors of hormone hypersecretion.  sst2-ANT, also called CYN-154806, was the most 
effective of a first series of peptidic somatostatin antagonists published (Bass et al., 
1996), and displays nanomolar affinity for SSTr2 and intermediate affinity for SSTr5.  
sst3-ODN-8 binds selectively and with high affinity to SSTr3, and both antagonists have 
been demonstrated to inhibit somatostatin-induced accumulation of cAMP (Bass et al., 
1996, Reubi et al., 2000a).  The structures of sst2-ANT and sst3-ODN-8 are shown in  
Fig. 29. 
 
 
Fig. 29:  Structures of two somatostatin antagonists.  X =D-Agl8(Me,2-naphthoyl). 
 
Both peptides are derived from octreotide, demonstrating the versatility of the 
octapeptide template.  It has been suggested to treat impaired secretion of growth 
hormone with somatostatin antagonists (Weckbecker et al., 2003), but thus far no such 
pharmaceutical has been developed for clinical use.  Recently, Ginj et al. (2006) have 
shown that 
111
In-DOTA-sst2-ANT and 
111
In-DOTA-sst3-ODN-8 had much higher tumor 
uptake and tumor-to-non-target organ ratios compared to the established somatostatin 
agonists 
111
In-DOTA-NOC and 
111
In-DTPA-TATE in biodistributions of HEK-sst3 and 
HEK-sst2 tumor-bearing nude mice, suggesting that they may be superior agents due to 
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their strong affinities to the somatostatin receptor and their prolonged retention in the 
target tissues despite a lack of internalization.  These data indicate that somatostatin 
antagonists may be suitable for targeting both SSTr2 and SSTr3, and therefore, the 
excellent targeting properties of sst2-ANT, combined with a very stable copper chelator 
like CB-TE2A, could result in a potent copper-64 radiopharmaceutical for PET imaging 
of SSTr2-positive neuroendocrine tumors. 
 
 
 
2.1.5.1 Synthesis and radiolabeling of 64Cu-CB-TE2A-sst2-ANT 
 
sst2-ANT was synthesized and coupled to CB-TE2A by the research group of 
Samuel Achilefu, Ph. D., WUSM.  The N-terminal acetyl group of the original peptide 
was substituted by one of the two acetate arms of CB-TE2A.  The same step had been 
necessary to produce 
111
In-DOTA-sst2-ANT, where one acetate group of DOTA replaced 
the N-terminal acetyl function in sst2-ANT (Ginj et al., 2006).  Radiolabeling of          
CB-TE2A-sst2-ANT with copper-64 was performed under conditions similar to the 
formation of 
64
Cu-CB-TE2A-Y3-TATE.  1 μg of CB-TE2A-sst2-ANT was incubated 
with 1–2.5 mCi of 64CuCl2 in 100 μl of 0.1 M ammonium acetate, pH 8, at 95 °C for    
1.5 h.  Radiochemical purity was confirmed by radio-TLC (C18 plate, mobile phase   
10% ammonium acetate:methanol = 3:7), and was >95%, rendering further purification 
unnecessary.  The Rf value of 
64
Cu-CB-TE2A-sst2-ANT was 0.58 ± 0.01 (N = 8), which 
was significantly different from 
64
Cu-CB-TE2A-Y3-TATE (0.63 ± 0.01, N = 9, Student’s 
t = 3.36, df = 15, P <0.01). 
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2.1.5.2 Receptor binding of 64Cu-CB-TE2A-sst2-ANT to AR42J cell membranes 
 
Saturation receptor binding experiments were performed to quantify binding of 
64
Cu-CB-TE2A-sst2-ANT to SSTr2 in a well-known model.  AR42J rat pancreatic 
carcinoma cells have been extensively used in somatostatin research and were, for 
example, used to evaluate 
64
Cu-CB-TE2A-Y3-TATE (Sprague et al., 2004).  Fig. 30 
shows the binding curve and Scatchard plot for 
64
Cu-CB-TE2A-sst2-ANT to AR42J 
membranes containing 20 μg of membrane protein.  The maximum receptor density was 
Bmax = 23,000 ± 950 fmol/mg, and the dissociation constant was Kd = 26.5 ± 2.4 nM.  
There was no ligand depletion, and the linear Scatchard plot indicates that there was one 
binding site for this antagonist on SSTr2.  
 
 
Fig. 30:  Receptor binding of 64Cu-CB-TE2A-sst2-ANT to AR42J cell membranes. 
 
 Data for 
64
Cu-CB-TE2A-Y3-TATE and 
nat
In-DOTA-sst2-ANT are shown in 
Table 13 for comparison. 
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Table 13:  Receptor binding data for 64Cu-CB-TE2A-sst2-ANT and two reference 
compounds. 
 64Cu-CB-TE2A 
-sst2-ANT 
64
Cu-CB-TE2A 
-Y3-TATE 
Sprague et al. (2004)  
nat
In-DOTA- 
sst2-ANT 
Ginj et al. (2006) 
Cell line AR42J AR42J HEK-sst2 
Kd/nM 26.5 ± 2.4 1.7 (1.2–2.4, 95% CI) - 
Bmax 23,000 ± 950 fmol/mg 1,596 fmol/mg 
(1,088–2103, 95% CI) 
354 ± 14 pM 
IC50/nM - 2.3 (1.7–3.2, 95% CI) 9.4 ± 0.4 
 
 
The Bmax values of Cu-CB-TE2A-sst2-ANT and In-DOTA-sst2-ANT cannot be 
compared directly, as the latter was published in pM, which is dependent on the assay 
volume used and cannot be standardized to protein mass without additional information.  
However, the Bmax value for the corresponding agonist and HEK-sst2 cells is given at     
23 ± 1.0 pM, thus resulting in an antagonist/agonist Bmax ratio of ca. 15.  The 
antagonist/agonist ratio for the 
64
Cu-CB-TE2A system investigated here was ca. 14 and 
thus surprisingly similar.  Thus, substantially more sst2-ANT, labeled with both     
copper-64 and indium-111, binds to the somatostatin receptor compared to common 
somatostatin agonists. 
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2.1.5.3  Biodistribution of 64Cu-CB-TE2A-sst2-ANT in AR42J tumor-bearing rats 
 
The in vivo targeting characteristics of 64Cu-CB-TE2A-sst2-ANT were tested in a 
biodistribution study in AR42J tumor-bearing rats, the same model that had been used to 
evaluate 
64
Cu-CB-TE2A-Y3-TATE (Sprague et al., 2004).  Blood clearance was rapid, 
with 0.30 ± 0.02 % ID/g at 1 h (Table 14), and a reduction by 90% to only 0.03 ± 0.01% 
ID/g at 20 h.  These activities in the blood are comparable to 
64
Cu-CB-TE2A-Y3-TATE 
(Sprague et al., 2004).  The kidney is the dose-limiting organ for many somatostatin-
based radiopharmaceuticals, and uptake was comparable to 
64
Cu-CB-TE2A-Y3-TATE at 
1 h, however, clearance from the kidney was reduced by only 28% at 20 h, whereas 74% 
of 
64
Cu-CB-TE2A-Y3-TATE had cleared the kidney at 24 h (Sprague et al., 2004).  
Unspecific uptake in the liver was higher than expected (>2% ID/g at all time points) 
from studies of 
64
Cu-CB-TE2A-Y3-TATE and 
64
Cu-TETA-Y3-TATE (<0.7% ID/g at all 
time points.  The SSTr-positive tissues pancreas (5.46 ± 0.60% ID/g), pituitary          
(3.03 ± 1.69% ID/g), and adrenals (5.77 ± 0.37% ID/g), as well as the AR42J tumor  
(4.20 ± 0.85% ID/g), showed high uptake at 1 h, but uptake was lower than that of    
64
Cu-CB-TE2A-Y3-TATE.  The retention of 
64
Cu-CB-TE2A-sst2-ANT activity at 20 h in 
the receptor positive tissues was 7% (pancreas), 10% (pituitary), 10% (adrenals), and 
17% (tumor).  These retention values were 2-fold higher for 
64
Cu-CB-TE2A-Y3-TATE 
(Sprague et al., 2004), and are significantly less than the uptake observed with          
111
In-DOTA-sst2-ANT (Ginj et al., 2006) in HEK-sst2 tumor-bearing nude mice          
(e.g. 22.84% ID/g in the tumor at 24 h).  Although absolute uptake values were expected 
to be lower in a rat model, clearance from target organs would not be expected to differ 
substantially.  Nonetheless, 
111
In-DOTA-sst2-ANT retention at 24 h in the tumor (102%) 
compared to 0.5 h was significantly higher (Ginj et al., 2006), despite the comparable 
values for pancreas (1%), pituitary (8%), and adrenals (10%).  It is indeed hard to explain 
why 
111
In-DOTA-sst2-ANT was retained in the HEK-sst2 tumor, yet cleared from all 
other SSTr-positive organs in the study by Ginj et al. (2006).  sst2-ANT may bind more 
strongly to the HEK-sst2 cells because these exclusively express SSTr2, whereas AR42J 
cells and most SSTr-positive tissues express a variety of SSTr subtypes. 
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Table 14:  Biodistribution 64Cu-CB-TE2A-sst2-ANT in male Lewis rats bearing AR42J 
tumors (N = 4 at 1 h, 4 h , and 4 h – block, N = 5 at 20 h).  Data is presented in % ID/g. 
Organ 1 h 4 h 4 h – block 20 h 
Blood 0.30 ± 0.02 0.06 ± 0.00 0.05 ± 0.01 0.03 ± 0.01 
Lung 0.79 ± 0.10 0.28 ± 0.02 0.27 ± 0.01 0.13 ± 0.01 
Liver 2.38 ± 0.48 2.69 ± 0.20 2.72 ± 0.11 2.24 ± 0.49 
Spleen 0.57 ± 0.09 0.50 ± 0.02 0.51 ± 0.01 0.37 ± 0.05 
Kidney 3.91 ± 0.64 3.25 ± 0.12 3.36 ± 0.11 2.81 ± 0.24 
Muscle 0.16 ± 0.02 0.04 ± 0.00 0.04 ± 0.00 0.02 ± 0.00 
Fat 0.13 ± 0.04 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
Heart 0.25 ± 0.03 0.09 ± 0.02 0.07 ± 0.01 0.04 ± 0.01 
Brain 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
Pituitary 3.03 ± 1.69 1.09 ± 0.12 0.64 ± 0.15 0.29 ± 0.10 
Bone 0.80 ± 0.07 0.41 ± 0.02 0.30 ± 0.02 0.22 ± 0.03 
Adrenals 5.77 ± 0.37 2.66 ± 0.20 1.54 ± 0.21 0.60 ± 0.10 
Pancreas 5.46 ± 0.60 2.01 ± 0.10 1.08 ± 0.04 0.37 ± 0.06 
Tumor 4.20 ± 0.85 3.30 ± 0.41 1.59 ± 0.29 0.70 ± 0.13 
Stomach 0.43 ± 0.16 0.15 ± 0.05 0.09 ± 0.01 0.08 ± 0.03 
Small intestine 0.37 ± 0.04 0.17 ± 0.01 0.15 ± 0.01 0.10 ± 0.01 
Upper large 
intestine 
0.44 ± 0.11 0.21 ± 0.01 0.23 ± 0.05 0.14 ± 0.03 
Lower large 
intestine 
0.37 ± 0.03 0.38 ± 0.06 0.36 ± 0.04 0.32 ± 0.11 
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 Blocking of specific uptake at 4 h by coinjection of a 600-fold excess of sst2-ANT 
lowered the uptake in target organs ca. 50%, without a significant increase in non-target 
organs.  The uptake of 
111
In-DOTA-sst2-ANT in target organs had been reduced by      
85–88% by blocking with DOTA-sst2-ANT and was clearly more effective. 
 Tumor-to-blood and tumor-to-muscle ratios at 4 h post-injection are shown in 
Table 15.  Compared to copper-64-labeled somatostatin agonists in the same animal 
model, 
64
Cu-CB-TE2A-sst2-ANT had higher specific uptake than 
64
Cu-TETA-Y3-TATE 
but lower than 
64
Cu-CB-TE2A-Y3-TATE.  The antagonist 
111
In-DOTA-sst2-ANT 
displayed the best tumor-to-non-target ratios, however, these studies were performed in a 
tumor-bearing nude mouse model. 
  
Table 15:  Tumor-to-non-target organ ratios for 64Cu-CB-TE2A-sst2-ANT and reference 
compounds (with data from Sprague et al., 2004, and Ginj et al., 2006). 
 Tumor-to-blood ratio (4 h) Tumor-to-muscle ratio (4 h) 
64
Cu-CB-TE2A-sst2-ANT 55 83 
64
Cu-CB-TE2A-Y3-TATE 156 243 
64
Cu-TETA-Y3-TATE 8.2 20 
111
In-DOTA-sst2-ANT 208 265 
 
 
 Somatostatin antagonists have far better tumor targeting properties than 
anticipated.  
64
Cu-CB-TE2A-sst2-ANT showed high uptake in a AR42J tumor-bearing rat 
model; however, the indium-111-labeled analogue had a better in vivo biodistribution in 
the HEK-sst2 tumor-bearing nude mouse model.  For a definitive comparison, both 
compounds would have to be tested in the same animal model. 
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2.2 COPPER-64-LABELED ANTI-EGFR ANTIBODY CETUXIMAB 
 
2.2.1 Introduction – EGFR and cancer 
 
As tumor cells are dependent on continuous input from external signaling 
molecules, growth factors play an important role in tumor growth and survival, 
predominantly via their stimulation of mitogenesis (Aaronson, 1991).  The first step in 
the signal transduction cascade triggered by many growth factors is their binding to a 
receptor in the cell membrane.  Indeed, many oncogenes are mutated versions of growth 
factor receptors, or their immediate binding partners.  Src, the first oncogene to be 
discovered (Stehelin et al., 1977, Oppermann et al., 1979), encodes a mutated receptor 
tyrosine kinase.  Membrane receptors of the tyrosine kinase family are the best-
characterized targets in cancer cells.  There are approximately 20 classes of receptor 
tyrosine kinases, including the epidermal growth factor (EGF), insulin, PDGF, FGF, 
VEGF, and HGF receptor families (Hubbard and Miller, 2007).  The EGF family 
(receptor tyrosine kinase class I) of membrane receptors, also called human epidermal 
receptor (HER) family, is one of the most relevant targets in this class.  There are four 
closely related receptors in this family (Laskin and Sandler, 2004):  EGFR (HER1, 
erbB1), HER2 (neu, erbB2), HER3 (erbB3), and HER4 (erbB4).  Ligands include EGF, 
amphiregulin, and TGF-α for EGFR, and a group of differentiation factors called 
neuregulins for HER3 and HER4.  Heparin-binding EGF, betacellulin, and epiregulin can 
stimulate EGFR and HER4.  In all cases, ligand binding is followed by formation of 
receptor homo- or heterodimers.  The functions of the four members of the EGFR family 
are intimately interrelated, as there are no known binding partners for HER2, and HER3 
lacks the tyrosine kinase activity.  Instead, HER2 acts as the preferred dimerization 
partner for all HER receptor tyrosine kinases (Grünwald and Hidalgo, 2002).  EGFR is 
associated
 
with oncogenic transformation, and dysregulation of EGFR
 
is associated with 
all of the key features of cancer,
 
such as autonomous cell growth, invasion, angiogenic 
potential,
 
and development of distant metastases (Grünwald and Hidalgo, 2002).  An 
increased expression of EGFR is the hallmark of many human tumors such as breast 
cancer, squamous cell carcinoma of the head and neck, and prostate cancer (Table 16). 
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Table 16:  EGFR expression in solid tumors (Salomon et al., 1995, Laskin and Sandler, 
2004). 
Tumor type Range of tumors 
expressing EGFR (%) 
Tumor type Range of tumors 
expressing EGFR (%) 
Head and neck 80–100  Prostate 40–80 
Colorectal 25–77 Bladder 53–72 
Pancreatic 30–50 Cervical 54–74 
Lung 40–80 Ovarian 35–70 
Esophageal 71–88 Breast 14–91 
Renal cell 50–90 Glioblastoma 40–50 
 
 
In many tumors, EGFR expression may act as a prognostic indicator, predicting 
poor survival and/or more advanced disease stage (Laskin and Sandler, 2004). 
EGFR (170 kDa) is a membrane-spanning glycoprotein and consists of an 
extracellular ligand-binding domain, a transmembrane domain, and an intracellular 
domain with tyrosine kinase activity.  Binding of ligand induces the dimerization of 
receptors, followed by activation of the cytoplasmic tyrosine kinase domain and the 
subsequent signal transduction cascade.  Signal termination occurs mainly by endocytosis 
of the activated receptor (Yarden, 2001, Grünwald and Hidalgo, 2002).  The signaling 
transduction cascade triggered by EGFR is shown in Fig. 31. 
 
RESULTS 
 68 
 
Fig. 31:  EGFR signal transduction (from Baselga, 2001). 
 
 
There are five strategies (Fig. 32) that have been proposed to target EGFR for 
cancer imaging and therapy (Grünwald and Hidalgo, 2003): 
 
1) Monoclonal antibodies (mAbs), which block the binding of activating ligands 
to the extracellular ligand-binding domain of the receptor 
2) Small-molecule inhibitors of the receptor’s intracellular receptor tyrosine 
kinase domain 
3) EGFR-targeting immunotoxins 
4) Antisense oligonucleotides that reduce the level of EGFR expression 
5) Inhibitors of downstream effectors within the EGFR signaling network 
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Fig. 32:  Therapeutic strategies to inhibit components of the EGFR signaling pathway 
(modified from Grünwald and Hidalgo, 2002). 
 
Of these approaches, small tyrosine kinase inhibitors and mAbs are the furthest 
along in clinical development.  The former are ATP mimetic molecules, which bind to 
the ATP binding site of the receptor’s intracellular tyrosine kinase domain, and inhibit the 
autophosphorylation of the receptor necessary for activation.  Fig. 33 shows two such 
pharmaceuticals that are now being used in the clinic. 
 
 
     
Fig. 33:  Structures of gefitinib (ZD1839, Iressa®) and erlotinib (OSI-774, Tarceva®). 
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Gefitinib is currently indicated for the treatment of locally advanced or metastatic 
non-small cell lung cancer (NSCLC) in patients who have previously received 
chemotherapy.  Erlotinib is approved for the treatment of locally advanced or metastatic 
non-small cell lung cancer that has failed at least one prior chemotherapy regimen.  It is 
also approved in combination with gemcitabine for treatment of locally advanced, 
unresectable, or metastatic pancreatic cancer. 
Cetuximab (C225, Erbitux
®
) was the first mAb targeted against the ligand-
binding site of EGFR to be approved in the United States and Europe for the treatment of 
patients with EGFR-expressing, metastatic colorectal carcinoma.  It is a chimeric human-
mouse antibody containing the human immunoglobulin G1 constant region, which was 
inserted to avoid problems associated with the generation of human antibodies against 
murine antibodies (HAMA).  Cetuximab binds competitively to the extracellular domain 
of EGFR with affinity comparable to the natural ligand (Kd = 0.1–1.0 nM) (Fan et al., 
1993, Goldstein et al., 1995, Mendelsohn, 1997).  Consequently, cetuximab binding 
inhibits autophosphorylation of EGFR and induces its internalization and possible 
degradation (Sato et al., 1983, Gill et al., 1984).  Cetuximab has also been shown to 
induce apoptosis in some cell lines and by a variety of mechanisms, e.g. the increase in 
the cellular contents of Bax and caspase-3, caspase-8, and caspase-9 (Mandal et al., 1998, 
Liu et al., 2000).  Inhibition of tumor progression by cetuximab via two more 
mechanisms has been proposed:  it was shown that cetuximab affected the regulation of 
the cell cycle and caused G1 arrest (Peng et al., 1996), and that the agent has anti-
angiogenetic properties (Perrotte et al., 1999, Bruns et al., 2000). 
Clinical trials have revealed significant variability in the response to cetuximab 
(Cunningham et al., 2004, Saltz et al., 2004, Wong, 2005).  A large-scale clinical study of 
329 patients with metastatic colorectal cancer that was refractory to treatment with 
irinotecan found a response rate of 10.8% (5.7–18.1%, 95% CI) with cetuximab 
monotherapy (Cunningham et al., 2004).  Combination therapy with irinotecan was 
significantly more successful (22.9%, 17.5–29.1%, 95% CI), but clinically significant 
activity of cetuximab alone was established.  The molecular determinants and 
mechanisms allowing one to predict responsiveness to cetuximab remain poorly 
understood.  Antitumor activity, based on both monotherapy and combination therapy, 
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was not predicted by relative expression levels of either total or activated EGFR in 
human tumor cell lines derived from colon, lung, breast and gastric carcinomas (Wild     
et al., 2006).  To complicate matters, colorectal cancer patients with EGFR-negative 
tumors (as determined by immunohistochemistry) have been found to respond to 
cetuximab-based therapies (response rate 25%, 4–46%, 95% CI) in a study by Chung  et 
al. (2005).  It is therefore possible that other members of the EGFR signaling pathway 
may serve as better molecular determinants of cetuximab efficacy.  One study examined 
the mRNA expression levels of cyclin D1, cyclooxygenase 2 (Cox-2), EGFR,   
interleukin 8 (IL-8), and VEGF in patients with EGFR-expressing metastatic colorectal 
cancer, and concluded that high expression levels of VEGF were associated with 
resistance to cetuximab, and low gene expression levels of Cox-2, EGFR, and IL-8 were 
significantly associated with overall survival (Vallböhmer et al., 2005).  Patients with 
lower levels of EGFR mRNA had a longer overall survival than patients with higher 
EGFR mRNA levels (7.3 vs. 2.2 months), underlining the critical role of EGFR over-
expression in the advanced stages of colorectal cancer.  The EGFR gene copy number 
may be another important predictor for successful cetuximab therapy:  When tumors of   
9 metastatic colorectal cancer patients with an objective response to cetuximab or 
panitumumab, and 21 patients with stable or progressive disease were screened for 
genetic changes in EGFR, increased copy numbers of EGFR were found in 89% of 
responders, and only 5% of non-responders (P <0.0001) (Moroni et al., 2005).  The 
concentration of cetuximab that completely inhibited proliferation of tumor cells in 
colorectal cancer cell lines with amplified EGFR copy number did not inhibit the 
proliferation of cells with unamplified EGFR (Moroni et al., 2005), suggesting that 
EGFR copy number may be an important factor to consider for cetuximab therapy.  The 
mutation status of the EGFR catalytic domain and some of its immediate downstream 
effectors, however, did not correlate with disease response (Moroni et al., 2005). 
The role of EGFR may also depend on the distinction between primary tumor and 
early metastatic stages (e.g. circulating tumor cells).  Spano et al. (2005) did not find a 
correlation between EGFR expression and survival in colorectal cancer patients, and 
Repetto et al. (2005) pointed out that this negative result may have been the consequence 
of screening primary tumors instead of circulating tumor cells or metastases, where 
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EGFR had been identified as a prognostic marker before (Giacomelli et al., 2003).  Taken 
together, both the role of EGFR in the progression of colorectal cancer, and the 
predictability of positive response to cetuximab therapy in this cancer remain poorly 
understood. 
The use of radiolabeled anti-EGFR antibodies for EGFR-expressing cancer 
diagnosis has become the subject of intense investigation as more mAbs with relevant 
and well-characterized specificities become available.  
64
Cu-DOTA-cetuximab has been 
successfully used to image EGFR-positive xenograft tumor models (Li et al., 2005b, Cai 
et al., 2007), and was used in this study for two purposes: 
 
As a first step to evaluate the potential efficacy of copper-64-labeled cetuximab in 
EGFR-positive advanced cervical cancer, a wide variety of cervical cancer cell lines were 
examined for EGFR mRNA expression, presence of the EGFR receptor on the cell 
surface, and internalization of 
64
Cu-DOTA-cetuximab (section 2.2.3). 
Cervical cancer is the most common gynecological cancer worldwide.  In the 
United States in 2004, more than 10,500 women were diagnosed, and 3,900 died (Jemal 
et al., 2004).  The majority of women present at an early stage of disease and are treated 
successfully with surgery or radiation, however, 25% of women with cervical cancer are 
diagnosed with advanced disease.  Current treatment for locally advanced cervical cancer 
consists of cisplatin-based chemotherapy and concurrent radiation.  Overall survival rates 
with this treatment are low, approximately 52% at 5 years (Hougardy et al., 2005). 
The role of EGFR in the tumorigenesis of cervical cancer has been debated over 
the last decade.  In one study, over-expression of EGFR was found in 72.5% of patients 
with invasive cervical cancer and in 25% of patients with cervical intraepithelial 
neoplasia (Kim et al., 1996).  Larger tumors had significantly higher receptor levels, 
suggesting that EGFR may play a role in malignant transformation.  However, two 
reports published shortly after claimed that EGFR is not related to the prognosis of 
cervical cancer (Scambia et al., 1998), or that EGFR may even be down-regulated in 
most cases of cervical cancer (Kimmig et al., 1997).  In the latter study, only 10% of 
tumors showed over-expression compared to normal cervical epithelium.  More recent 
studies have established the role of EGFR over-expression as a predictor of poor 
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prognosis (Kersemaekers et al., 1999), and associated EGFR with impaired prognosis 
with respect to disease-free survival and overall survival (Kim et al., 2002).                  
Co-expression of EGFR and Cox-2 was also suggested as a potent molecular risk factor 
in carcinomas of the cervix (Kim et al., 2004).  At any rate, it is clear now that the role of 
EGFR in cervical cancer is highly variable. 
The range of cervical cancers over-expressing EGFR is now being given at      
54–74% (Laskin and Sandler, 2004), and pharmaceuticals targeting EGFR could 
diversify diagnostic tools and treatment, at least in certain subtypes of cervical 
carcinomas.  This study aimed at correlating transcription, expression, and receptor 
function of EGFR in several established cervical cancer cell lines, using 
64
Cu-DOTA-
cetuximab.  A positive correlation between EGFR expression and 
64
Cu-DOTA-cetuximab 
binding and uptake would lay the foundation for the imaging of EGFR-positive cervical 
tumors.  It would also have potential in selecting those cervical cancer patients who may 
be responsive for anti-EGFR treatment.  Finally, 
64
Cu-DOTA-cetuximab may be a 
candidate itself for the therapy of EGFR-positive cervical cancer. 
 
Secondly, 
64
Cu-DOTA-cetuximab was used to further investigate the nuclear 
localization of copper-64, utilizing two clones of the colorectal cancer cell line HCT 116 
positive and negative for the tumor suppressor protein p53.  As discussed above, copper 
does not exist in unbound ionic form in biological systems, but is complexed by a variety 
of small molecules and macromolecules.  Copper chaperones assure the trafficking of 
copper to the correct cuproproteins.  To date, no chaperones have been identified that 
traffic copper to the cell nucleus, however, it is clear that copper localizes to the cell 
nucleus in living cells.  Here, a potential role for the tumor suppressor protein p53 in the 
trafficking of copper to the nuclei of tumor cells was examined. 
Many signaling pathways center around p53, and it has been suggested to divide 
then into five components (Levine et al., 2006): 1) stress signals that activate the 
pathway, including oxidative stress, DNA damage, and hypoxia;  2) upstream mediators 
that detect and interpret these stress signals, e.g. ATM, CHK2, and p19ARF;  3) core 
regulation of p53 via activation or degradation by several proteins, e.g. Mdm2 and COP1;  
4) downstream events, mainly transcriptional activation or protein-protein interactions;  
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and 5) the final outcome of p53 activation, upon which it accumulates in the nucleus, 
where it transcriptionally regulates the expression of various genes: growth arrest, 
apoptosis or DNA repair. 
p53 mutations occur in over 50% of human cancers.  These are often missense 
mutations, which lead to the synthesis of a stable protein that can accumulate in the cell 
nucleus but has lost its DNA-binding function (Soussi and Beroud, 2001).  Such a p53 
mutation
3
 of one allele can lead to tumor progression by assuming a dominant-negative 
role via hetero-oligomerization with functional p53 protein expressed by the second, 
wild-type allele, thus rendering the oligomer inactive (Milner and Medcalf, 1991).   
The DNA-binding domain of p53 contains zinc, and there is in vitro evidence that 
copper may displace zinc in the p53 structure (Hainaut et al., 1995).  In addition to the 
possibility that copper might bind to p53 itself, there is also evidence that p53 facilitates 
the transport of other copper-based proteins to the nuclei of tumor cells.  Azurin is a 
cupredoxin protein secreted by the bacterium Pseudomonas aeruginosa, which has been 
shown to have cytotoxic effects on J774 macrophages and human breast cancer cells 
(Yamada et al., 2002a, Yamada et al., 2002b).  The induction of apoptosis by azurin is 
independent of its redox activity and involves complex formation with p53 and 
translocation to the nucleus (Goto et al., 2003, Punj et al., 2003, Punj et al., 2004). 
To examine the influence of p53 on copper transport to the nucleus, clones of the 
human colorectal cancer cell line HCT 116 positive or negative for p53 were exposed to 
copper-64 (section 2.2.4).  In HCT 116 –/– cells, both wild-type alleles of p53 present in 
the HCT 116 +/+ clone had been knocked out (Bunz et al., 1998).  These cell lines were 
kindly provided by Bert Vogelstein, Ph. D. (Johns Hopkins University).  Both unspecific 
and receptor-mediated uptake mechanisms for copper into the cytosol were tested for 
differences in subsequent nuclear localization of copper-64.  [
64
Cu]copper acetate was 
chosen as a tracer that enters cells unspecifically via the copper transporter hCtr1, and 
64
Cu-DOTA-cetuximab was selected for specific uptake via the EGF receptor.  Both   
HCT 116 clones are positive for EFGR. 
                                                   
3
  Michalovitz et al. (1991) classify p53 mutations in three groups: 1) null mutations which inactivate p53 
and do not directly lead to transformation;  2) dominant-negative mutations which interfere with functional 
p53 expressed from the wild-type allele;  3) positive dominant mutations where the mutant p53 acquires 
new oncogenic activity and thus is directly involved in transformation. 
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2.2.2 Synthesis and radiochemistry of 64Cu-DOTA-cetuximab 
 
DOTA was conjugated to cetuximab in 0.1 M Na2HPO4 (pH 7.5) using an 
adaptation of the method described by Lewis et al. (2001c).  DOTA-mono-NHS-tris(tBu) 
ester was dissolved in 0.1 M Na2HPO4, and pH was adjusted to 7.4 by adding                
0.1 M NaOH (Fig. 34).  An aliquot of this solution was added to the concentrated 
cetuximab in a molar ratio of DOTA-mono-NHS-tris(tBu) ester:cetuximab = 120:1, 
followed by incubation at 4 C overnight with gentle mixing.  Small molecule reactants 
were removed using a Centricon 100 filtration device, and the conjugate was collected 
from the membrane. 
 
 
 
Fig. 34:  Synthesis of DOTA-cetuximab (DOTA-C225). 
 
 Radiolabeling of DOTA-cetuximab with copper-64 was performed in                
0.1 M ammonium citrate (pH 6) at 40 °C (Fig. 35).  
64
Cu-DOTA-cetuximab was 
produced with a specific activity of 10–25 μCi/μg (0.37–0.93 MBq/μg; 1.5–3.8 nCi/fmol 
[560–1,430 Bq/fmol]).  Initial radiochemical purity ranged from 75–100%.  For       
yields <95%, 
64
Cu-DOTA-cetuximab was challenged with 5 μl of 10 mM EDTA to 
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complex free copper-64.  
64
Cu-DOTA-cetuximab was then isolated with a miniature size 
exclusion column, resulting in final radiochemical purities ranging from 98–100%. 
 
 
Fig. 35:  Radiolabeling of DOTA-cetuximab (DOTA-C225) with copper-64. 
 
 
 
2.2.3 64Cu-DOTA-cetuximab and cervical cancer cell lines with varying levels of 
EGFR expression 
 
In a preliminary study, transcriptional profiling of nine cervical cancer cell lines 
using Affymetrix U133Plus2 GeneChip Microarrays was performed (Mark A. Watson, 
Ph. D., WUSM) to assess cellular EGFR mRNA levels based on ten different 
oligonucleotide probe sets (Fig. 36).  The assay measured relative expression, and the cell 
lines were grouped in two classes (low- and high-expressing) based on their composite 
EGFR signals.  The EGFR gene was also sequenced in those nine cervical cancer cell 
lines, and several novel sequence alterations that lead to non-conservative amino acid 
changes were identified (Mark A. Watson, Ph. D., WUSM, data not shown).  
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Fig. 36:  Relative expression of EGFR in nine cervical cancer cell lines based on 
Affymetrix U133Plus2 GeneChip Microarrays (Mark A. Watson, Ph. D., WUSM). 
 
 The expression profile ranged from very high in the CaSki cell line, which 
displayed very high relative expression for all ten EGFR oligonucleotide probe sets, to 
very low in the C-33A line, which showed the lowest level of relative expression for all 
ten probe sets, suggesting that there is no EGFR mRNA present in C-33A cells.  Five 
cervical cancer cell lines, covering the entire range of EGFR mRNA levels, were chosen 
for the quantification of EGFR protein and its function: 
 
  CaSki > ME-180 > DoTc2 4510 >> HeLa > C-33A 
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2.2.3.1 Receptor binding of 64Cu-DOTA-cetuximab 
 
Competitive receptor binding curves were measured by displacing 
64
Cu-DOTA-
cetuximab with cetuximab on isolated membranes of the five selected cervical cancer cell 
lines.  A representative experiment is depicted in Fig 37.  Complete binding curves were 
obtained for CaSki (IC50 = 1.64 nM, 1.18–2.28 nM, 95% CI) and ME-180 cells           
(IC50 = 1.33 nM, 1.08–1.63 nM, 95% CI), and the experiment clearly showed that     
64
Cu-DOTA-cetuximab did not bind to C-33A cell membranes even when no competitor 
was present.  However, no upper plateau could be obtained for DoTc2 4510 and HeLa 
membranes. 
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Fig. 37:  Competitive binding of 64Cu-DOTA-cetuximab to membranes from five cervical 
cancer cell lines. ■ = CaSki, ∆ = ME-180, ● = DoTc2 4510,  = HeLa,▼ = C-33A. 
 
Saturation receptor binding of 
64
Cu-DOTA-cetuximab to the EGFR receptor was 
performed in order to determine EGFR receptor densities on the cell membrane and thus 
correlate protein and mRNA levels of EGFR.  All receptor binding studies were carried 
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out with a defined number of live cells at 4 °C, and the amount of bound 
64
Cu-DOTA-
cetuximab was standardized to protein mass using a BCA protein assay.  Live cells were 
used in this experiment, because membrane preparation and storage in frozen condition 
damaged the membranes of DOTc2 4510, HeLa, and C-33A cells.  The binding curves 
are shown in Fig 38. 
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Fig. 38:  Saturation receptor binding of 64Cu-DOTA-cetuximab to five cervical cancer 
cell lines. ■ = CaSki, ∆ = ME-180, ● = DoTc2 4510,  = HeLa,▼ = C-33A. 
 
The values for EGFR binding affinity (Kd) of 
64
Cu-DOTA-cetuximab in the 
EGFR-positive cell lines were very similar (0.1–0.7 nM), as was expected for the same 
substrate-receptor interaction.  These values are in the range of the Kd reported for 
unmodified cetuximab (Kd = 0.1–1.0 nM) (e.g. Goldstein et al., (1995)).  Therefore, 
conjugation to DOTA and complexing with copper-64 did not affect the affinity of 
cetuximab towards its antigen.  The EGFR receptor concentration (Bmax, given in 
fmol/mg total cellular protein) was found to mimic the relative levels of EGFR 
expression as determined by microarray analysis:  CaSki (2,130) > ME-180 (820) > 
DoTc2 4510 (610) > HeLa (310) > C-33A (0) (Fig. 38, Table 17, p. 82).  Under these 
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experimental conditions, mRNA levels of EGFR in the five cell lines selected are 
translated in the same relative order to EGFR protein. 
As a control experiment, the binding parameters were also determined using 
isolated membrane preparations of CaSki and ME-180 cells (Fig. 39). 
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Fig. 39:  Saturation receptor binding of 64Cu-DOTA-cetuximab to membranes of CaSki 
(■) and ME-180 (∆) cervical cancer cell lines. 
 
 The Kd was estimated at 0.24 ± 0.03 nM for both cell lines, and maximum 
receptor densities were 3,650 ± 120 fmol/mg for CaSki cells, and 3,050 ± 100 fmol/mg 
for ME-180 cells.  These receptor numbers were higher for both cell lines than in the cell-
based assay, which was expected, as they were standardized to membrane protein mass 
instead of total cellular protein.  As in the cell-based assay and with transcriptional 
profiling, CaSki cells displayed a stronger EGFR signal than ME-180 cells. 
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2.2.3.2 Internalization of 64Cu-DOTA-cetuximab 
 
Ligand binding to EGFR is usually followed by rapid dimerization, activation of 
the intracellular tyrosine kinase activity, and receptor internalization and degradation.  
Internalization of 
64
Cu-DOTA-cetuximab was chosen as an indicator for EGFR receptor 
function in the four cell lines that were positive for EGFR in receptor binding assays.   
The amount of 
64
Cu-DOTA-cetuximab internalized in a 4-h period is shown in Fig. 40. 
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Fig. 40:  Internalization of 64Cu-DOTA-cetuximab into four cervical cancer cell lines.    
■ = CaSki, ∆ = ME-180, ● = DoTc2 4510,  = HeLa.  
 
The internalization experiment revealed the same relative order for EGFR 
function and thus confirmed previous quantification of EGFR mRNA and protein levels.  
CaSki cells internalized approximately 50,000 fmol/mg of 
64
Cu-DOTA-cetuximab within 
4 h, which corresponds to ratio of internalized 
64
Cu-DOTA-cetuximab:receptor = 24, as 
estimated from the Bmax, indicating recycling of receptors to the cell surface rather than 
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degradation after internalization, and/or continuous EGFR synthesis.  The ratios for   
ME-180 (28), DoTc2 4510 (25), and HeLa (20) were very similar, and complement this 
analysis of EGFR expression and function in cervical cancer cell lines with highly 
varying level of EGFR expression, summarized in Table 17. 
 
Table 17:  Quantification of EGFR mRNA and protein levels in five cervical cancer cell 
lines. 
 Cell line EGFR 
expression 
Bmax 
(fmol/mg) 
Internalization 
at 4h (fmol/mg) 
Ligand molecules 
internalized/receptor 
CaSki ++++ 2,130 ± 60 50,500 ± 1,000 24 
ME-180 +++ 820 ± 40 22,700 ± 400 28 
DoTc2 
4510 
++ 610 ± 20 15,500 ± 400 25 
HeLa + 310 ± 110 6,100 ± 100 20 
C-33A – NA NA NA 
 
 
These consistent results encourage advancing to animal studies after 
determination of the in vitro cytotoxicity of cetuximab.  If cervical cancer tumor-bearing 
mouse models were developed with the cell lines investigated, in vivo monitoring of 
cetuximab therapy by microPET imaging with 
64
Cu-DOTA-cetuximab could be used to 
investigate if enhanced EGFR expression and function translates to better response rates 
to cetuximab therapy in cervical cancer models.  Changes in EGFR expression during and 
after a cetuximab regime could be monitored by gene expression microarray analysis and 
give insights into the mechanism of cancer therapy with cetuximab. 
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2.2.4 64Cu-DOTA-cetuximab and nuclear localization of copper-64 in the HCT 116 
colon cancer cell line 
 
2.2.4.1 Internalization and nuclear uptake of [64Cu]copper acetate 
 
HCT 116 +/+ and HCT 116 –/– cells were incubated with [64Cu]copper acetate 
over a 24-h time course to measure internalization.  Copper-64 accumulated in both lines 
over time and reached approximately 20% ID/mg at 24 h.  Minimal difference was 
observed between the two cell lines (Fig. 41A).  p53 status thus had no apparent 
influence on transport of copper-64 via the hCtr1 transporter.  The difference in nuclear 
uptake of copper-64, however, was significant (Fig. 41B):  At the end of the 24-h time 
course, copper-64 accumulation in the nuclei was 2-fold higher in HCT 116 +/+ cells 
compared to HCT 116 –/– cells (8.26 ± 0.13 vs. 4.05 ± 0.07% ID/mg cellular protein,     
N = 3, Student’s t = 29.27, df = 4, P <0.0001).  Even though uptake of copper-64 from 
[
64
Cu]copper acetate into cells was not influenced by p53 status, transport of this 
radiometal to the nucleus was significantly higher in the p53 expressing cell line. 
 
 
Fig. 41: Internalization (A) and nuclear localization (B) of [64Cu]copper acetate in   
HCT 116 cell lines positive (□) and negative (▲) for p53 (N = 3) in % ID/mg. 
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2.2.4.2 Receptor binding of 64Cu-DOTA-cetuximab 
 
Saturation receptor binding experiments with 
64
Cu-DOTA-cetuximab and isolated 
HCT 116 +/+ and HCT 116 –/– cell membranes showed that there was no significant 
difference in the binding characteristics between the two cell lines (Fig. 42).  The 
dissociation constant (Kd) was 0.95 ± 0.26 nM for HCT 116 +/+ cells and 1.13 ± 0.22 nM 
for HCT 116 –/– cells.  These values are comparable to dissociation constants reported 
for unmodified cetuximab, which range from 0.1–1.0 nM (Naramura et al., 1993, 
Goldstein et al., 1995).  Maximum EGF receptor densities (Bmax) were very similar as 
well:  1,950 ± 180 fmol/mg for HCT 116 +/+ cells, and 2,180 ± 150 fmol/mg for        
HCT 116 –/– cells. 
 
 
Fig. 42: Saturation receptor binding of 64Cu-DOTA-cetuximab to cell membranes 
isolated from HCT 116 cell lines positive (□) and negative (▲) for p53.  
 
It was important to demonstrate that EGF receptor numbers were comparable for 
both cell lines with different p53 status in order to exclude the possibility that a 
difference in receptor numbers would confound the results of internalization, nuclear 
uptake, and efflux studies with 
64
Cu-DOTA-cetuximab. 
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2.2.4.3 Internalization, efflux and nuclear uptake of 64Cu-DOTA-cetuximab 
 
Internalization and nuclear uptake experiments with 
64
Cu-DOTA-cetuximab were 
performed in the same manner as described for [
64
Cu]copper acetate.  Fig. 43A shows the 
uptake of 
64
Cu-DOTA-cetuximab into both HCT 116 cell lines in % ID/mg.  As was the 
case with [
64
Cu]copper acetate, internalization was similar in both lines.  However, 
uptake did not increase between the 4-h and 24-h time point.  It is possible that the 
receptor-mediated uptake of 
64
Cu-DOTA-cetuximab was saturated at 4 h, whereas 
unspecific uptake of [
64
Cu]copper acetate increased over the entire 24-h time course.  At 
24 h, the total amount of internalized 
64
Cu-DOTA-cetuximab was 43.7 ± 1.3% ID for         
HCT 116 +/+ cells vs. 42.2 ± 3.3% ID for HCT 116 –/– cells (N = 6, Student’s t = 0.4262, 
df = 10, P = 0.68, data not shown).  As predicted from similar Kd and Bmax values for the 
interaction of 
64
Cu-DOTA-cetuximab and the EGF receptor on the two HCT 116 cell 
lines, a difference in receptor-mediated endocytosis of 
64
Cu-DOTA-cetuximab could not 
be observed. 
When isolated nuclei were measured for copper-64 activity after incubation with 
64
Cu-DOTA-cetuximab (Fig. 43B), numbers were higher in HCT 116 +/+ cells compared 
to HCT 116 –/– cells (0.56 ± 0.05% vs. 0.36 ± 0.03% of internalized activity/mg cellular 
protein at 24 h, N = 6, Student’s t = 3.263, df = 10, P <0.01).  Those values correspond to 
10.3 ± 1.0% and 7.0 ± 0.5% of internalized 
64
Cu-DOTA-cetuximab (N = 6, Student’s       
t = 2.969, df = 10, P = 0.01, data not shown).  In contrast to the analogous experiment 
with [
64
Cu]copper acetate, when a significant difference had not been seen at early time 
points, more copper-64 from 
64
Cu-DOTA-cetuximab appeared in the nuclei of           
HCT 116 +/+ cells as early as 1 h, with the difference being statistically significant at 4 h 
(0.75 ± 0.09% vs. 0.47 ± 0.05% of internalized activity/mg, N = 6, Student’s t = 2.739,   
df = 10, P = 0.02, Fig. 43B). 
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Fig. 43:  (A) % ID/mg of 64Cu-DOTA-cetuximab internalized in HCT 116 cell lines 
positive (□) and negative (▲) for p53.  (B) Percentage of internalized activity localized 
to the nuclear fraction of HCT 116 cells per mg (N = 6 with two independent copper-64 
productions). 
 
It is hypothesized that copper-64 dissociates from 
64
Cu-DOTA-cetuximab and is 
complexed by a different protein before entering the cell nucleus.  It is possible that this 
new complex also translocates to other cell compartments or leaves the tumor cell.  To 
rule out that the observed difference in nuclear uptake between the two HCT 116 cell 
lines resulted from a variation in release of copper-64 into the medium, copper-64 efflux 
was monitored for 20 h after an uptake period of 4 h.  Fig. 44 shows the efflux profiles of 
both cell lines.  They retained comparable amounts of copper-64 from internalized    
64
Cu-DOTA-cetuximab throughout the time course, with the exception of increased 
efflux of copper-64 from HCT 116 –/– cells at 4 h.  This time point may be an outlier, 
and the overall profiles suggest that the difference in copper-64 efflux between HCT 116 
cell lines is minimal. 
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Fig. 44:  Efflux of 64Cu-DOTA-cetuximab from HCT 116 cell lines positive (□) and 
negative (▲) for p53.  Efflux is expressed as the percentage of retained activity; the 
activity at t = 0 (when the radioactive media was removed) is 100%. 
 
 To test for the integrity of the HCT 116 cell lines utilized in this study, which 
have been passaged for several decades, and to ensure the absence of clonal artifacts,         
HCT 116 +/+ cells were treated with p53 siRNA (small interfering RNA, short 
interfering RNA, silencing RNA) to down-regulate p53 mRNA and p53 protein.  After 
three days, these cells were exposed to 25 µCi of [
64
Cu]copper acetate, and cell nuclei 
were isolated and measured for copper-64 activity.  Nuclear uptake was significantly 
lower in HCT 116 +/+ cells treated with p53 siRNA (0.126 ± 0.008% ID/mg, N = 3) 
compared to untreated HCT 116 +/+ cells (0.252 ± 0.003% ID/mg, N = 2, Student’s         
t = 12.38, df = 3, P <0.01).  There was no statistical significance between down-regulated 
HCT 116 +/+ cells and HCT 116 –/– cells (0.165 ± 0.033% ID/mg, N = 2, Student’s         
t = 1.491, df = 3, P = 0.23).  Thus, down-regulation of p53 mRNA and protein in       
HCT 116 +/+ cells led to nuclear localization of copper-64 more similar in quantity to 
HCT 116 –/– cells than to HCT 116 +/+ cells.  This control experiment reduces the 
probability that clonal artifacts were responsible for the copper-64 nuclear uptake 
patterns observed in the two HCT 116 clones. 
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In summary, the data presented here demonstrate a potential mechanism for 
increased toxicity of copper-64 radiopharmaceuticals for targeted radiotherapy of cancer 
involving the tumor suppressor protein p53.  Copper-64 radiopharmaceuticals may show 
greater localization of copper-64 in tumor cell nuclei in tumors that express wild-type 
p53 compared to p53 null or p53 mutant expressing tumor cells.  This increased 
localization of copper-64 in the nuclei may cause increased DNA damage to cells, and 
therefore improved tumor cell killing.  In addition, a direct or indirect role for p53 in the 
transport of copper into the cell nucleus was identified. 
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3. DISCUSSION 
 
Over the past few decades, the use of the non-standard radionuclide copper-64 
[t1/2 = 12.7 h, β
–
 (0.573 MeV, 38.4%), β+ (0.655 MeV, 17.4%), EC (43.8%), Auger 
electron emission] has substantially increased, due to its favorable half-life and the decay 
by both electron and positron emission, which renders it useful for medical imaging via 
positron emission tomography (PET) and for targeted radiotherapy of cancer.  As a 
radiometal, copper-64 cannot be covalently introduced to a biomolecule as is the case 
with the more frequently used PET tracers carbon-11 and fluorine-18.  Instead it must be 
incorporated as a copper complex, which is most often achieved via a bifunctional 
chelator (BFC).  Copper-64 has been used as a tracer to elucidate biochemical processes, 
but radiolabeling of peptides, antibodies, and other proteins constitutes its most 
prominent application. 
Within the field of peptide targeting of cell membrane receptors over-expressed in 
human disease, much attention has been given to analogues of the neuropeptide 
somatostatin to target neuroendocrine tumors.  The chemistry and biology of somatostatin 
analogues has been researched by several means in this study:  First, a human cell line 
stably transfected with SSTr2 was evaluated for somatostatin analogue binding.  Second, 
new linkers for cross-bridged BFCs were tested in vitro.  Third, looking at the 
intracellular fate of somatostatin-derived radiopharmaceuticals, the localization of 
copper-64 from somatostatin analogues to the cell nucleus of tumor cells was investigated 
with compounds of different chelator stabilities.  Finally, a new somatostatin antagonist 
labeled with copper-64 was evaluated in vitro and in vivo. 
 
As a contribution to a study describing the creation and characterization of a 
human non-small cell lung cancer cell line that stably expresses various levels of SSTr2, 
membranes of several clones of A427 cells were prepared, and receptor binding 
parameters were determined using the well-characterized somatostatin analogue        
64
Cu-TETA-octreotide (Parry et al., 2007).  The three clones A427-5, A427-2, and 
A427-7 had very similar binding affinities for 
64
Cu-TETA-octreotide, yet displayed 
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increasing maximum SSTr2 receptor densities (Table 18).  This series of new cell lines 
will be a valuable research tool for several reasons: 
1) The clones are stably transfected with SSTr2, yet they do not express any 
other SSTr subtype, which means that all somatostatin-mediated effects can 
be attributed to SSTr2. 
2) Clones with three different levels of SSTr2 expression on the cell surface 
(A427-7 > A427-2 > A427-5), as well as a negative control (A427-4) are 
available for different research needs.  For example, imaging studies can be 
designed to examine how much SSTr2 expression is necessary to conveniently 
detect neuroendocrine tumors via PET imaging. 
3) These A427 clones are the first example of a human cell line with varying 
levels of SSTr2 expression, and could potentially replace the commonly used 
rat pancreatic carcinoma lines AR42J and CA20948. 
 
 
Table 18:  Summary of receptor binding parameters of copper-64-labeled somatostatin 
analogues. 
Analogue Cell line IC50 (nM) Kd (nM) Bmax (fmol/mg) 
64
Cu-TETA-octreotide A427-7 ND 1.5 ± 0.1 7,000 ± 2,800 
64
Cu-TETA-octreotide A427-2 ND 2.4 ± 0.1 2,750 ± 250 
64
Cu-TETA-octreotide A427-5 ND 3.3 ± 0.2 1,300 ± 150 
64
Cu-BS353 AR42J 2.9 (2.6–3.3) ND ND 
64
Cu-BS354 AR42J 1.9 (1.7–2.2) 0.60 ± 0.07 1400 ± 40 
64
Cu-TETA-Y3-TATE A427-7 4.87 ± 1.11 0.22 ± 0.02 5,440 ± 1,110 
64
Cu-CB-TE2A-Y3-TATE A427-7 3.71 ± 1.09 0.61 ± 0.24 11,400 ± 1,960 
64
Cu-CB-TE2A-sst2-ANT AR42J ND 26.5 ± 2.4 23,000 ± 950 
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The incorporation of radiometals into radiopharmaceuticals is achieved via 
bifunctional chelators, which complex the metal ion and covalently link the complex to 
the biomolecule.  Optimal BFCs rapidly incorporate the metal ion, and form stable 
complexes that persist in biological systems, which means that they must be resistant to 
acidic conditions and reduction-oxidation reactions.  The recent development of cross-
bridged heteromacrocyclic BFCs has substantially widened the spectrum of molecules to 
incorporate radiocopper into peptides and antibodies.  One such BFC, CB-TE2A, has 
been conjugated to the somatostatin analogue Y3-TATE and shown very promising 
pharmacokinetics in vivo (Sprague et al., 2004).  One major disadvantage of CB-TE2A-
Y3-TATE was unspecific uptake in the kidneys with high retention even at 24 h.  Two 
derivatives of CB-TE2A-Y3-TATE, BS353 and BS354, contain linker functions that can 
deprotonate at physiological pH, and thus the copper-64 radiopharmaceutical is of neutral 
charge.  The rationale for this approach stemmed from the observation that positively 
charged complexes tend to slowly clear from the kidney, which has been shown 
previously with 
111
In-DTPA-peptide conjugates, as well as copper-64-labeled 
azamacrocycles (Rogers   et al., 1996, Akizawa et al., 1998, Jones-Wilson et al., 1998, 
Akizawa et al., 2001b, Akizawa et al., 2001a).  CB-TE2A is linked to Y3-TATE via a 
benzamide group in BS353, and via a sulfonamide group in BS354.  Both copper-64 
radiopharmaceuticals were tested for their somatostatin receptor binding characteristics 
with AR42J rat pancreatic carcinoma cell membranes.  IC50 values for both compounds 
and the dissociation constant Kd for BS354 were in the lower nanomolar range (Table 18) 
and thus comparable to other commonly used somatostatin analogues, which led to their       
in vivo evaluation.  However, radiolabeling with copper-64 was inconvenient, and 
biodistribution studies revealed that the incorporation of ionizable linker groups could not 
reduce unspecific uptake in the kidneys (Thaddeus J. Wadas, Ph. D., WUSM, personal 
communication).  Thus, further development of these compounds would not likely result 
in improved somatostatin analogues compared to CB-TE2A-Y3-TATE.  
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CB-TE2A-Y3-TATE and TETA-Y3-TATE were used to study the intracellular 
fate of copper-64-labeled somatostatin analogues containing chelators with differing      
in vivo stability.  It has been demonstrated previously that copper-64 from                 
64
Cu-TETA-octreotide localized to the nucleus of AR42J rat pancreatic tumor cells and 
hypothesized that dissociation of the radiometal from the chelator is the first step in this 
process (Wang et al., 2003).  Here, 64Cu-TETA-Y3-TATE and 64Cu-CB-TE2A-           
Y3-TATE were compared for nuclear localization of copper-64 in A427-7 cells.          
Y3-TATE-based radiopharmaceuticals are highly specific for somatostatin receptor 
subtype 2, have a higher affinity – typically IC50 <2 nM (Reubi et al., 2000b) – and are 
more rapidly internalized into cells expressing this receptor than octreotide-based 
analogues (Anderson et al., 1998, Lewis et al., 1999c).  64Cu-TETA-Y3-TATE 
demonstrated higher uptake into tumor and other somatostatin-receptor rich tissues than 
64
Cu-TETA-octreotide in CA20948 tumor-bearing rats and AR42J-tumor bearing severe 
combined immunodeficiency (SCID) mice (Lewis et al., 1999a).  It was subsequently 
demonstrated that 
64
Cu-CB-TE2A-Y3-TATE showed lower unspecific uptake in blood 
and liver and greater tumor uptake compared to 
64
Cu-TETA-Y3-TATE (Sprague et al., 
2004).  
When designing a radiopharmaceutical for peptide receptor radiotherapy, one of 
the goals is to maximize damage to the tumor cells.  Irradiating the DNA is an effective 
way to injure and eventually kill cells;  thus a radionuclide that localizes to the nucleus of 
a tumor cell potentially enhances the efficacy of the radiopharmaceutical.  This may be 
especially true for radionuclides whose ranges in tissues are short.  In addition to           
β+ emission, β– emission, and electron capture, copper-64 emits two Auger electrons per 
decay (840 eV and 6.8 keV), and due to the very restricted range of these low energy 
electrons in biological tissues (0.05 and 1.5 μm, respectively, Richard Laforest, Ph. D., 
WUSM, personal communication), nuclear localization of copper-64 could increase the 
probability of cell killing from DNA damage.  Recoil energy released during the 
transmutation of copper-64 to stable zinc-64 or nickel-64 may also lead to cell killing, if 
copper-64 is in close proximity to DNA molecules (Apelgot et al., 1989).  Thus far, 
chelators have been optimized for high stability to increase uptake in target organs and 
avoid accumulation of the radiometal in non-target tissues.  However, for targeted 
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radiotherapy with copper-64-labeled peptides or monoclonal antibodies, the use of a 
chelator that complexes copper-64 less stably after uptake into the cell could indeed 
prove to be more efficacious than using a chelator that complexes the copper radionuclide 
more stably. 
This study investigated the binding characteristics of 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-Y3-TATE to somatostatin receptors in A427-7 non-small cell lung 
carcinoma cells.  The IC50 values compared well to those of related somatostatin 
analogues (Reubi et al., 2000b).  SSTr2 density (Bmax) on A427-7 cells was 
approximately 2-fold higher for 
64
Cu-CB-TE2A-Y3-TATE compared to 
64
Cu-TETA-  
Y3-TATE, whereas a 10-fold higher Bmax value had previously been observed for      
64
Cu-CB-TE2A-Y3-TATE in AR42J cells (Sprague et al., 2004).  As AR42J cells 
express SSTr1, SSTr2, SSTr3, and SSTr5, differences in binding affinities to 
somatostatin receptor subtypes other than SSTr2 were hypothesized to explain the 
observed maximum receptor densities, as the assay could not distinguish between binding 
to the various subtypes.  A427-7 cells only express SSTr2, so here the confounding 
influence of other receptor subtypes cannot account for the higher Bmax observed for 
64
Cu-CB-TE2A-Y3-TATE, although the difference was not as pronounced as with 
AR42J cells.  The Cu-CB-TE2A moiety of 
64
Cu-CB-TE2A-Y3-TATE has a charge of +1, 
whereas the Cu-TETA moiety of 
64
Cu-TETA-Y3-TATE is negatively charged due to the 
presence of two extra carboxylic acid groups.  This change from a positive to a negative 
charge on the chelator could have an effect on the binding of the entire molecule to the 
somatostatin receptor, although the Kd was not significantly affected. 
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-Y3-TATE differ substantially with 
respect to their in vitro and in vivo stability of the copper-64 chelate, and this had 
important consequences for the translocation of copper from these compounds to the cell 
nucleus of A427-7 cells.  The half-life of Cu(II)-CB-TE2A in 5 N HCl at 90 °C is 154 h, 
whereas Cu(II)-TETA has a half-life of <5 min (Woodin et al., 2005).  In rat liver 
metabolism studies in vivo, copper-64 from 64Cu-TETA was found to dissociate and to 
bind to proteins (e.g. superoxide dismutase) at much higher levels than from              
64
Cu-CB-TE2A (Boswell et al., 2004).  The experimental results obtained in this study 
with A427-7 cells confirm this stability pattern.  In A427-7 cells incubated with        
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64
Cu-CB-TE2A-Y3-TATE, there was only minimal copper-64 localization in the nuclear 
fraction over a 24-h time course, whereas incubation with 
64
Cu-TETA-Y3-TATE led to a 
6-fold increase over the same time period.  The hypothesis of
 
copper-64 dissociation from 
the chelator before localizing to the nucleus does not take into account the fate of the 
peptide portion of the radiopharmaceutical within cells, which may be subject to 
degradation during the internalization pathway, e.g. by lysosomal processes.  Other 
researchers have proposed the transport of intact somatostatin radiopharmaceuticals to the 
nucleus (Hornick et al., 2000), although it has been demonstrated that the amount of 
111
In-DTPA-octreotide delivered to AR42J cell nuclei is very small (~5% of                
cell-associated activity) (Wang et al., 2003).  The amount of copper-64 from 64Cu-TETA-
Y3-TATE that localized to the A427-7 nuclei at 4 h and 24 h (1.3% ± 0.1% and         
9.4% ± 1.7%, respectively) was substantially lower than for 
64
Cu-TETA-octreotide in 
AR42J cells at the same time points (10% and 20%, respectively) (Wang et al., 2003).  
This is not likely due to the use of octreotide vs. Y3-TATE, as all nuclear uptake values 
were normalized to the percent of agent that was cell-associated, and differences in SSTr 
binding and internalization were accounted for.  Additionally, the same chelator (TETA) 
was used for both sets of experiments. 
Dosimetry estimates were obtained from the uptake and efflux data for           
64
Cu-TETA-Y3-TATE and 
64
Cu-CB-TE2A-Y3-TATE in A427-7 cells.  Several 
preliminary experiments had established that the ratio of somatostatin analogue to 
somatostatin receptors was not excessive, and that decay of copper-64 rather than efflux 
of the radiopharmaceuticals would account for lower radiation doses at later time points.  
The calculations showed that it was not possible to deliver more than 1 Gy to A427-7 
cells.  Treatment of the cells with external beam irradiation at a radiation dose of 1 Gy 
killed less than 20% of the cells.  A study which used another somatostatin analogue 
(DOTA-Y3-octreotide) labeled with the β– emitter lutetium-177, achieved approximately 
65% cell killing of Capan-2 cells at a dose of 1.53 Gy (Nayak et al., 2005).  However, 
this effect can only partially be attributed to somatostatin receptor-mediated 
internalization of 
177
Lu-DOTA-Y3-octreotide, because the radiolabeled chelator       
177
Lu-DOTA itself also caused 53% cell killing of Capan-2 cells at a dose of 1.25 Gy 
(Nayak et al., 2005).  This study with internalized copper-64-labeled somatostatin 
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analogues delivered a low dose to A427-7 cells, in part because of their large size 
(diameter = 19 μm).  Additionally, the transport to the A427-7 nuclei of copper-64 from 
TETA-Y3-TATE did not contribute significantly to the dose to the tumor cell nuclei, 
most likely because nuclear localization did not increase substantially until the 24-h time 
point, unlike in AR42J cells, where transport to the nucleus occurred as early as 4 h 
(Wang et al., 2003).  Cell killing experiments with A427-7 confirmed that absorbed doses 
of 1 Gy or less were insufficient to cause substantial cell death of tumor cells. 
 
CB-TE2A was also conjugated to the octreotide derivative sst2-ANT, a 
somatostatin antagonist which has recently been shown to have excellent targeting 
properties for somatostatin-positive tumors in the form of 
111
In-DOTA-sst2-ANT (Ginj   
et al., 2006).  Somatostatin antagonists have not been the focus of intensive research, 
because they do not internalize and thus were thought to have tumor retention times that 
are too short for effective imaging or therapy.  In addition, they do not trigger the 
somatostatin signaling cascade, which means that the anti-proliferative effects of 
somatostatin analogues, e.g. by suppression of hormone hypersecretion, cannot be 
delivered by somatostatin antagonists.  Contrary to previous predictions, 
111
In-DOTA-
sst2-ANT (and other indium-111-labeled somatostatin antagonists) displayed a tumor 
retention of up to 72 h, exceedingly high target-to-non-target organ ratios, and produced 
excellent SPECT images (Ginj et al., 2006).  A copper-64-labeled somatostatin 
antagonist could be used for PET imaging, which is a more sensitive imaging modality 
than SPECT.  sst2-ANT was chosen over other promising somatostatin antagonists     
(e.g. sst3-ODN-8), as more research has been done on SSTr2 than on any of the other less 
widespread SSTr subtypes.  CB-TE2A was the bifunctional chelator of choice as its 
kinetic inertness and acid stability promised a sharper tumor-to-background profile than 
the more commonly used chelators DOTA and TETA.  The standard for comparison for 
copper-64-labeled somatostatin analogues is 
64
Cu-TE2A-Y3-TATE in a AR42J tumor-
bearing rat model, which was chosen for in vivo evaluation of 64Cu-TE2A-sst2-ANT. 
There were two important findings in the receptor binding of 
64
Cu-TE2A-       
sst2-ANT to isolated AR42J tumor cell membranes:  First, the dissociation constant Kd 
was in the nanomolar range, although one order of magnitude higher than Y3-TATE-
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based agonists (Table 18).  Ginj et al. (2006) measured IC50 values instead of the Kd, 
which also were in the nanomolar range, but cannot be compared directly to dissociation 
constants.  Second, the maximum receptor density Bmax was found to be increased by a 
factor of 14 compared to 
64
Cu-TE2A-Y3-TATE in the same model, which is extremely 
encouraging seeing that 
64
Cu-TE2A-Y3-TATE is the somatostatin agonist with the 
comparatively highest receptor densities (see Table 18, Sprague et al., 2004).  Elevated 
numbers of binding sites for somatostatin agonists were also found by Ginj et al. (2006), 
and this characteristic may be responsible for the excellent pharmacokinetics and imaging 
properties reported in that study.  However, in vivo evaluation of 64Cu-TE2A-sst2-ANT 
by means of a biodistribution in AR42J tumor-bearing male Lewis rats failed to show an 
improvement over 
64
Cu-TE2A-Y3-TATE (Sprague et al., 2004).  There was significant 
uptake in the tumor and other organs expressing somatostatin, however, unspecific 
uptake in the kidney, and the liver, was high, and target-to-non-target organ ratios were 
much lower than for 
64
Cu-TE2A-Y3-TATE, especially at 20 h.  However, these results of 
one preliminary in vivo study may not be conclusive, and copper-64-labeled somatostatin 
antagonists need to be more closely evaluated. 
 
Radiolabeled monoclonal antibodies are the second major class of molecules for 
the targeted imaging and therapy of tumors, next to peptides.  The monoclonal chimeric 
anti-EGFR antibody cetuximab was conjugated with DOTA and labeled with copper-64 
in this study for two purposes:  to probe the usefulness of cetuximab for the imaging and 
therapy of advanced cervical cancer, and to further examine the nuclear uptake of copper 
by identifying a protein that may be involved in this transport.  Cetuximab has been 
approved for the clinical treatment of advanced metastatic colorectal cancer, as well as 
advanced head-and-neck cancer in Europe and the United States, however, effective 
predictors of a positive response to cetuximab treatment have not yet been elucidated.  
Conjugation of cetuximab to more advanced cross-bridged BFCs, e.g. CB-TE2A, has not 
been considered, as the methodology for radiolabeling with copper-64 at temperatures 
suitable for antibody chemistry (<40 °C) has not yet been developed.  Antibodies, like all 
larger proteins, are prone to denaturation at temperatures commonly used for the 
radiolabeling of cross-bridged BFCs (95 °C). 
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The use of Gardasil, a recombinant vaccine against HPV (human papilloma virus) 
Types 6, 11, 16, and 18, was approved by the FDA in 2006 and the European Union in 
2007.  While this is an important step in the battle against cervical cancer, the viral types 
for which this vaccine provides protection are only responsible for 70% of cervical 
cancer cases.  Also, the vaccine will provide no protection for women already exposed to 
the included strains (Merck&Co., 2006).  Therefore, the need for advancement in the 
diagnosis and treatment of cervical cancer will persist.  Before the usefulness of 
cetuximab for cervical cancer patients will be evaluated clinically, the series of 
experiments presented here aimed at correlating EGFR mRNA expression, EGFR 
receptor numbers present on the cell membrane (determined as binding of 
64
Cu-DOTA-
cetuximab), and EGFR function (determined as internalization of 
64
Cu-DOTA-
cetuximab) in five human cervical cancer cell lines.  These cell lines differ not only in 
EGFR expression, but also in many other molecular aspects, e.g. mutations in the EGFR 
gene or the expression of downstream effectors of EGFR.  The cervical tumors of 
patients presenting in hospitals are just as heterogeneous, and hopefully, insights gained 
from experiments like the ones presented here will soon be applicable to tailor specific 
therapies depending on the molecular configuration of individual tumors.  There have 
been several recent reports on whether response of cancer to cetuximab is correlated to 
EGFR mRNA copy number or EGFR protein levels: Moroni et al. (2005) demonstrated a 
correlation in response to cetuximab in patients with metastatic colorectal cancer and 
increased EGFR gene copy number.  In contrast, Vallböhmer et al. (2005) did not find a 
significant correlation between EGFR gene expression in the tumor and patient response, 
possibly because of small sample size.  However, it was observed that patients with 
higher gene expression of EGFR had a shorter overall survival.  It has also been reported 
that patients with no detectable EGFR (as determined by immunohistochemistry) have 
the potential to respond to cetuximab (Chung et al., 2005).  It appears that a more 
quantitative measure of EGFR is needed in order to accurately determine whether there is 
any correlation between EGFR gene expression and/or EGFR protein levels, and 
response to cetuximab.  Ultimately, molecular imaging of EGFR with PET/CT and    
64
Cu-DOTA-cetuximab may be a very sensitive alternative measure of EGFR compared 
to traditional methods. 
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A clear correlation was found between mRNA levels of EGFR and protein 
expression as determined by saturation binding experiments with 
64
Cu-DOTA-cetuximab.  
In addition, the degree of 
64
Cu-DOTA-cetuximab internalization also correlated with both 
the mRNA and protein levels of EGFR.  CaSki cells, which showed the highest relative 
EGFR mRNA levels and had a strong positive response to all oligonucleotide probe sets 
under investigation, were also found to have the highest maximum EGF receptor 
densities and they internalized more 
64
Cu-DOTA-cetuximab than the other cell lines.     
C-33A cells responded negatively to all oligonucleotide probe sets, and no EGFR could 
be detected by 
64
Cu-DOTA-cetuximab binding assays.  The other three cell lines had 
intermediate responses that were consistent for all three approaches in the order CaSki > 
ME-180 > DoTc2 4510 >> HeLa > C-33A.  The next steps should be to determine the 
efficacy of cetuximab cell killing in the panel of cervical cancer cell lines grown in 
culture, and to evaluate the uptake of 
64
Cu-DOTA-cetuximab in these cell lines grown in 
mice in vivo using microPET.  Ultimately, a correlation of microPET imaging with 
cetuximab therapy in the tumor-bearing mouse models could set the stage for the imaging 
of cervical cancer with copper-64-labeled cetuximab. 
 
The human colorectal carcinoma cell line HCT 116 and the EGF receptor served 
as a model to take first steps towards elucidating the mechanism of copper transport to 
the cell nucleus.  It is widely accepted that copper is cytotoxic and does not exist in 
unbound form in vivo (e.g. Linder and Hazegh-Azam, 1996, Rae et al., 1999).  Instead, 
copper is bound by a variety of molecules, including transport proteins, 
metallochaperones, and copper redox enzymes.  Thus, it can be assumed that copper 
enters the cell nucleus bound to a transport or chaperone protein.  The studies presented 
here indicate that the tumor suppressor protein p53 is directly or indirectly involved in the 
process of copper transport to tumor cell nuclei.  p53 protein is maintained at very low 
levels in the absence of cellular stress (Oren, 2003).  It can be activated by many 
conditions such as DNA damage, hypoxia, chromosomal aberrations, telomere 
shortening, and others, whereupon it accumulates in the nucleus (Ostrakhovitch and 
Cherian, 2004), acting as a sequence-specific transcriptional regulator.  Copper-64 
administered as [
64
Cu]copper acetate and 
64
Cu-DOTA-cetuximab entered the nuclei of 
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HCT 116 +/+ cells, which express p53, in significantly greater amounts than was the case 
with HCT 116 –/– cells, which lack both p53 alleles.  In the case of [64Cu]copper acetate, 
the metal is transported into the tumor cells via the hCtr1 transporter, whereas           
64
Cu-DOTA-cetuximab, enters the cell by receptor-mediated endocytosis.  These 
different uptake mechanisms may account for the observation that the uptake of        
64
Cu-DOTA-cetuximab into HCT 116 +/+ nuclei was significantly increased after 4 h of 
exposure to the radiopharmaceutical, whereas a significant increase of [
64
Cu]copper 
acetate uptake occurred only at 24 h.  Control experiments showed that uptake of 
[
64
Cu]copper acetate and 
64
Cu-DOTA-cetuximab into the cells, as well as receptor 
binding parameters and efflux of 
64
Cu-DOTA-cetuximab were not significantly different 
between p53 positive and negative cell lines.  Thus, increased trafficking of copper-64 
into HCT 116 +/+ cell lines was not confounded by increased uptake or reduced efflux.   
Additional control experiments showed that nuclear localization of copper-64 in        
HCT 116 +/+ cells was similar to HCT 116 –/– cells when p53 siRNA was used to down-
regulate the p53 gene. 
Copper toxicity is correlated with apoptotic cell death, and translocation of p53 
from the cytosol into the nucleus has been shown to occur in cells treated with 200 μM 
copper supplied as cupric sulfate (Narayanan et al., 2001).  The experiments above show 
that presence of p53 in turn increases the amount of copper-64 that is transported to the 
nucleus of HCT 116 cells, however, there are several possible mechanisms of how this 
may occur.  Copper is capable of displacing zinc from metal-binding sites in proteins and 
has been shown to bind to p53 in vitro (Hainaut et al., 1995), thus one possibility is that 
p53 itself is responsible for the increased transport of copper-64 into the nuclei of      
HCT 116 +/+ cells.  Another option is that one of the many binding partners of p53 
complexes copper-64 and is transported to the nucleus together with p53.  A third 
potential mechanism involves proteins from genes whose expression is upregulated by 
the transcriptional regulator p53 after exposure to the radiocopper.  However, this is 
unlikely the case in this model system, considering that copper-64 from 
64
Cu-DOTA-
cetuximab appears in the nucleus as early as 1 h.  Finally, it is possible that HCT 116 +/+ 
cells express a protein spectrum fundamentally different from HCT 116 –/– cells in 
quality and quantity even in the ground state before exposed to any external stressor like 
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radiation.  This implies that the transcription of an as of now unknown copper-binding 
protein would be activated by basal levels of p53.  Whatever the exact mechanism, a 
direct or indirect effect of the tumor suppressor protein p53 on nuclear localization of 
copper was demonstrated utilizing two copper-64 radiotracers with different cell uptake 
mechanisms. 
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4. SUMMARY AND CONCLUSIONS 
 
This study investigated several somatostatin analogues labeled with copper-64 for 
imaging and targeted therapy of SSTr positive cancer.  Among three new cross-bridged 
bifunctional chelators coupled to Y3-TATE, 
64
Cu-CB-TE2A-Y3-TATE had the most 
favorable tumor targeting properties.  The introduction of ionizable linker groups could 
not remedy the slow clearance from the kidney, and other modifications will be necessary 
to resolve this issue. 
The emerging idea of using the copper-64-labeled somatostatin antagonist     
64
Cu-CB-TE2A-sst2-ANT as a tumor targeting agent will require further experimentation.  
This radiopharmaceutical showed promising initial results in a biodistribution study in 
male Lewis rats, however, it should be compared to 
111
In-DOTA-sst2-ANT in the same 
model.  Options include the HEK-sst2 cells which were used in the original 
characterization of 
111
In-DOTA-sst2-ANT in nude mice, as well as a direct comparison in 
the AR42J/rat model, or in a model based on the A427-7 cell line highly expressing 
SSTr2.  The in vivo evaluation of 64Cu-CB-TE2A-sst2-ANT by microPET imaging is 
pending. 
Nuclear localization of copper-64 from two somatostatin analogues differing in 
their chelate stability strengthened the hypothesis of copper-64 dissociation from the 
bifunctional chelator prior to trafficking to the nucleus.  However, the increased nuclear 
uptake of copper-64 from the less stable 
64
Cu-TETA-Y3-TATE did not result in a 
significant effect on cell killing of A427-7 cells.  In experiments with [
64
Cu]copper 
acetate and the EGFR-antibody 
64
Cu-DOTA-cetuximab, the tumor suppressor protein p53 
was identified as a mediator of the nuclear transport of copper.  Future studies will have 
to elucidate the exact role of p53 in this process:  Is it binding copper itself, or are other 
proteins involved?  Immunoprecipitation studies and Western blots could probe the role 
of p53 binding partners, and the influence of genes regulated by p53 on copper transport 
could be investigated by gene profiling.  These experiments will aim at identifying a 
chaperone protein for copper delivery to the nucleus, which is hypothesized to exist given 
the low concentration of free ionic copper in live cells. 
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64
Cu-DOTA-cetuximab was also utilized in five cervical cancer cell lines with a 
wide range of EGFR expression.  EGFR quantification by saturation receptor binding, 
and EGFR function as determined via internalization of 
64
Cu-DOTA-cetuximab closely 
followed the expression pattern of these cell lines found via EGFR mRNA profiling.  
This constitutes a first step in the evaluation of cetuximab for the treatment, and of    
64
Cu-DOTA-cetuximab for the imaging of advanced cervical cancer, as EGFR expression 
on the tumor cell surface clearly can be quantified and visualized with this experimental 
system.  However, intensive research on EGFR in colorectal cancer has shown that 
EGFR expression alone may not be a good prognostic indicator, and many other factors, 
such as specific EGFR mutations, and over-expression of other members of the EGFR 
pathway etc. may be equally important.  Sequencing of EGFR in the five cervical cell 
lines investigated here could identify a role for specific mutations, and the development 
of tumor-bearing rat models would allow microPET imaging with 
64
Cu-DOTA-
cetuximab and the investigation of cervical cancer therapy with cetuximab.  Thus, 
possible correlations between mutation status, EGFR expression and therapeutic efficacy 
of cetuximab could be established. 
Copper-64 has been used in this study to probe the basic biochemical process of 
intracellular copper trafficking, and for the targeting of cell surface receptors via 
radiolabeled peptides and antibodies, providing an example of the powerful combination 
of radiopharmaceutical chemistry and cell biology. 
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5. MATERIALS AND METHODS 
 
5.1  MATERIALS 
 
Chemicals.  All chemicals were purchased from Sigma-Aldrich (Saint Louis, 
Missouri), if not mentioned otherwise.  1,4,8,11-tetraazacyclotetradecane-1,4,8,11-
tetraacetic acid (TETA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
mono(N-hydroxysuccinimide ester) (DOTA-NHS) were obtained from Macrocyclics 
(Dallas, Texas), and 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane 
(CB-TE2A) was provided by Gary Weisman, Ph. D. (University of New Hampshire).  
Y3-TATE was synthesized and conjugated to TETA and CB-TE2A by CSBio (San 
Diego, California) using previously published methods (Sprague et al., 2004).  
Cetuximab (C225, Mr = 152,000) was obtained at a concentration of 2 mg/ml in            
0.1 M ammonium citrate, pH 6 from ImClone Systems (New York City, New York).  
sst2-ANT was synthesized on solid phase and conjugated to CB-TE2A by Sam     
Achilefu, Ph. D. (WUSM). 
 
Cells.  The stable transfection of A427 non-small cell lung cancer cells with 
SSTr2 has been described elsewhere (Parry et al., 2007).  A427-7 cell medium (minimum 
essential medium (Eagle) in Earle’s BSS) was obtained from Gibco (Carlsbad, 
California) and supplemented with 1 mM non-essential amino acids, 10 mM sodium 
pyruvate, and 10% fetal bovine serum (FBS, Gibco).  AR42J cells (obtained from the 
ATCC) were cultured in Kaighn’s modification of Ham’s F12 medium (F12K) with        
2 mM L-glutamine modified to contain 1.5 g/l sodium bicarbonate (Hyclone, Logan, 
Utah), supplemented with 20% FBS.  CaSki cells (obtained from the ATCC) were 
cultured in RPMI 1640 medium with 2 mM L-glutamine modified to contain                  
10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/l glucose, and 1.5 g/l sodium bicarbonate 
(Hyclone), supplemented with 10% FBS.  HeLa cells were obtained from the ATCC and 
C-33A cells from Paddy Ross, Ph. D., WUSM.  Both lines were cultured in minimum 
essential medium (Eagle) in Earle’s BSS and 2 mM L-glutamine modified to contain    
1.5 g/l sodium bicarbonate (TCSC) and supplemented with 1 mM non-essential amino 
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acids (TCSC), 10 mM sodium pyruvate (TCSC), and 10% FBS.  ME-180 cells (obtained 
from Paddy Ross, Ph. D., WUSM) were cultured in McCoy’s 5A medium with             
1.5 mM L-glutamine and 2.2 g/l sodium bicarbonate (TCSC), supplemented with         
10% FBS.  DoTc2 4510 cells (obtained from Paddy Ross, Ph. D., WUSM) were cultured 
in Dulbecco’s Modified Eagle’s Medium with 4 mM L-glutamine, 4.5 g/l glucose and   
1.5 g/l sodium bicarbonate (TCSC), supplemented with 10% FBS.  HCT 116 +/+ and 
HCT 116 –/– cell lines were kindly provided by Bert Vogelstein, Ph. D. (Johns Hopkins 
University), and cultured in McCoys 5A medium containing 10% FBS. 
 
Buffers.  The composition of buffers is specified in each section below.  Peptides 
and antibodies with BFCs for radiolabeling with copper-64 were handled in buffers free 
of trace metals, as these compete with radiocopper and reduce specific activity (Wadas 
and Anderson, 2006).  All buffers for radiolabeling with copper-64, and the citrate and 
phosphate buffers used for the synthesis of DOTA-cetuximab were stirred with      
Chelex
®
 100 Resin (5 g/l, BioRad, Hercules, California) over night and filtered using a   
1 liter, 0.2 μm Nylon sterilizing low extractable membrane filter system (Corning Inc., 
Corning, New York). 
 
Instruments.  A Branson Sonifier Cell Disrupter, and a Sorvall RC2-B centrifuge 
were used to prepare cell membranes for receptor binding experiments.  Size-exclusion 
HPLC used for conjugation of DOTA-cetuximab and purification of radiolabeled      
64
Cu-DOTA-cetuximab conjugate was accomplished on a Superose 12 HR 10/300 
column (Amersham Biosciences, Uppsala, Sweden) with a Waters (Milford, 
Massachusetts) 2487 dual  absorbance detector, and an Ortec Model 661 (EG&G 
Instruments, Oak Ridge, Tennessee) radioactive detector.  The mobile phase was           
20 mM HEPES, 150 mM NaCl, pH 7.3, eluted at a flow rate of 0.5 ml/min.       
Millenium 32 software (Waters) was used to quantify chromatograms by integration.  A 
Beckman 8000 automated well-type gamma counter (Fullerton, California) was used to 
measure internalization, efflux and nuclear uptake samples.  The gamma counter or a               
1450 Microbeta liquid scintillation and luminescence counter (Perkin Elmer, Boston, 
Massachusetts) were used to measure receptor binding.  UV/VIS absorption of peptide 
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stock solutions was measured with a PerkinElmer Lambda 25 UV/VIS spectrometer, and 
absorption of samples on 96-well plates was measured with a PerkinElmer HTS 7000 
BioAssay Reader.  Radio-thin layer chromatography plates were analyzed on a BioScan 
(Washington, D.C.) AR2000 Radio-TLC System equipped with a 10% (vol/vol) 
methane/argon gas supply and PC computer interface running WinScan v.3 analysis 
software. 
 
Production of copper-64.  Copper-64 was produced as previously reported on a 
biomedical cyclotron CS-15 at Washington University School of Medicine (McCarthy    
et al., 1997). 
 
 
 
5.2 BCA PROTEIN ASSAY 
 
Protein concentrations in isolated cell membranes, internalization, efflux, and 
nuclear uptake samples, and DOTA-cetuximab conjugations were determined using a 
bicinchoninic acid (BCA) protein assay (Pierce, Rockford, Illinois) (Smith et al., 1985).  
Samples were distributed on transparent 96-well plates, and the BCA reagent mixture 
was added in one step.  In this assay, copper from the reaction mixture binds to protein in 
the sample, forming a deep blue complex (biuret reaction).  One cupric ion forms a 
complex with four to six nearby peptide bonds, and the intensity of the color is 
proportional to the number of complexed peptide bonds.  During an incubation at 37 °C 
for 30 min, the alkaline medium reduced cupric to cuprous ion, which formed a water-
soluble complex with bicinchoninic acid (BCA) in a ratio of 1:2.  The absorbance was 
measured at a wavelength of 562 nm, and protein concentrations were calculated from a 
standard curve obtained by a serial dilution of bovine serum albumin (BSA,                 
0.1–2 mg/ml). 
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Fig. 45:  Two representative BSA standard curves for BCA protein assay. 
 
 Two standard curves obtained with different plates on different days are shown in 
Fig. 45.  Each curve is strongly linear (r2 >0.99 in both cases), and there is little error 
within individual measurements.  However, slight changes in incubation time, 
temperature or reagents had a dramatic impact on slope and y-intercept, making it 
necessary to obtain a new standard curve for each experiment, with the protein sample 
under investigation on the same 96-well plate. 
 
 
 
5.3 CHEMICAL SYNTHESES 
 
DOTA-cetuximab (DOTA-C225).  3 mg (19.7 nmol, 1.5 ml) of cetuximab were 
transferred into a Centricon centrifugal filter device with YM-30 MW membranes 
(Millipore, Billerica, Massachusetts).  A buffer exchange from 0.1 M ammonium citrate 
(pH 6.0) to 0.1 M Na2HPO4 (pH 7.5) was achieved by three centrifugation steps (4,250g, 
80 min, 4°C) with 2 ml phosphate buffer added each time.  Cetuximab was recovered 
(~85%, 16.8 nmol) and the volume brought to 500 μl with phosphate buffer.  DOTA-
NHS (5.40 mg, 8.59 μmol) was dissolved in 400 μl phosphate buffer and the pH was 
increased to 7.5 with 0.1 M NaOH.  The neutralized DOTA-NHS (1.27 mg, 2.02 μmol,  
ratio DOTA-NHS:cetuximab = 120:1) was added to the cetuximab solution and rotated 
over night at 4°C.  The buffer was reverted to 0.1 M ammonium citrate (pH 6.0) using the 
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Centricon method described above.  Seven spins (4,250g, 80 min, 4°C) with 2 ml citrate 
buffer each were performed to remove all unreacted small molecules.  The exact amount 
of bioconjugated antibody was measured using a BCA protein assay, and DOTA-
cetuximab (4–7.5 μg/μl) was stored at 4 °C. 
 
 
 
5.4 RADIOCHEMISTRY 
 
Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64 
followed the guidelines put forth by Wadas and Anderson (2006). 
 
UV spectroscopy to determine peptide concentrations.  All peptides and 
chelator-peptide conjugates were dissolved in ddH2O or 0.1 M ammonium acetate with 
the pH adjusted to the value suitable for the labeling of the respective compound with 
copper-64.  The exact concentration was determined via UV/VIS spectroscopy using the 
Lambert-Beer equation 
 
 
 
with A being the absorption at a wavelength of 280 nm, ε being the molar extinction 
coefficient of the respective compound, d being the length of the cuvette (1 cm), and c 
being the concentration of the peptide or chelator-peptide conjugate in mol/l.  The molar 
extinction coefficient ε was estimated for each compound from its amino acid sequence 
as the sum of the molar extinction coefficients of single amino acids as follows:           
120 M
–1
 cm
–1
 for cysteine, 1,280 M
–1
 cm
–1
 for tyrosine, 5,690 M
–1
 cm
–1
 for tryptophan, 
and 9,050 M
–1
 cm
–1
 for 4-nitro-phenylalanine. 
 
Radio-TLC.  Thin-layer chromatography of copper-64-labeled somatostatin 
analogues was performed using thin-layer chromatography plates (MKC18F silica gel   
60 Å, 2.5 x 7.5 cm, layer thickness 200 μm, Whatman, Florham Park, New Jersey) with 
10% ammonium acetate:methanol = 3:7 as mobile phase.  Uncomplexed copper-64 
MATERIALS AND METHODS 
 108 
remains at the origin under these conditions.  The Rf values for specific 
radiopharmaceuticals are specified below.  
64
Cu-DOTA-cetuximab was assayed for 
radiochemical purity after complexation of free copper with EDTA on Silica gel 
impregnated glass fiber sheets (Pall Life Sciences, East Hills, New York) with            
10% ammonium acetate:methanol = 3:7 as mobile phase.  
64
Cu-EDTA migrates with the 
solvent front under these conditions, whereas 
64
Cu-DOTA-cetuximab remains at the 
origin.  Chromatograms were dried before the reading with a radio-TLC scanner. 
 
64
Cu-TETA-octreotide.  Radiolabeling of TETA-octreotide with copper-64 was 
achieved by incubating 1 μg of chelator-peptide conjugate with 19–37 MBq (0.5–1 mCi) 
of [
64
Cu]cupric acetate in 100–150 μl of 0.1 M ammonium acetate (pH 5.5) for 1 h at RT.  
Radiochemical purity was confirmed by radio-TLC (Fig. 46). 
 
64
Cu-TETA-Y3-TATE.  TETA-Y3-TATE (1 μg) was labeled with 19–74 MBq 
(0.5–2 mCi) of [64Cu]cupric acetate by incubation in 100–150 μl of 0.1 M ammonium 
acetate (pH 5.5) for 1 h at RT as previously described to yield 
64
Cu-TETA-Y3-TATE 
(Lewis et al., 1999d).  Radiochemical purity was confirmed by radio-TLC (Fig. 46). 
 
 
 
Fig. 46:  Representative radio-TLC scans of 64Cu-TETA-octreotide (left, radiochemical 
purity 97.2%, Rf = 0.53) and 
64Cu-TETA-Y3-TATE (right, radiochemical purity 99.3%, 
Rf = 0.62). 
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64
Cu-CB-TE2A-Y3-TATE.  
64
Cu-CB-TE2A-Y3-TATE was produced by 
incubating 1 μg of CB-TE2A-Y3-TATE with 9–37 MBq (0.25–1 mCi) of [64Cu]cupric 
acetate in 100–150 μl of 0.1 M ammonium acetate (pH 8.0) for 1.5 h at 95 ºC as 
previously described (Sprague et al., 2004).  Radiochemical purity was confirmed by 
radio-TLC (Fig. 47). 
 
 
64
Cu-CB-TE2A-sst2-ANT.  CB-TE2A-sst2-ANT (1–2 μg) was labeled with     
19–111 MBq (0.5–3 mCi) of [64Cu]cupric acetate by incubation in 100–150 μl of          
0.1 M ammonium acetate (pH 8.0) for 1.5 h at 95 ºC.  Radiochemical purity was 
confirmed by radio-TLC (Fig. 47). 
 
 
Fig. 47:  Representative radio-TLC scans of 64Cu-CB-TE2A-Y3-TATE                         
(left, radiochemical purity 95.8%, Rf = 0.62) and 
64Cu-CB-TE2A-sst2-ANT               
(right, radiochemical purity 99.0%, Rf = 0.57). 
 
 
64
Cu-DOTA-cetuximab (
64
Cu-DOTA-C225).  Radiolabeling of DOTA-
cetuximab with copper-64 was carried out by adding approximately 100 μg of the 
conjugate to 0.5–2 mCi (19–74 MBq) 64CuCl2 in 0.1 M ammonium citrate buffer, pH 5.5, 
followed by a 1 h incubation at 40 °C.  The radiochemical purity of the resulting       
64
Cu-DOTA-cetuximab was determined by size-exclusion HPLC (Fig. 48) and         
radio-TLC (Fig. 49).  See section 5.1 for HPLC and TLC conditions.  If necessary,             
64
Cu-DOTA-cetuximab was challenged with 5 μl of 10 mM EDTA to complex free 
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copper-64.  
64
Cu-DOTA-cetuximab was then isolated with a Zeba
TM
 Desalt Spin column 
(0.5 ml, Pierce, Rockford, Ilinois) to obtain radiochemical purities >95%. 
 
 
Fig. 48:  Representative size-exclusion chromatogram of 64Cu-DOTA-cetuximab. 
Retention time on radioactivity detector (A) ca. 23.2 min, on UV spectrometer at          
280 nm (B) ca. 22.8 min.  Free [64Cu]copper citrate eluded at ca. 34.5/33.8 min. 
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Fig. 49:  Representative radio-TLC scan of 64Cu-DOTA-cetuximab (radiochemical purity 
95.7%, Rf = 0.00);  peak at Rf = 0.89 (4.3%) is 
64Cu-EDTA. 
 
 
 
5.5 RECEPTOR BINDING 
 
Assays were conducted with isolated cell membranes if possible.  For cervical 
cancer cell lines, receptor binding was measured with a protocol modified for live cells.  
 
Preparation of cell membranes.  Cell cultures (usually four 175 cm
2
 culture 
flasks or eight 75 cm
2
 flasks) were harvested at confluency.  The culture medium was 
aspirated, and cells were washed with 5 ml ice-cold 20 mM Tris-HCl buffer (pH 7.4).      
5 ml homogenizing buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2 · 6 H2O, 0.5 µg/ml 
aprotinin, 200 µg/ml bacitracin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin A) were 
added to each flask, and the cells were carefully removed from the surface of the flask 
using a cell scraper tool, and transferred into centrifuge tubes.  The cell suspension was 
exposed to ultrasound from the probe sonifier cell disrupter on setting 5 for                      
2 x 15 seconds.  The membranes were pelleted with a Sorvall centrifuge (5,000g, Rotor 
SLA-1500) for 10 min at 4 C.  The supernatant containing cytosolic debris was 
aspirated, and the pellet resuspended in homogenizing buffer.  Membranes were used on 
the same day or stored at –80 C. 
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Assays with isolated cell membranes.  Assays were performed on a 96-well 
Multiscreen  Durapore filtration plate (Millipore, Billerica, Massachusetts) in binding 
buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2 · 6 H2O, 0.1% BSA, 0.5 µg/ml aprotinin, 
200 µg/ml bacitracin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin A) using methods 
previously described with some modifications (Sprague et al., 2004).  Membrane peptide 
mass per well depended on the estimated maximum receptor densities (Table 19,     
Table 20).  In competitive binding assays, small amounts of the radiopharmaceutical 
(typically at a concentration of 0.03–0.07 nM, see Table 20) were displaced with 
increasing concentrations (typically 0.01 nM–1 μM) of the corresponding unlabeled 
pharmaceutical.  In some cases, complexes with 
nat
Cu were used for displacement.  In 
saturation binding assays, increasing concentrations of the copper-64
 
radiopharmaceutical 
were added to membranes to measure total binding, and unspecific binding was 
determined by conducting the assay in the presence of an excess of unlabeled drug.  
These blocking agents are listed in Table 19.  After incubation at room temperature for   
2 h, the medium was removed with a vacuum manifold and the membranes were washed 
twice with 200 l binding buffer.  Binding was measured with a gamma counter or an 
automated scintillation and luminescence plate reader, depending on instrument 
availability.  In case of the former, membranes were punched from the 96-well plate, 
placed in microfuge tubes, and transferred to the gamma counter.  In case of the latter, 
OptiPhase ‘Super-Mix’ (25–50 μl, PerkinElmer) was added to each well, and bound 
activity was measured with the plate reader.  In competitive binding assays, IC50 values 
were estimated from non-linear curve fitting of bound radiopharmaceutical vs. the sum of 
the concentrations of copper-64- and unlabeled drug using Prism (GraphPad, San Diego, 
California) software.  In saturation binding assays, specific binding was obtained by 
subtraction of unspecific binding from total binding.  Maximum binding capacities (Bmax) 
were estimated from non-linear curve fitting of specific binding vs. the concentration of 
copper-64-labeled radiopharmaceutical using Prism. 
 
Assays with live cells.  Cervical cancer cells were cultured in their respective 
growth media in 24-well plates, with a certain number of cells per well (see Table 19) 
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seeded the day before the experiment.  The cells received 2 ml of fresh medium and were 
cooled to 4 ºC.  Increasing concentrations (0.005 nM–10 nM) of 64Cu-DOTA-cetuximab 
were added, and unspecific binding was determined by conducting the assay in the 
presence of an excess (200 nM) of cetuximab.  After an incubation at 4 ºC for 4 h, the 
medium was aspirated and the cells were washed twice with 1 ml HBSS. 0.9 ml of          
1 N NaOH were added, and cells were lysed at 90 ºC for 30 min.  Samples were 
transferred into microfuge tubes and bound activity was measured with gamma counter.  
To standardize to protein content, three cell samples were lysed with 0.5 % SDS in PBS 
after the 4-h incubation period and analyzed for protein mass.  Specific binding was 
obtained by subtraction of unspecific binding from total binding.  Maximum binding 
capacities (Bmax) and binding affinities (Kd) were estimated from non-linear curve fitting 
of specific binding vs. the concentration of 64Cu-DOTA-cetuximab using Prism. 
 
Table 19:  Experimental conditions for saturation receptor binding experiments. 
Analogue Cell line Cells/ 
well 
Membranes/
well (μg) 
Blocking agent 
64Cu-TETA-octreotide A427-7 – 5 TETA-octreotide 
64Cu-TETA-octreotide A427-2 – 20 TETA-octreotide 
64Cu-TETA-octreotide A427-5 – 20 TETA-octreotide 
64Cu-BS354 AR42J – 30 Y3-TATE 
64Cu-TETA-Y3-TATE A427-7 – 5 TETA-Y3-TATE 
64Cu-CB-TE2A-Y3-TATE A427-7 – 5 CB-TE2A-Y3-TATE 
64Cu-CB-TE2A-sst2-ANT
 AR42J – 20 CB-TE2A-sst2-ANT 
64Cu-DOTA-cetuximab CaSki 105 10 Cetuximab 
64Cu-DOTA-cetuximab ME-180 105 10 Cetuximab 
64Cu-DOTA-cetuximab DoTc2 4510 105 – Cetuximab 
64Cu-DOTA-cetuximab HeLa 5·104 – Cetuximab 
64Cu-DOTA-cetuximab C-33A 1.5·105 – Cetuximab 
64Cu-DOTA-cetuximab HCT 116 +/+ – 10 Cetuximab 
64Cu-DOTA-cetuximab HCT 116 –/– – 10 Cetuximab 
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Table 20: Experimental conditions for competitive receptor binding experiments. 
Pharmaceutical Cell line Membranes/ 
well (μg) 
Displaced tracer c(tracer) 
(nM) 
natCu-BS353 AR42J 25 64Cu-CB-TE2A-Y3-TATE 0.031 
natCu-BS354 AR42J 25 64Cu-CB-TE2A-Y3-TATE 0.031 
natCu-TETA- 
Y3-TATE 
A427-7 31.25 64Cu-TETA-Y3-TATE 0.070 
natCu-CB-TE2A-
Y3-TATE 
A427-7 12.5 64Cu-CB-TE2A-Y3-TATE 0.057 
Cetuximab CaSki 50 64Cu-DOTA-cetuximab 0.050 
Cetuximab ME-180 50 64Cu-DOTA-cetuximab 0.050 
Cetuximab DoTc2 4510 50 64Cu-DOTA-cetuximab 0.050 
Cetuximab HeLa 50 64Cu-DOTA-cetuximab 0.050 
Cetuximab C-33A 50 64Cu-DOTA-cetuximab 0.050 
 
 
 
 
5.6 INTERNALIZATION, EFFLUX, AND NUCLEAR UPTAKE EXPERIMENTS 
 
Internalization of somatostatin analogues, [
64
Cu]copper acetate, and       
64
Cu-DOTA-cetuximab.  A427-7, cervical cancer, HCT 116 +/+ or HCT 116 –/– cells 
(ca. 5·10
5 
cells/well) were seeded in 6-well plates containing their respective growth 
medium and incubated at 37 °C, 5% CO2 until 80% confluent.  On the day of the assay, 
the medium was aspirated and replaced with 3 ml fresh growth medium.  For 
determination of unspecific internalization of somatostatin analogues or 
64
Cu-DOTA-
cetuximab, one set of wells was incubated with unlabeled pharmaceutical (100- to 1000-
fold excess) at 37 °C, 5% CO2 for 10 min to block receptors.  Somatostatin analogues in 
various amounts (see RESULTS section), [
64Cu]copper acetate (25 μCi/10 μl) or       
64
Cu-DOTA-cetuximab (3.6 μCi, 0.38 μg/15 μl) were added and incubated at 37 °C,    
5% CO2 for various time points, when the radioactive medium was aspirated, and the 
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plate was washed twice with 2 ml PBS.  To collect the surface-bound fraction for 
receptor-mediated processes, each well was treated with 20 mM sodium acetate in PBS 
(pH 4.0 for peptides, pH 3.0 for antibodies) and was incubated at 4 °C for 10 min 
followed by a second 20 mM sodium acetate in PBS (pH 4.0/3.0) wash without 
incubation, which was pooled with the first rinse.  The cellular fraction was dissolved 
with 0.5% SDS in PBS, and all fractions were counted for radioactivity with a gamma 
counter.  The percentage internalized was the amount of activity in the final cell pellet, 
corrected for activity in the blocked fractions and background activity, and normalized to 
protein content. 
 
Efflux of somatostatin analogues, and of 
64
Cu-DOTA-cetuximab.  For efflux 
experiments, cells (ca. 5·10
5 
cells/well) were seeded in 6-well plates and allowed to 
adhere overnight.  Cells were fed 3 ml fresh growth medium on the morning of the 
experiment, the copper-64-labeled pharmaceutical was added to each well, and cells were 
incubated at 37 C, 5% CO2 for 4 h.  The radioactive medium was removed, and the cells 
were washed twice with ice-cold PBS.  Fresh growth medium (3 ml) was added to each 
well, and the cells were incubated for various time points, when the media was removed 
and the cells were washed twice with ice cold PBS.  The surface-bound fraction was 
determined as described for internalization experiments.  The cells were solubilized in 
0.5% SDS in PBS, and the solution was transferred to a microfuge tube, and counted for 
radioactivity on a gamma counter. 
 
Nuclear localization of copper-64 derived from somatostatin analogues, 
[
64
Cu]copper acetate, and 
64
Cu-DOTA-cetuximab.  For isolation of HCT 116 cell 
nuclei, the procedure of Wang et al. (2003) was used.  The experiments were performed 
in T-175 flasks containing approximately 5·10
7
 cells at the beginning of the time course.  
Copper-64-labeled somatostatin analogues (in a ratio of receptor:peptide = 10:1 as 
determined by the respective Bmax), [
64
Cu]copper acetate (25 µCi), or 
64
Cu-DOTA-
cetuximab (4.0 μCi, 0.33 μg/20 μl) were added, and after various incubation times, the 
cells were pelleted and resuspended in CSK buffer (0.5% Triton X-100, 300 mM sucrose, 
100 mM NaCl, 1 mM EGTA, 2 mM MgCl2, and 10 mM PIPES, pH 6.8) and incubated 
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on ice for 2 min.  Cell lysates were centrifuged at 560g for 5 min at 4 °C, and the 
supernatant was discarded.  The nuclear pellet was resuspended in 1 ml CSK buffer 
without Triton X-100, and centrifuged at 560g at 4 °C for 5 min.  The supernatant was 
discarded, and the nuclear pellet was counted with a gamma counter.  Aliquots of nuclei 
were assayed qualitatively for purity by fluorescence microscopy after staining with a 
1:10 dilution of FITC (3 μg/ml) and propidium iodide (7 μg/ml).  Micrographs were 
obtained at 100-, 200-, and 1000-fold magnification.  The yield of nuclei was determined 
by counting the initial cell number and the collected nuclei using a hemocytometer.  The 
percentage in the cell nucleus was determined by the gamma counts in the pure nucleus 
divided by gamma counts internalized into whole cells, and was corrected for the yield of 
nuclei for isolation yields <90%. 
 As an additional control in the HCT 116 system, nuclear uptake of [
64
Cu]copper 
acetate was determined in HCT 116 +/+ cells after down-regulation of p53 by p53 
siRNA, and compared to untreated HCT 116 +/+ and HCT 116 –/– cells.  Cells were 
seeded in T-75 flasks so that they were 30–40% confluent after 24 h.  200 µl TransPassTM 
R1 Transfection Reagent (New England BioLabs, Boston, Massachussetts) were mixed 
with 5 ml serum-free medium and incubated for 15 min at RT.  20 µl p53 ShortCut
®
  
siRNA Mix (New England BioLabs) was added, followed by another 15 min incubation 
at RT and addition of 43 ml medium with serum.   HCT 116 +/+ were given 12 ml/flask 
of this mixture and grown for 48 h under standard conditions.  A change to fresh medium 
was followed by additional 24 h of incubation, and nuclear localization experiments were 
then conducted as described above. 
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5.7 DOSIMETRY 
 
Internalization/efflux data were replotted in dps/cell per hour, and disintegrations 
per cell over the course of the experiment were calculated with the area-under-curve 
function of GraphPad Prism.  To the total number of disintegrations was added the 
number of disintegrations past the last time point (24 h) assuming only physical decay 
(no biological washout from the cell surface or nucleus).  The absorbed dose to whole 
cells and to the nuclei was calculated from the total number of decays by a linear 
combination of S values and disintegration numbers, using cellular S values for      
copper-64, a cell radius of 10 μm, and a nuclear radius of 9 μm (Goddu et al., 1997).  
Medical Internal Radiation Dose (MIRD) methodology for cellular dosimetry considers 
either the whole cell as the source organ, or the cell surface, the cytoplasm and the 
nucleus.  In this experiment, the cytoplasm activity was provided by the difference 
between the measured internalized activity and the activity assigned to the nucleus.  The 
total absorbed dose to the cell nucleus is provided by: 
 
 
 
and the absorbed radiation dose to the whole cell is 
 
  
 
where ACy, AC, ACS and AN are the total number of disintegrations in the cytoplasm, in the 
whole cell, at the cell surface and in the nucleus.  The S(target organ←source organ) are 
the cellular S values in Gy/Bq∙s.  These calculations were performed with the assumption 
that the absorbed dose from decay occurring in neighboring cell does not contribute to the 
total dose of a given cell.  This assumption is justified here since the experiment was 
performed in a single layer cell culture and the distance is relatively large.  Calculations 
were assisted by Richard Laforest, Ph. D., WUSM. 
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5.8 ANIMAL BIODISTRIBUTION STUDY 
 
 
64
Cu-CB-TE2A-sst2-ANT (27 μCi, 250 ng) was injected intravenously via the tail 
vein into AR42J tumor-bearing rats.  Tissue biodistribution data in %ID/g were obtained 
at 1 h, 4 h, and 20 h post-injection using methods described in Lewis et al. (1999a).  
Additional tumor-bearing rats were coinjected with 150 μg of sst2-ANT to examine        
in vivo uptake specificity via the somatostatin receptor at 4 h post-injection.  All organs 
were weighed and measured with a gamma counter. 
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B. ABBREVIATIONS 
 
α-MSH α-Melanocyte-stimulating hormone 
ATCC  American type culture collection 
ATP  Adenosine triphosphate 
ATSM  Diacetyl bis(N4-methylthiosemicarbazone) 
BCA  Bicinchoninic acid 
BFC  Bifunctional chelator 
BSA  Bovine serum albumin 
CAA  Cell-associated activity 
cAMP  Cyclic adenosine monophosphate 
C225  Cetuximab 
CB-TE2A 4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane 
CCK  Cholecystokinin 
CCO  Cytochrome-c oxidase 
CI  Confidence interval 
CNS  Central nerve system 
Cox-2  Cyclooxygenase 2 
CP  Ceruloplasmin 
CT  Computed tomography 
DBM  Dopamine-β-monooxygenase 
df  Degrees of freedom 
DOTA  1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTA-NHS 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(hydroxy-
succinimide ester) 
DTPA Diethylenetriaminepentaacetic acid 
EC  Electron capture 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
eNOS Endothelial nitric oxide synthase 
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FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FDA Food and drug administration 
FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
GI Gastro-intestinal 
GPCR G-protein-coupled receptors 
GRP Gastrin-releasing peptide 
GRPR Gastrin-releasing peptide receptor 
HAMA Human antibodies against murine antibodies 
HBSS Hank’s Balanced Salt Solution 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HER Human epidermal receptor 
HGF Hepatocyte growth factor 
HPV Human papilloma virus 
ID Initial dose 
IGF-1 Insulin-like growth factor 1 
IL Interleukin 
MAPK Mitogen-activated protein kinase 
MFU Mean fluorescent unit 
MIRD Medical Internal Radiation Dose 
Mr  Molecular weight 
MRI Magnetic resonance imaging 
MT  Metallothionein 
nNOS  Neuronal nitric oxide synthase 
NSCLC Non-small cell lung cancer 
PAM  Peptide-α-amidating monooxygenase 
PBS  Phosphate buffered saline 
PDGF  Platelet-derived growth factor 
PET  Positron emission tomography 
PI  Propidium iodide 
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PIPES  Piperazine-N,N′-bis(2-ethanesulfonic acid) 
PTSM  Pyruvaldehyde bis(N4-methylthiosemicarbazone) 
RGD  Arg-Gly-Asp 
RT  Room temperature 
SCID  Severe combined immunodeficiency 
SCLC   Small cell lung cancer 
SDS  Sodium dodecyl sulfate 
siRNA  Small interfering RNA, or short interfering RNA, or silencing RNA 
SOD   Superoxide dismutase 
SPECT Single photon emission computed tomography 
SSTr  Somatostatin receptor 
SSTr2  Somatostatin receptor subtype 2 
sst2-ANT Ac-NH-(4-NO2-Phe)-cyclo[(D)Cys-Tyr-(D)Trp-Lys-Thr-Cys]-(D)Tyr-NH2 
TCSC  Washington University Medical School Tissue Culture Support Center 
TETA  1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid 
TGF-α  Transforming growth factor α 
TGN  Transgolgi network 
VEGF  Vascular endothelial growth factor 
VIP  Vasoactive intestinal peptide 
WUSM Washington University School of Medicine 
Y3-TATE Tyrosine
3
-octreotate = (D)Phe-cyclo[Cys-Tyr-(D)Trp-Lys-Thr-Cys]-Thr 
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